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ABSTRACT 
Background 
Musculoskeletal arteriovenous malformations (AVMs) result from abnormal angiogenesis and 
belong to congenital vascular malformations (CVMs) group. AVMs persist and have associated 
morbidity and even mortality. The aetio-pathogenesis of AVMs is unknown. This study 
analyses histological morphology and the immunohistological expression of specific 
angiogenesis and hypoxia markers in comparison with control tissues in patients with CVMs. 
CVM pO2 was further assessed. This work was performed to gain insight into possible 
mechanisms involved in aetio-pathogenesis of CVMs. 
 
Methods  
Thirty three consecutive CVMs and 10 control specimens were analysed morphologically using 
routine techniques, histochemical (H&E, Masson Trichrome, Elasic Von Gieson, Toluidine 
blue) and immunohistochemical (CD68, CD3, CD20, Factor VIII, actin 1-α, ki67 and S100). 
Further immunohistochemical studies analysed VEGF A, VEGFR-1, Tie-2, αV 3 and αV 5 
integrins, HIF-1α and HIF-2α, CAIX.  The neutral endopeptidase (NEP) was studied by 
immunostaining for CD10 on 38 CVMs. Intraoperative blood samples from CVMs were 
analysed for pO2. 
 
Results 
Macrophages (p<0.0001), mast cells (p<0.0001), vessel number (p=0.0004) and diameters 
(p=0.0005) were significantly higher in the CVMs compared to controls. The expression of all 
angiogenesis markers were significantly higher in CVMs comparing to controls. HIF-1α, HIF-
2α and CD10 (p=0.0002) were over-expressed in CVMs. There was a positive correlation 
between HIF-2α expression and VEGF A (p=0.0001), VEGFR-1 (p=0.0043), Tie-2 (p=0.03), 
αVβ3 (p=0.029), αVβ5 (0.045), CD10 (p=0.0002) and inflammatory cells in CVMs. 
Comparisons of CVM and arterial blood pO2 were not significant (p=1). 
 
Discussion 
Inflammation and imbalance of angiogenic and hypoxia markers are implicated in CVM 
pathogenesis. HIF-2α may play a more important role in CVM pathgogenesis than HIF-1α. 
CVM blood has an arterial pattern in spite of expressing HIF. CD10 may be a potential marker 
for CVMs in biopsies. Molecular patterns and potential signalling pathways involved in CVM 
pathogenesis are implicated in this work. This enhanced clinico-pathological correlation should 
improve therapeutic options and efficacy. 
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1. INTRODUCTION 
1.1 DEFINITION OF CONGENITAL VASCULAR MALFORMATIONS 
Congenital vascular malformations (CVMs), also known as vascular anomalies are common 
vascular lesions with a heterogeneous clinical, anatomical, histological and patho-physiological 
presentation. Vascular anomalies occur mainly in the skin, which is the largest organ of the 
body. They are known to represent proliferations of abnormal blood vessels or morphological 
defects of the circulatory system that arise during foetal development (Lee, 2004). CVMs are 
thought to be present at birth but they are not always obvious (Kohout et al, 1997, Vikkula et al, 
1998, Lee et al, 2007). The majority of CVMs are sporadic and isolated and occur in healthy 
subjects.  CVMs may also be extensive, affecting multiple anatomical regions, when they may 
be part of recognised familial syndromes (Fishman et al, 1993, Blei et al, 1998, Rosen et al, 
2000, Connors et al, 2005). Their anatomy is variable depending on the type and size of vessel 
involved as well as on the degree of shunting resulting from the communication of the arterial 
with the venous side, when this exists. Further details will be given in the following chapters 
when each sub-category is discussed. 
Vascular malformations have often been referred as haemangiomas by various specialists 
without realising that the two conditions were fundamentally different (Mulliken, 1988). CVMs 
can occur anywhere in the body. The focus of this research work is on all types of peripheral 
CVMs with a special emphasis on venous malformations  and arteriovenous malformations 
(AVMs), which pose the most difficult clinical challenges and are the most dangerous vascular 
anomalies (Lee, 2004). Visceral vascular anomalies or berry aneurysms have been studied 
within other sub-specialty fields and their aetio-pathogenesis appears to differ from that of 
peripheral vascular lesions. CVMs are associated with morbidity, high recurrence, and 
occasional cardiac mortality. Only a small proportion of CVMs can be completely cured 
(Szilagyi et al, 1976, Enjolras et al, 2000). The lack of scientific knowledge regarding CVMs 
leads to sub-optimal management of millions of affected individuals. Little research has been 
conducted on these lesions and data in literature addresses largely haemangiomas, which in 
many instances are not the most challenging sub-category of CVMs. 
Although several theories regarding the causes of CVMs have been advanced over the 
years, their aetiology remains unknown. Amongst the most favoured theories is the concept of 
abnormal development of the vascular tree, which can take place at different developmental 
stages. The aim of this work is to study pathways of abnormal angiogenesis in CVMs and to 
explore the relationship with hypoxia and morphology of the lesion in an attempt to advance 
knowledge of aetiology of CVMs to facilitate better future therapy. 
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This introductory chapter describes classification of CVMs, which is the most controversial 
issue over these lesions. Furthermore, the epidemiology and risk factors for CVMs, the 
diagnosis, symptoms and treatment of CVMs are discussed. The existing aetio-pathogenetic 
concepts for CVMs and the background for this study are detailed. 
1.2 HISTORICAL ISSUES OVER CLASSIFICATION AND TERMINOLOGY OF CVMs 
One of the most complex issues about CVMs is the clinical, aetiological and 
pathological classification.  
The lack of standard, clear and simple classifications added to the confusion over the 
use of generic terms with respect to these lesions, in spite of extensive published work in the 
attempt to clarify this matter (Lee, 2004, Hand et al, 2002, Lee et al, 2007, Jackson et al, 1993, 
etc). This is the result of poor understanding of CVMs and profound lack of knowledge of the 
intrinsic mechanisms involved in the development and expansion of CVMs and often led and 
still leads to inappropriate diagnosis and management. (Mueller et al, 1999).  
Besides the confusion between CVM and haemangioma, or between the terminologies 
allocated to either lesion, there are supplementary misunderstandings resulting from the use of 
name-based eponyms such as Klippel-Trenaunay syndrome, Parkes-Weber syndrome, Proteus 
syndrome, Maffucci syndrome, Kasabach-Merritt syndrome, Sturge-Weber syndrome, etc, often 
using various names for same condition. To add even more to the complexity to the 
terminology, these eponymous syndromes represent in most cases complex combined vascular 
malformations. 
There has been a large spectrum of stages with many various classifications of vascular 
anomalies and especially of their most commonly encountered sub-category, haemangiomas (or 
vascular birthmarks or nevi) being elaborated over many decades. These classification systems 
reflect the understanding of the disease process at the time and were based on a mixture of 
clinical appearance of the lesions, extent, anatomical location, embryology, dynamics of growth, 
histopathological features, maturity of endothelium, natural history and other features. Most 
proposed classification systems proved extensive and too complicated to be widely accepted 
and used. From failure to initially differentiate between different vascular anomalies, the 
classification systems gradually developed into accepted classifications of CVMs and improved 
terminology. Some of the crucial turning points are overviewed below. 
1.3 EVOLUTION OF CLASSIFICATION OF CVMs 
Details of CVM classification issues over many years are given in the Appendix section. 
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1.4 CONTEMPORARY ACCEPTED CLASSIFICATIONS OF CVMs 
Overwhelmed with many classification systems, it is undoubtedly clear that none of 
them provide all the information required by the specialist to safely formulate an appropriate 
diagnosis in every situation and proceed with the best management plan. From all this extensive 
information it is important to retain that the Hamburg classification (see Appendix) is now 
generally accepted as the standard classification for CVMs.  
In addition, the current classification from the ISSVA (International Society for the 
study of Vascular Anomalies) (see Appendix) is benefiting from increasing general acceptance. 
Many clinicians still find the simplest, easiest to use and most useful classifications of vascular 
anomalies are those dividing them based on proliferative or static features into haemangiomas 
and vascular malformations and those separating them based on haemodynamics into high and 
low flow. The distinction of a vascular anomaly as a tumour or a malformation has proven 
clinically useful. However, the uncertainty in clinical application of CVMs classification 
systems continues as many authors do not adhere to any of these classifications, so the medical 
literature is abundant in reports of ‘haemagiomas’ that are actually vascular malformations or a 
combination of vascular anomalies. 
Vascular malformations and especially venous malformations and AVMs represent the 
main focus of this study. Over the next chapters reference will be mostly made to these lesions 
as well as to haemangiomas, from which they could still be difficult to distinguish on occasions.  
1.5 EPIDEMIOLOGY OF CVMs 
It is common that patients with vascular anomalies have seen a number of physicians 
before they can have a realistic answer to their problem. Often physicians are puzzled when 
confronting the magnitude of problems patients with vascular anomalies pose, commonly 
because of lack of comprehensive experience in this domain. This is because a variety of 
specialists are usually involved in the study and diagnosis of these lesions and explains why 
multidisciplinary centres dedicated to the management of these lesions have been established. 
Although such centres exist all over the world, especially in the United States, there is currently 
no such centre in the UK as yet.  
An inquiry was made to the Health Episode Statistics in the UK with respect to patients 
with vascular anomalies admitted to hospitals, proportion of patients undergoing surgery, 
interventional radiology procedures or conservative treatment, treatment of complications such 
as ulcers within hospitals or community, outpatient visits, health care expenditure and disability 
costs for patients with vascular anomalies but no clear records were obtained, most likely due to 
mislabelling of these lesions. 
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1.5.1 Incidence, prevalence and demographic data of CVMs 
There is no current published data regarding the incidence and prevalence of vascular 
anomalies or any of their sub-categories in the UK. Vascular anomalies are very common skin 
disorders and they are estimated to occur in up to 5% of newborns (Hohenleutner et al, 2007). It 
has been reported that in the United States, 40,000 children are born with vascular anomalies 
every year (Astner, 2005). It is however important to differentiate the proliferating vascular 
lesions from permanent malformations. 
It is estimated that haemangioma, the most common benign soft tissue tumour of 
childhood occurs in 1-3% of newborns and may be identified in 10-12% of Caucasian infants 
(Fishman et al, 1993, Takahashi et al, 1994, Esterly, 1995, Drolet et al, 1999, Lee et al, 2007). 
The prevalence of haemangiomas is estimated at 120 per 1,000 children. Approximately 30-
50% are present at birth but become obvious during the first weeks of life, usually between the 
first and second weeks of life (Finn et al, 1983, Esterly et al, 1996). The median age for the 
appearance of most cutaneous haemangiomas is two weeks after birth (Mulliken et al, 2000). 
Female to male infants’ ratio is 3.5:1 but the reason for this gender discrepancy has not been 
established. The sex ratio in preterm infants was 1:1.4 (Amir et al, 1986). Few comments have 
been made on the gender predominance and suggestions were made that complications and 
especially ulcerated lesions occur mostly in girls (Vittori at al, 1977, Bowers et al, 1960, 
Mulliken et al, 1988). The incidence of haemangiomas has been reported to increase to 20% in 
premature neonates (Amir et al, 1986), in infants whose mothers had chorionic villus sampling 
(10 times higher) (Powell, West et al, 1987, Burton, Schulz et al 1995) and in twins.  They 
occur in all races but appear less frequently in Africans and Asians (0.8-1.4%). They are usually 
solitary but multiple lesions have been reported in 20% of affected individuals (Jackson et al, 
1993, Blei et al, 1998). Although many authors reported haemangiomas to occur more 
frequently in prematures (Garzon et al, 2006, Finn et al, 1983, Moroz, 1983), other authors 
found equal frequency in premature and full-term infants (Holmdahl, 1955, Jacobs, 1957). 
Between 15% and 30% of infants have more than one haemangioma (Margilath et al, 1965, 
Moroz, 1983). The majority of haemangiomas occur in the head and neck region (60%), 
followed by the trunk (25%) and the extremities 15%) (Finn et al, 1983, Wananukul, 2002). In 
other series, no anatomical preference for site has been noted (Pratt, 1976, Margilth et al, 1965, 
Simpson, 1959). Superficial haemangiomas have been found to be the most common, 
representing 50-60% of all haemangiomas. The figure quoted in the literature for lesions with 
both a superficial and a deep component is 25-35% and 15% for deep haemangiomas. Visceral 
haemangiomas are known to be uncommon, but the accuracy of this presumption is 
questionable because asymptomatic lesions may go undetected (Mulliken et al, 2000). They do 
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not occur in adolescents or adults (Vikkula et al, 1998). Haemangiomas are not an inheritable 
condition but a family history has been reported in 10% of patients (Margilth, 1965, Moroz, 
1983, Finn et al, 1983), possibly because they are common lesions. Although they are 
considered sporadic, involvement of autosomal dominant mechanisms have been reported (Blei 
et al, 1998). It has been estimated that 10% of patients have affected family members and is 
suspected that this figure may be even higher. In contrast, other authors (Cheung et al, 1997) 
compared the concordance of haemangioma in monozygotic and dizygotic twins and identified 
no evidence of a strong predisposing inherited component. 
Vascular malformations are usually present at birth (Mulliken et al, 1982 and Fishman 
et al, 1993) but they are not always obvious. 
They are less common than haemangiomas but with the variability within this 
classification it is hard to determine their incidence. The overall incidence of vascular 
malformations in the general population has been quoted at 1.2-1.5% (Tasnadi, 1993, Eifert et 
al, 2000).This is higher than other congenital malformations but lower than haemangiomas. 
Each of their categories could be localised or diffuse (Villavicencio, 2007). 
Venous malformations (VMs) are the most common referrals to centres for vascular 
anomalies, representing up to 50% of patients (Vikkula et al, 1998). It has been reported that 
venous malformations account for two thirds of all vascular malformations (Simon et al, 2006). 
Predominantly venous congenital malformations are quoted at 70% (Mulliken, 2000, Eifert, 
2000). Other authors indicated that VMs may exist in about 30-50% of the population although 
they may not be recognised due to their deep location. 15-20% of venous malformations are 
believed to be mixed lesions (Lee et al, 2002, Lee et al, 2005).  
Arterial malformations are usually diagnosed in infancy or childhood (Fishman and 
Mulliken, 1993). Intra-cranial AVMs are more common than extra-cranial AVMs in the head 
and neck region, but they do not represent the area of interest of this study. Peripheral AVMs 
are most frequent in the head and neck, followed by limbs, trunk and viscera. They are usually 
noted at birth (40%) but often ignored due to their initial harmless appearance. There is no 
predominance by gender (Enjolras et al, 2000). 
Capillary malformations (‘port-wine stain’) are typically noted at birth but they are less 
common, with reports of 0.3% infants identified (Jacobs et al, 1976). 
Approximately 75% of lymphatic malformations occur in the neck and 25% in axilla, 
but less commonly other areas may be affected. They occur early in childhood and it is 
estimated that 65% are present at birth, 80% become obvious within the first year of life 
(Mueller et al, 1999) and 90% will be diagnosed by the age of two years (Brown et al, 1998). 
Occasionally they appear in adolescence or adulthood. 
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The combined vascular malformations seem to be sporadic and they are often located 
on extremities and often only one side is affected. Affected individuals often present bone 
and/or cartilage abnormalities or overgrowth (Vikkula et al, 1998). 
1.5.2 Risk factors, triggers and exacerbating factors for CVMs 
Historical perspective 
In 1970s, the concepts around congenital malformations, including the vascular 
anomalies were influenced by superstition and speculation. Kaplan in a review of hamartomas 
(from Greek, ‘hamartia’, ‘to sin’- defined as a developmental defect) published in 1977 gave an 
example of a child born with a giant birthmark and concluded that it was dangerous for a 
woman to look at monkeys during her pregnancy.  
Various authors attributed congenital malformations either to teratology, genetic 
factors, chromosomal changes, maternal risk factors such as viral, metabolic, nutritional, or 
drugs (Warkany, 1971). These opinions remained hypotheses and stimulated the research in 
these domains.  
As CVMs are not a single disease, but comprise many specific diagnoses, each of them 
may be distinct in risk factors. There are currently no known risk factors associated with 
development of either vascular malformations or haemangiomas. 
There is a general consensus resulting from observational studies over many years that 
haemangiomas are associated with female gender, light skin types, head and neck location, 
premature infants, especially those weighing less than 1500g (Amir et al, 1986, Pratt, 1955, 
Powell et al, 1987, Chiller et al, 2002). Birthmarks and specifically haemangiomas were 
reported in a study as having a higher incidence in children with parents exposed to pesticides in 
the floriculture industry (Munoz et al, 1990). 
Few prospective studies (Roganovic et al, 2002, Mertens et al, 1998, Johnson et al, 
2006) reported an association between childhood malignancy and birthmarks. In one study 
(Johnson et al, 2006) children diagnosed with cancer had a three-fold higher risk of presenting a 
birthmark comparing to those without cancer. Due to the small number of cases with birthmarks 
within these studies, it was not possible to determine whether any specific vascular anomaly 
was more commonly associated with specific malignancies or to determine associations of 
birthmarks with other confounder factors such as gender. It was notable that no genetic 
syndromes known to be associated with childhood malignancies were recorded in subjects with 
vascular anomalies (Johnson et al, 2006). 
Trauma, surgery, infection, physiological hormonal changes (puberty, pregnancy) or 
hormonal therapy, have been consistently reported to activate vascular malformations and 
especially arteriovenous malformations from ‘dormancy’, representing an asymptomatic status 
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to symptomatic lesions. The relationship between these potential precipitating factors and 
vascular malformations is unclear (Rosen et al, 2000) and they remain hypothetical, as vascular 
malformations may become active in the absence of any obvious precipitating factor. 
1.6 DIAGNOSIS, SYMPTOMS, EXAMINATIONS AND NATURAL HISTORY OF CVMs 
Only the lesions representing the object of this study, vascular malformations with 
emphasis on venous malformation and arteriovenous malformations will be presented from now 
on and no attempt will be made to elaborate on all cutaneous vascular malformations or vascular 
syndromes as they represent a vast subject. Lymphatic malformation represents a different 
entity that is not represented in this study.  However, reference will be made to haemangiomas 
as they are the main lesions to differentiate from vascular malformations. 
1.6.1 Symptoms, clinical signs, triggers and exacerbating factors 
Haemangiomas 
Haemangiomas vary considerably in their clinical features depending on their size, 
depth, stage of evolution or location. Most lesions are asymptomatic but pain may be a feature 
for some lesions.  
Infantile heamangiomas are present at birth and may be represented by a variety of 
precursor lesions, which gradually develop during the first weeks of life (Hidano, 1972). They 
typically appear like a barely visible spot, or a small reddish macule that develops thread-like 
teleangiectases or appearance of ‘cherry’ vascular tufts that may grow quickly to become raised 
and lobulated lesions (Gampper et al, 2002). The precursor lesions may be a flat, erythematous 
patch that resembles a bruise or a cluster of small erythematous papules, with or without a pale 
halo. Those evolving into a deep haemangioma may be blue or purple in colour. Rarely, a 
superficial ulceration may be the first sign of a haemangioma. 
The congenital haemangioma represent a tumour that is fully developed at birth and 
does not exhibit the natural course of infantile haemangioma. These lesions are bright red, 
elevated, lobulated nodules or plaques that feel rubbery and fade on applying pressure.  
Haemangiomas have sizes varying from few millimetres to greater than 20 centimetres 
in diameter but most haemangiomas reach a maximum size of 0.5-5cm.  Few venous tributaries 
are found at the periphery of the lesion, commonly. Most haemangiomas remain well 
circumscribed but rarely, they may be segmental. Deep haemangiomas, located in the deep 
dermis and subcutaneous tissue may have normal overlying skin or can appear purple-blue, 
poorly circumscribed and compressible. The overlying skin may present dilated veins or small 
teleangiectasias as a landmark. Their consistency is firm, rubbery, tense, and expands with 
increased intravascular pressure such as crying, activity or dependency of the affected part 
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(Esterly, 1996). These lesions may be warm on palpation. Tenderness on palpation is a variable 
and uncommon feature. 
Many haemangiomas consist of both a superficial and a deep component. Ulceration 
occurs in 5-10% of haemangiomas, especially the mixed superficial and deep lesions. Secondary 
infection is common but cellulitis, abscess formation and bacteremia are rarely reported. 
Intermittent bleeding is common but major haemorrhage is exceptional. 
Those lesions resulting in complications such as infection or ulceration may exhibit 
additional symptoms according to the area involved and extent of the lesion. Visual obstruction, 
amblyopia and strabismus can occur when a haemangioma involves the eyelids or periorbital 
tissues. Airway obstruction is a rare complication of haemangiomas affecting upper lips, 
cervical parapharyngeal or palatal regions. 
Diffuse neonatal haemangiomatosis is a potentially life-threatening condition 
characterized by numerous cutaneous haemangiomas which coexist with visceral 
haemangiomas. 
Cosmetic impairment or disfigurement is an additional complaint of the affected 
individuals, again depending on the lesion location and extent.  
The appearance of haemangiomas may deviate from their classical presentation during 
various phases in their evolution and their alternative clinical features are presented in the 
natural history section. 
Vascular malformations 
Venous anomalies are present at birth but they are not always evident. They are slow-
flow (or low flow, or LF – see appendix to introduction) type of vascular malformation and 
appear like compressible subcutaneous masses with a bluish discoloration of the overlying skin. 
Most venous malformations are asymptomatic but they may become painful in association with 
their enlargement and pressure on surrounding structures. Venous malformations of the head 
and neck are usually unilateral and cause facial asymmetry and progressive distortion of the 
features. Intra-orbital venous malformations can result in exophthalmia. Pharyngeal, laryngeal 
or cervical-oropharyngeal venous malformations can cause airway obstruction and sleep apnea. 
Venous malformations affecting an extremity can involve the skin only or can extend into the 
muscles, joints and bone and may lead to leg-length discrepancy. Intraosseous venous 
malformations can cause pathological fractures.  
Hyperhydrosis over the lesion is common. Stagnation of blood within venous malformations 
causes localised coagulopathy and patients may experience recurrent episodes of 
thrombophlebitis with associated pain. 
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The majority of venous malformations are isolated but they can occur as part of known 
clinical syndromes such as Maffucci syndrome or blue bleb nevus syndrome. 
VMs present like blue or purple nodules affecting the skin, with prominent surrounding veins 
and calcified phleboliths (Requena et al, 1997).  
Arteriovenous malformations are usually noted at birth but given little importance due 
to their innocent appearance and may be mis-diagnosed for capillary malformations or 
haemangiomas. They vary in clinical presentation from asymptomatic spots, a macular rash to 
erythematous plaques or variable size pulsating nodules or masses with an audible bruit and 
throbbing pain. Physical examination is usually adequate to separate arteriovenous 
malformations from venous malformations as the presence of a thrill, bruit, or pulsation 
indicates the presence of an arterial component within the vascular anomaly. Large AVMs 
causing an increased cardiac output may demonstrate reflex bradycardia after compressing the 
lesion (Branham’s sign) which is another clinical sign that is not associated with a purely 
venous malformation (Enzinger, 1988). The increased flow and pressure in the draining veins 
may result in varicosities. Shunting of blood diminishes nutritive flow and this may result in 
skin necrosis, ulceration or bleeding. Of all CVMs, they may be associated with bone alteration 
and may lead to hyperdynamic circulation and congestive heart failure. Lower extremities 
affected with AVMs may be complicated by pelvic tilting and scoliosis due to leg length 
discrepancy. Haemangiomas rarely affect bone, whereas vascular malformations are reported to 
affect bone in 35% of cases (Mulliken et al, 1986). 
1.6.2 Natural history 
Limited knowledge regarding the natural history and biological behaviour of vascular 
anomalies is available. The best description is attributed to Mulliken and Glowacki in their 
biological classification of vascular anaomalies. Rapid growth during the first four weeks is the 
historical hallmark of haemangiomas. Most haemangiomas undergo a proliferative and an 
involutional phase with an intermediate phase of inactivity. These are followed by the involuted 
phase. The length of each phase varies, but generally the proliferative phase lasts for weeks to 
months. As the lesion grows, it becomes elevated and lobulated with tumoral appearance. 
Superficial haemangiomas rarely continue to grow beyond the age of 10 months but deep 
haemangiomas may continu to enlage slowly for few more months. The proliferative phase may 
be associated with superficial ulceration in about 10% of cases, with larger haemangiomas 
ulcerating more frequently (Esterly, 1996). Ulceration leads to scarring and there is no evidence 
that this would result in more rapid regression. After the proliferative phase, haemangiomas 
may remain quiescent for a period or may begin to involute. 
Chapter 1 – Introduction 
 35 
The involuting phase usually begins at the end of the first year or during the second year 
of life, but variations are reported. Usually the lesion loses its red colour but whilst some lesions 
may become darker, others lighten and blanch. The lesion becomes softer and flatter, decreasing 
in size. The haemangioma shrinks from the centre of the lesion but this is less obvious with 
deep lesions. Some lesions, such as lip lesions are most likely to persist or involute only 
partially. The time of onset and rapidity of involution of a lesion varies considerably and cannot 
be predicted. Most published series report 50-65% involution by 5 years of age, 75% by 7 years 
of age, and up to 90% by 9 years of age (Margilath, 1965, Esterly, 1996). On occasions the 
involution process takes longer. Nearly normal skin is restored in approximately 50% of 
children. (Connors et al, 2005). 10-20% of patients reach the involuted phase with residual skin 
changes such as redundant skin, scars, hypo-pigmentation, dilated veins or teleangiectasia. This 
is more common for lip, nose, eyelid or ear lesions. 
Although haemangiomas cause significant distress for parents and possibly for children, 
most of them are benign conditions and do not require invasive diagnostic tests or treatment. 
The natural history of vascular malformations is distinct from haemangiomas. Most 
vascular malformations have a slow, steady enlargement. They do not possess the potential for 
independent growth, but progressive vascular dilatation usually occurs (Meyer et al, 1991, 
Mulliken et al, 1982, Rao et al, 1992). They get progressively worse with time or persist 
lifelong, unchanged and sometimes undetected, but never involute spontaneously. They can 
manifest at any time during life. Venous malformations expand slowly and often enlarge during 
puberty. They can manifest as pain as a result of vessel dilatation, bleeding, haematoma, 
haemarthrosis, pathologic fracture, soft tissue over-growth, thrombosis, thrombophlebitis, low-
grade disseminated intravascular coagulation. Usually they are non-lethal in comparison with 
the arteriovenous malformations, which can be limb or life-threatening (Lee et al, 2007). The 
potential of these lesions to recur represents a significant problem for those diffusely infiltrating 
malformations categorised as ‘extratruncular’ and this matter should be given serious 
consideration, balancing risks and benefits, when treating these lesions. 
The clinical history of AVMs varies considerable. They may remain dormant for years 
before becoming symptomatic. Many lesions are silent or have minimal clinical or cosmetic 
symptoms but others have severe associated conditions such as varicosities, superficial 
phlebitis, venous stasis ulcers due to venous hypertension, pain, pressure from mass effect, 
haemorrhage and ischaemic complications. Pelvic AVMs can lead to severe pain, pelvic 
congestion, sexual dysfunction, high-output cardiac failure and haemorrhage. Extremity lesions 
in children may cause leg length discrepancy, disfiguring bone or soft tissues overgrowth if left 
Chapter 1 – Introduction 
 36 
un-treated (Zhou et al, 2005, Mulliken et al, 1982, Abdool-Carrim et al, 1990). The natural 
history of progressive lesions is best given by Schobinger staging (appendix to introduction). 
Expansion of the arterio-venous channels within AVMs occurs as a result of increased 
blood flow through collateralisation and recruitment of adjacent vessels and not due to 
proliferation of cells (Takahashi et al, 1994). Ischaemia may lead to the proliferation of the 
lesion as it was noted following ligation of the proximal feeding vessels (Coleman, 1973). 
Arteriovenous malformations may have aggressive growth patterns resulting in 
functional or cosmetic deformity or in cardiovascular compromise. Unfortunately, venous 
malformations and arteriovenous malformations are mostly incurable (Lee, 2002). Szilagyi et al 
in 1976 also indicated that it would be inaccurate to claim a ‘cure’ for most vascular 
malformations. It is estimated that eradication can be performed safely in about 15% of lesions 
(Riles et al, 2006). There is virtually no data in literature quantifying the natural history of 
peripheral vascular malformations but there are figures reported for arteriovenous 
malformations of the brain. This indicates that the natural history of an un-ruptured AVM has a 
1-2% bleeding rate and once ruptured a 2-4% annual risk of re-bleeding as well as an associated 
mortality risk of up to 1% per year (Mattle et al, 2000). 
Rapidly involuting congenital haemangioma (RICH) and non-involuting congenital 
haemangioma (NICH) 
Two rare distinctive haemangiomas have been defined separately from the infantile 
haemangioma. They have similar clinical appearance and some histological similarities but 
different natural history. Boon et al first described in 1996 a separate entity of haemangioma 
that can proliferate in utero and manifest as fully developed tumours at birth. These 
haemangiomas are further described in literature (Berenguer et al, 2003) as rapidly involuting 
congenital haemangioma (RICH). These are usually large vascular tumours fully developed at 
birth and unlike the common infantile haemangiomas they fail to further grow postnatal. They 
instead regress, usually by 1 year. 
Another type of congenital haemangioma was described by Enjolras et al in 2001 and 
named non-involuting congenital haemangioma (NICH). This lesion occurs in utero, has no sex 
prevalence and it is known to grow with the patient, does not involute, persists or expands 
slightly. It was noted that biopsy or partial excision of NICH did not lead to recurrence or 
expansion, as reported to be seen after the incomplete excision of arterio-venous malformations. 
There are very few reports in the literature of spontaneous disappearance of congenital 
arteriovenous malformations affecting the renal tract (Kubota et al, 2003). Spontaneous 
disappearance of cerebral and dural arteriovenous malformations has been reported in about 30 
cases. The natural history of these lesions is unknown but few hypotheses trying to explain their 
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regression have been put forward. All had as end-point mechanism thrombosis in the vessels 
comprising the lesion. This may be caused by compression due to haemorrhage and haematoma 
formation, vasospasm and oedema causing reduction of blood flow or increased blood 
turbulence with alteration in flow dynamics. It has also been suggested that the vessels within a 
vascular malformation may become thrombosed more easily than normal vessels and the flow 
velocity and direction are not constant. They may easily change according to the pressure 
balance in the nidus, which in turn may be influenced by various physical or chemical factors. 
1.6.3 GLUT-1 – immunohistochemical marker for haemangiomas 
Positive endothelial cell (EC) staining with GLUT-1, the erythrocyte-type glucose 
transporter protein, has been noted during all growth phases of congenital haemangiomas (North 
et al, 2000). GLUT-1 is a high affinity glucose transporter protein and may facilitate cell 
growth. Its high expression in proliferating haemangiomas may explain this role. The 
persistence of high GLUT-1 expression in late-involuting haemangiomas suggests that this is 
not just an adaptation to the increased demand of the lesion during its proliferative phase.  
GLUT-1 appears to be a reliable and highly specific immunohistochemical marker to juvenile 
haemangiomas and previous reports indicate that it does not occur in vascular malformations. 
GLUT-1 expression was shown to be independent of the mitotic activity of the lesion (North et 
al, 2000). It is highly expressed by ECs during early foetal development but this feature is lost 
as the cells differentiate. As the foetus develops, GLUT-1 expression disappears from most 
micro-vessels but persists in most areas of the brain and in other locations with blood-tissue 
barrier function.  
This marker is a useful diagnostic tool in differentiating late-phase involuting 
haemangiomas and vascular malformations of similar morphology. Why the ECs of infantile 
haemangiomas maintain GLUT-1 expression and what is the origin of the ECs comprising these 
lesions remains unknown. RICH and NICH demonstrate lack of immunoreactivity to GLUT-1, 
suggesting that these lesions are different from the haemagioma of infancy. The following 
pictures are examples of GLUT-1 immunopositivity. 
                        a)    b) 
 Figure 1. 1. Positive GLUT-1 expression in RBCs in a) glomus tumour; b) haemangioma (stained 
brown) 
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1.6.4. Investigations 
Details of tests required to confirm diagnosis and plan treatment of CVMs are given in the 
appendix section. 
1.7 TREATMENT OF CVMs 
The variety of treatment modalities available for CVMs at present are detailed in the Appendix 
section. 
1.8 THEORIES AROUND AETIO-PATHOGENESIS OF CVMs 
1.8.1. Blood vessel development - vasculogenesis and angiogenesis 
The vascular system is built by two processes, vasculogenesis and angiogenesis. During 
vasculogenesis in humans, a primitive vascular plexus is established from endothelial precursors 
(Breugem, 2001) and the primary circulation is established by the end of the third week of 
development. The angiogenesis represents the formation of new vessels from these pre-existing 
vessels by migration and proliferation of ECs (Brugem, 2001, Isner et al, 1999). This is a 
multistep process involving both the endothelium and the extracellular matrix. 
The development of a functioning vascular network requires a perfect degree of 
coordination between different cell types undergoing complex changes, and is essentially 
dependent upon signals exchanged between these cell types. Vasculogenesis is largely restricted 
to early embryogenesis, whereas angiogenesis occurs during embryogenesis and in the postnatal 
state. The development of new blood vessels is an uncommon physiological event in adults. In 
the normal adult the turnover of ECs is very low, in humans in the order of years (Denekamp, 
1984). The cardiovascular system is the first organ system that forms during embryonic 
development. The embryonic vascular system develops during the third week of foetal life from 
mesodermal cells of the ‘blood islands’ forming the primary capillary network.  ECs originate 
from an embryonic mesoderm during the initial phase of the vascular development. Although 
initially located in the region of the yolk sac, these cells eventually populate the mesenchyme 
throughout the foetus; the peripheral cells of the islands give rise to endothelial tubes, and the 
central cells give rise to the haematopoietic elements. The first step in the formation of blood 
vessels is the emergence of the inner lining cells, the ECs. It has recently become evident that 
the primary capillary plexus is made of at least two distinct types of ECs: arterial and venous 
ECs. An arterial EC type is characterised by its specific expression of Ephrin-B2 and a venous 
type expresses specifically EphB4 (Gerety et al, 1999, Wang et al, 1998). These cells then 
associate into tubular structures and other cells types (smooth muscle cells and pericytes), 
organise themselves around them to make the vessel wall. Structural specialisations such as 
tight junctions or regionalised adhesion molecules are acquired by differentiating EC. Further 
changes in size and mural structure lead to the formation of arteries, capillaries, veins and 
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lymphatics, each with their own characteristics. Vasculogenesis and angiogenesis are the result 
of a series of genetic events that depend on the orderly expression of at least two sets of 
tyrosine-kinase receptors, one set largely influencing endothelial differentiation and 
proliferation and the other governing vascular wall formation and vascular bed morphogenesis 
(Cines etal, 1998).  Initial events in vasculogenesis are dependent on fibroblast growth factor 
(FGF) and vascular endothelial growth factors A and B (VEGF A and B). Under their influence, 
ECs differentiate from mesoderm of the blood islands, proliferate, and migrate. The pattern of 
endothelial differentiation is further determined by VEGF C, the receptor to which (VEGFR-3) 
is expressed on ECs destined to become veins and lymphatics (Cines et al, 1998). Continued 
growth of ECs and modelling of vascular walls is dependent on the expression of an additional 
set of thyrosine-kinase receptors, Tie-1 and Tie-2. The biding of Tie-2 by its ligand, 
angiopoietin 1, plays a critical role in the induction of components of the vessel wall, as 
mutations in the genes for either result in defective vessels with poorly formed muscle walls and 
micro-aneurysms. In contrast to formation of blood vessels in the embryo, new vessel formation 
in the postnatal state occurs largely as a result of micro-vessel formation from differentiated 
ECs. Angiogenesis is governed by a complex interaction of pro-angiogenic and anti- angiogenic 
factors
 
which are under tight control so that there is little, if any, increase in vessels number in 
the normal state
 
(Cines et al, 1998, Johnson, 1976). However, in response to stimuli such as 
tissue injury or hypoxia, this balance is perturbed and angiogenesis occurs. These substances 
therefore serve as ‘signals’ that influence growth, migration, and the permeability of ECs. 
During angiogenesis ECs acquire protease, which permits them to digest basal lamina and move 
in the direction of the signal. Foremost among the signalling substances are VEGF and FGF. 
Once separated from the parent vessel, ECs acquire small vacuoles or primitive lumens, which 
fuse with lumens of adjacent endothelium to form capillary channels. Although the mechanism 
by which these signals are processed by the ECs is still the subject of intense inquiry, it appears 
that endothelial junctions (adherens junctions) play a pivotal role
 
(Dejana, 1997). This 
specialised apparatus, consisting of a trans-membrane protein VE (vascular endothelial) 
cadherin bound in its intracellular domain to VE cadherins of adjacent cells, localises or traps 
extra-cellular signalling molecules. The extra-cellular signals, in turn, alter the cadherin-catenin 
complex, thereby modifying the confluence and permeability of the EC. The cadherin-catenin 
complex is also involved in intracellular signalling from the cytoplasm to the nucleus such as 
gene expression is affected. The primary capillary network is remodelled by regression, 
sprouting, splitting or fusion of pre-existing vessels and ECs differentiate into arterial and 
venous types (Yancopoulos et al, 1998). The stabilisation of the vascular network occurs when 
peri-ECs and pericytes are recruited to the vessel wall. They inhibit ECs proliferation and 
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migration by stimulating production of extracellular matrix and basement membrane formation 
(Ramsauer et al, 2002). Stabilisation of a blood vessel is a stage when remodelling has ceased, 
new branches are not developing and luminal size is constant (Folkman et al, 1996). 
To conclude, angiogenesis can be defined as a multi-step complex process, which 
involves EC activation, increased blood vessel permeability, and local re-arrangement of the 
basal membrane and extra-cellular matrix. Faults in angiogenesis mechanisms appear to govern 
the pathology of vascular anomalies but the intimal deficiencies in the signalling pathways are 
still to be identified. Limited research data investigating angiogenesis pathways in CVMs is 
available and this is largely restricted to haemangiomas. 
1.8.2 The role of angiogenesis in development of CVMs 
Laboratory-based research in vascular anomalies lagged behind clinical studies, but the 
aetiology of CVMs is likely to represent a multifactorial process. With increased understanding 
of the mechanisms of angiogenesis, vascular anomalies are assumed to be the result of faulty 
angiogenesis. The hypothesis that tumour growth is angiogenesis-dependent was first proposed 
in 1971 by Folkman and subsequently proven by a variety of experiments including genetic 
methods. Little research has addressed this field. Woolard (1922) indicated that CVMs may 
represent focal persistence of primitive vascular elements but this has never been proven 
scientifically. Many theories have been advanced to explain pathogenesis of haemangiomas and 
the most accepted appear to involve increased angiogenesis (Johnson, 1976). These advances 
are not equalled by similar progress in research work related to vascular malformations (except 
cerebral AVMs and those associated with hereditary haemorrhagic teleangiectasia, which do not 
represent the focus of this work). Bastide et al (1990) concluded that the fundamental concepts 
of embryology and organogenesis allow a better understanding of the pathological 
characteristics of vascular malformations. He indicated that any cessation or disturbance in the 
development of the circulatory system will be the source of a vascular anomaly. The stage in 
which the changes occur will influence the type of the vascular lesion. 
Chiller et al in 2003 pointed out that vascular remodelling, which is part of angiogenesis 
focused on the interactions between pericytes and ECs, was demonstrated to be defective in 
some experimental models and in some familial cases of vascular malformations. 
Haemangiomas 
The pathogenesis of haemangioma is still not understood. There is evidence suggesting 
that pericytes and ECs play a key role (Chang et al, 1999). In this study the majority of mRNA 
for bFGF and VEGF, which were up-regulated, was localised in pericytes and ECs, the most 
abundant cell types in the haemangiomas studied.  
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Another theory is that incomplete maturation of the vessels in the embryo may result in 
vascular endothelial rests that proliferate after birth more rapidly than normal blood vessels. 
Although this is just a speculation, it could explain the increased incidence of haemangiomas in 
premature infants as the likelihood of immature autonomous rests would be greater in these 
infants than in full-term infants (Finn et al, 1983, Amir et al, 1986).  
Other studies have also demonstrated that haemangioma cells cultured in vitro behave 
more like foetal cells, exhibiting a spindle-shape rather than epitheloid morphology, lower 
levels of expression of platelet-EC adhesion molecule-1 and von Willebrand factor, and 
production of interstitial type I collagen rather than epithelium-specific type IV collagen 
(Dosanjh et al, 2000). 
The mechanisms that control the involution of haemangiomas are also poorly 
understood. Frischer et al, 2004, demonstrated that increased placental growth factor expression 
in haemangiomas is predictive of involution. 
Another hypothesis is that proliferation of ECs is a response to factors secreted by 
surrounding cells. Smoller and Apfelberg speculated that haemangiomas proliferated from a 
primitive, uncontrolled stem cell (Smoller et al, 2006). 
Another observation is that vessel growth in haemangiomas is associated with 
infiltration of mast cells, which have been found to stimulate migration of ECs, an important 
component of angiogenesis. Heparin released from mast cells has been shown to potentate this 
process (Folkman, 1986). Tan et al, 2004, suggested that mast cells may have a function in both 
the EC proliferation and the involution of haemangiomas. They also speculated that certain 
effectors elicited by mast cells may participate in the life cycle of haemangiomas.  
The presence of abnormal arteries in some patients with extensive haemangiomas has 
been attributed to developmental field defects that occur at approximately 8 to 10 weeks of 
gestational age (Kishnani et al, 1995, Opitz et al, 1992, Pascual-Castroviejo et al, 1996). 
Haemangiomas have been reported to be the result of an alteration in angiogenesis that allow 
the uncontrolled proliferation of vascular elements.  
A few authors have investigated the complex interplay of pro- and anti-angiogenic 
factors involved in normal and pathologic processes. (Folkman et al 1987, Klagsbrun et al 1991, 
Folkman et al 1997). The various stages of haemangiomas can be distinguished by different 
cellular markers (Takahashi, 1994) but the primary causative defect in haemangiogenesis 
remains unknown. Nguyen et al (2004) suggest that haemangioma may be a result of 
vasculogenesis (the formation of primitive blood vessels from in-situ mesenchymal precursor 
cells) rather than angiogenesis (the sprouting of capillaries from pre-existing vessels). Dadras et 
al (2004) established strong expression of lymphatic endothelial hyaluronan receptor-1 and 
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CD34 in haemangioma tissue during the proliferative phase and postulated a maturational arrest 
in the ECs of proliferating infantile haemangiomas.  
Kleinman et al (2003) demonstrated increased levels of circulating EC precursor cells in 
children with haemangiomas. Yu et al (2004) demonstrated the presence of EC precursor cells 
in proliferating haemangiomas and indicated that these cells contribute to the early growth of 
haemangioma. 
Vascular malformations 
Arteriovenous malformations have been reported to be the result of errors of vascular 
development between the 4
th
 and 6
th
 weeks of gestation, clearly distinct from haemangiomas 
(Takahashi, 1994). Most vascular malformations are sporadic (non-familial) but some may be 
inherited in an autosomal dominant pattern (e.g. hereditary haemorrhagic teleangiectasia, 
lymphatic anomalies, etc). Molecular studies indicate that vascular anomalies are caused by 
dysfunctional signalling processes that regulate proliferation and apoptosis, differentiation, 
maturation, and adhesion of vascular cells (Vikkula et al, 1998). Chiller et al (2001) indicated 
they are most likely caused by localised dysfunction in pathways regulating vascular 
embryogenesis, especially the molecular events responsible for vascular remodelling. Chiller et 
al (2003) pointed out that vascular remodelling, which is the part of angiogenesis that centres on 
the interactions between pericytes and ECs, has been shown to be defective in experimental 
models and in familial cases of vascular malformations.  
Vikkula et al (1998) emphasised that TGF-β signalling is important for the proper 
maintenance of capillaries. When this signalling pathway is altered, the capillary bed is dilated, 
allowing direct arteriovenous flow and the formation of AVM.  
The lack of a suitable animal model for the study of haemangiomas and vascular 
malformations limits clinically relevant research but in our present study we have undertaken 
experiments on human tissue obtained with ethical approval from individuals suffering with 
these conditions. 
1.8.3 Angiosomes theory 
Taylor et al (1987) introduced important anatomical concepts aiming to better 
understand vascular anatomy but also, to provide the basis for explaining certain pathological 
processes. They introduced the term of ‘angiosomes’ and explained that the body is a three-
dimensional jigsaw made up of composite blocks of tissue (’angiosomes’) supplied by named 
source arteries. This concept is important in understanding the management of CVMs and more 
details are given in the Appendix section.  
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1.8.4 The genetic theories 
Wang (2005) stated that genetic factors play a critical role in the pathogenesis of 
vascular anomalies. Further details are provided in the Appendix section. 
1.9 HISTOLOGICAL MORPHOLOGY OF CONGENITAL VASCULAR 
MALFORMATIONS 
1.9.1 Haemangiomas 
There are few recognised histologic features specific to haemangiomas or vascular 
malformations and thus, these two entities are often difficult to distinguish using routine 
histology. Some lesions have features applicable to both categories, which imply that present 
classifications may not reflect the in vivo situation and they are clinically less than satisfactory.  
Proliferative haemangiomas represent complex networks of ECs (Mulliken et al, 1982). 
Chang et al (1999) found that haemangiomas were composed of a heterogenous population of 
cells with a predominance of vascular elements, ECs and pericytes. Routine histopathology of 
these lesions varies according to the stage of the haemangioma. In early stages they are 
characterised by non-encapsulated masses and dense cords of mitotically active, plump ECs in 
close association with pericytes. The basement membranes are well-developed around primitive 
vessels. The histological basis of the rapid expansion of haemangiomas is the uncontrolled EC 
proliferation. As the haemangioma proliferates, the vascular lumen enlarges. As involution 
progresses, the ECs continue to mature and gain a flatter appearance. The vascular lumen 
continues to enlarge until few, mature ectatic vessels remain. The proliferating endothelial mass 
is replaced with fibro-fatty tissue. Various degrees of epidermal atrophy, scar tissue and loss of 
elastic tissue can be seen in late involuting lesions (Antaya, 2006). In a pathomorphological 
analysis of 310 CVMs, Leo (1990) found that haemangiomas of small vessels of the arterial and 
venous type are most of the time accompanied by arterio-venous (a-v) microshunts but 
haemangiomas involving only capillaries do not contain a-v microshunts. Haemangiomas in 
connection with vascular malformations are malformations and not tumours. They have no 
proliferative tendency and usually do not undergo malignant transformation (Leu, 1990). 
One of the most interesting findings on histological examination of these lesions was 
the presence of stromal mast cells and macrophages in some of these lesions. Studies 
quantitating mast cells in haemangiomas are scanty and not uniform. Increased numbers of mast 
cells found in haemangiomas have not been clearly linked to their pathogenesis (Glowaki et al, 
1982). Details of presence and possible role of these cells in haemangiomas are given in the 
next sub-chapter. 
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1.9.2 Vascular malformations 
The exact histological morphology of vascular malformations and any derived clinical 
relevance is unclear. Time, intensity and duration of the aetiologic factors determine the size of 
the vessels involved and the severity of the alteration (Leu, 1990). AVMs are not recognised as 
neoplasms but they are locally aggressive. Limited data available in relation to the 
histopathology of AVMs suggest they are extremely complex containing multiple lacunae septa, 
diverticula, labyrinths and polypoid structures as well as thickening of the intima. Large vessel 
malformations are often accompanied by a-v macroshunts. They connect well-differentiated 
arteries and veins or dysplastic arteries and veins, which have thick walls with enlarged 
muscular medial layers. The elastic membranes may be absent or rudimentary. Dysplastic veins 
appear ‘arterialised’ with a hypertrophic media musculature and hypertrophy of elastic 
membranes and fibres.  In later stage these veins undergo degeneration with atrophy of the wall, 
loss of elastic fibres, and replacement of the smooth muscles by collagen, ectasia or aneurysm 
formation. Arteries or veins of less typical structure are directly connected with no intermittent 
capillary vessels (Leo, 1990). The confluence point of the abnormal vessels in AVMs is 
clinically/radiologically called a ‘nidus’. Details of this are given in the next chapter. Formation 
of thrombus was frequently observed. The stroma between blood vessels may show fibrosis and 
calcification. Proliferation and leakage of capillaries as a consequence of raised intra-capillary 
pressure may be a feature (Pasyk, 1987).  
Previous authors indicated that the embryonic vascular system initially consists of 
interlacing blood spaces in the primitive mesenchyme. Further differentiation involves the 
development of primitive capillary network, followed by a ‘retiform stage’, when the primitive 
capillaries coalesce into large plexiform structures. Blood begins to flow through the retiform 
plexus from an ‘arterial’ to a ‘venous’ side. In the maturation phase, the primitive elements are 
replaced by mature vascular stems. AVMs are presumed to represent focal persistence of 
primitive vascular elements. Depending on the stage at which this failure occurs, the abnormal 
communication may range from just above capillary level to large vessel communications. Leu 
(1990) stated that the morphology of the vascular malformations appears simple amd 
monomorphous compared with the clinical issues on classification. He indicated an important 
difference was between malformations with and without a-v shunts because they were 
responsible for the haemodynamic consequences of the lesion.  
AVMs are still difficult to distinguish histologically from haemangiomas. The evidence for mast 
cells presence/absence in vascular lesions other than haemangiomas is absent or rather obscure 
and known data is discussed in the next sub-chapter. 
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1.9.3 ECs in CVMs 
Dysfunction of the EC is central to a number of pathologies, including the two major 
killers of the Western society (atherosclerosis and cancer) (Bicknell, 1996). Research work over 
recent years established that there is extensive endothelial heterogeneity. Details of EC and how 
are these related to CVM pathogenesis can be found in the Appendix section. 
1.10 ANGIOGENESIS IN CVMs 
Angiogenesis markers 
Folkman (1995) suggested that uncontrolled angiogenesis is the cause of haemangioma 
proliferation and that the increased endothelial proliferation may be the result of abnormal 
levels of angiogenic stimulators and inhibitors.  
Takahashi et al, in 1994 reported elevated levels of bFGF and VEGF in proliferative 
haemangiomas using immunohistochemistry. Chang et al (1999) also found elevated levels of 
VEGF and bFGF in proliferative specimens when compared to involuted or involuting 
specimens and concluded that haemangioma proliferation is the result of aberrant gene up-
regulation of these angiogenic growth factors, at least in part.  
1.10.1 Inflammatory cells in triggering angiogenesis 
The most studied and important inflammatory cells with roles in angiogenesis are mast 
cells and macrophages. 
Mast cells 
Mast cells have a variety of activities and their properties make them active in many 
biological responses. They were originally identified by Ehrlich who named them (Mast = well 
fed, or fattening in German) because of the specific granules. Their functions include 
phagocytosis and antigen processing, cytokine production, release of pre-formed (histamine, 
proteoglycans, proteases) or newly formed (leukotrienes, prostaglandins) mediators 
(Frangogiannis et al, 1998). Mast cells express an array of adhesion molecules and other surface 
receptors that allow them to interact with other cells or stimuli (Metcalfe et al, 1997). These 
characteristics allow mast cells to play an important role in angiogenesis, as well as other 
processes and conditions such as tissue remodelling, wound healing, chronic inflammatory 
conditions and allergies (Metcalfe et al, 1997, Gordon et al, 1990, Meininger et al, 1992, 
Schwartz et al, 1994). 
Mast cells develop from haematopoietic stem cells. They become mature in peripheral 
tissues where they reside and at this stage they are not found within the blood vessels 
(Wedemeyer et al, 2000). Mast cells are abundant in the skin, gastrointestinal and respiratory 
tracts. They are often found in close vicinity of blood vessels, nerve fibres, epithelial surfaces or 
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fibroblasts, all these structures representing possible targets for mast cell-derived mediators 
(Stead et al, 1987, Blair et al, 1997). 
Mast cells are known to produce histamine (White et al, 1987). Histamine exerts its 
biological activities through histamine-1, -2 and -3 receptors. Heparin and chondroitin sulphates 
are proteoglycans produced by mast cells. Heparin, which is present in large quantities in mast 
cells secretory granules, is thought to participate in angiogenesis (Taylor et al, 1982, Folkman 
eta la, 1983, Fraser et al, 1983) by stimulating the migration and proliferation of ECs. 
Carboxypeptidase A, chymase and tryptase are neutral proteases found in human mast cells 
secretory granules, all with important roles in angiogenesis (Serafin et al, 1987) Activated mast 
cells can produce lipid-derived mediators such as cyclo-oxygenase (prostaglandin D2), 
lipoxygenase (leukotrienes), arachidonic acid metabolites with important inflammatory 
activities (Li et al, 2000). Mast cells also secrete tumor necrosis factor (TNF-α), interleukin IL-
1α, IL-1β, IL-3, IL-4, IL-5, IL-6, IL-8, VEGF, transforming growth factor (TGF-β), basic 
fibroblast growth factor (bFGF), epithelial growth factor (EGF), platelet-derived growth factor 
(PDGF), monocyte chemoattractant protein-1 (MCP-1) (Church et al, 1997, Norrby et al, 1997). 
Human mast cells are structurally and functionally heterogeneous (Kitamura et al, 
1989). Irani et al in 1986 indicated that human mast cells have different neutral protease 
content, depending on their location. These proteases, which represent the majority of granule 
protein, are markers of different types of mast cells. Mucosal mast cells contain tryptase without 
chymase by contrast to connective tissue mast cells that contain both chymase and tryptase. 
Multiple factors are able to activate mast cells including cytokines (White et al, 1993, Taylor et 
al, 1995). The degranulation of the mast cells involves fusing of the membrane of the granules 
containing histamine with the cell membrane such as they become part of the cell membrane 
and their content dissolves and is secreted. The mast cell left behind is a viable degranulated or 
partially degranulated cell. Eady et al, 1979 found a significant correlation between the number 
of mast cells and number of blood vessels in the dermis. Rakusan et al, 1990 noted changes in 
the mast cell density during capillary proliferation, which may indicate a role of these cells in 
angiogenesis. The intimal mechanisms of mast cell involvement in angiogenesis are still 
unclear. Research work has concentrated on the production of angiogenic factors from mast 
cells (Levi-Schaffer et al, 2001). Activated mast cells can release pre-formed VEGF and they 
can sustain its release by continuing to secrete the protein (Boesiger et al, 1998). Mast cells also 
produce and secrete FGF, which has known angiogenic effects. Mast cells can produce IL-8 
(Moller et al, 1993, Lin et al, 2001), which has been shown to be a potent pro-angiogenic in 
studies related to tumour angiogenesis (Lin et al, 2001). TGF-β and TNF-α are involved in 
angiogenesis and both cytokines can be produced by mast cells (Church et al, 1997, Norrby, 
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1997). Heparin found in mast cells may be involved in angiogenesis by stimulating the 
migration and proliferation of ECs (Taylor et al, 1982, Folkman et al, 1983, Fraser et al, 1983, 
Thornton et al, 1983, Azizkhan et al, 1980). It has been shown that heparin can stimulate the 
induction of FGF (Thornton et al, 1983). Histamine and mast cell proteases such as tryptase and 
chymase may also be proangiogenic (Meininger et al, 1995, Muramatsu et al, 2000, Ribatti et al, 
2000). Mast cells also secrete type VIII collagen that may be involved in angiogenesis, given 
the evidence of its implication in the assembly of ECs (Ruger et al, 1994). Angiogenesis 
mediators such VEGF, FGF-2 and PDGF have been quoted as mast cell chemotactic factors 
(Gruber et al, 1995). Recent data indicates that human mast cells are a source and target of 
angiogenic factors and they might play a role in angiogenesis through the expression of several 
forms of VEGFs and their receptors (Detaroaki et al, 2009). The theories surrounding the 
presence and roles of mast cells in CVMs are discussed in the next sub-chapter, in relation to 
the histological morphology of CVMs. 
Macrophages 
Monocytes and macrophages were originally classified as cells belonging to the 
reticulo-endothelial system by Aschoff in 1924. Van Furth et al (1972) proposed the term of 
mononuclear phagocyte system for these cells. Macrophages originate in the bone marrow and 
they develop in stages, from stem cell, committed stem cell, monoblast, pro-monocyte, 
monocyte (bone marrow, then peripheral blood) and finally macrophages are reaching tissues. 
Within the process of migration of blood monocytes into tissues, to become macrophages, 
monocytes continue to differentiate to become multifunctional tissue macrophages, which do 
not re-enter the circulation. Monocytes are considered immature macrophages, although they 
may be fully functional for their location. Macrophages have been classified into normal and 
inflammatory macrophages. Normal macrophages are those found in connective tissues and the 
inflammatory macrophages are present in various exudates. It is well-known that macrophages 
are heterogeneous cells as their isolation from different anatomical sites has a diversity of 
phenotypes and properties. Because cell function is linked to the signals received from the cell 
microenvironment, the macrophage heterogeneity is said to be the results of the unique 
conditions within specific tissues. Macrophages are called ‘activated’ when they exhibit 
specifically increased functional activity. Within this category there were two classes with 
distinct phenotypes, identified by Stein et al, as classically activated macrophages (express Th1-
like phenotype) and alternatively activated macrophages ( express Th2-like phenotype). Both 
types express a wide range of plasma membrane receptors, suggestive of their interaction with 
other cells, extracellular ligants from plasma, extracellular matrix and microorganisms. 
Macrophages play an important role in pathogen recognition and clearance, removal of 
Chapter 1 – Introduction 
 48 
senescent cells. They have multiple biological functions, they are involved in the immune 
response, and they act as killer cells or regulatory cells of the inflammatory response. They also 
contribute to tissue re-organisation by secreting enzymes such as hyaluronisdase, elastase, 
collagenase, antiproteases and regulatory growth factors. Macrophages have the potential to 
potentate the remission of an inflammatory process by releasing TGF-β, PGE2, IL-10. One of 
their major roles is the induction and modulation of angiogenesis. They were shown for many 
years to be key players in the regulation of physiologic and pathologic angiogenesis (Polverini 
et al, 1977). Macrophages become angiogenic in conditions of low oxygen tension, in presence 
of lactate, pyruvate or hydrogen ions and they can be activated by cytokines such as IFN, GM-
CSF, PAF, or MCP. They respond to hypoxic conditions by up-regulation of hypoxia-inducible 
factors (HIFs). The cascade of subsequent events may lead to over-expression of VEGF by 
macrophages located in hypoxic areas, with its inherent pro-angiogenic properties (Burke et al, 
2001). Macrophages are found in hypoxic area in tumors (tumor associated macrophages – 
TAM) but also in ischaemic areas of wounds, atherosclerotic plaques or joints affected with 
rheumatoid arthritis. What is driving these cells to hypoxic locations is still unknown, although 
a few theories implicating chemokines and other chemoattractant factors such as monocyte 
chemotactic protein (MCP-1) have been launched. Macrophages are able to promote all stages 
of the angiogenic process by means of their own products, when they are specifically activated. 
Macrophages produce factors able to induce migration and differentiation of ECs. Two of the 
most important are human angiogenic factor (HAF) and angiotropin. Other factors produced by 
macrophages and capable of inducing proliferation in capillary endothelium are bFGF, TGF, 
GM-CSF, M-CSF, VEGF, IL-8, substance P. Whilst many angiogenic factors have been shown 
to be produced by macrophages, the way they coordinate the angiogenic response is not well 
understood. Macrophages also release factors that act indirectly by attracting or activating 
angiogenic cells as well as factors that inhibit migration or mitosis of ECs (monocyte-derived 
EC inhibitory factor – MECIF-, macrophage-derived EC inhibitor - MD-ECI -, thrombospodin 
I, IFN. Classically activated macrophages tend to promote inflammation, extracellular matrix 
(ECM) destruction, apoptosis, while alternatively activated macrophages promote ECM 
construction, cell proliferation and angiogenesis. Macrophages have the capacity to induce and 
then, down-regulate the formation of new capillary blood vessels.  The persistence of high 
numbers of macrophages in tumours is associated with on-going growth, neo-vascularisation 
and poor prognosis (Crowther et al, 2001). By contrast, tumours depleted of macrophages have 
a reduced capacity to induce neovascularisation. It is suspected that the prolonged or excessive 
neo-vascularisation in pathological states is the result of a combination of over-production of 
mediators of angiogenesis associated with a lack of naturally occurring inhibitors of 
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angiogenesis. It is becoming increasingly clear that genetic control may be responsible for 
regulating angiogenesis and that expression of macrophages angiogenic activity is under the 
negative control of a suppressor element (Rastinejad et al, 1989).Better understanding of the 
angiogenic activity of macrophages is necessary as this may have therapeutic implications in 
many conditions where angiogenesis is dis-regulated, including possibly CVMs. An account of 
current data available in respect to macrophages in CVMs is given in the next sub-chapter, 
where the histological morphology of CVMs is discussed. 
1.10.2 Cytokines and growth factors – their role in angiogenesis, classification and regulation 
Foremost among the signalling substances with roles in angiogenesis are VEGF and their 
receptors, FGF, angiopoietin-1 and their receptors. 
VEGF A/VEGF-R1 and VEGF family 
VEGF A, which is selective for vascular endothelium is one of the best known 
cytokines involved in vasculogenesis, physiological and pathological angiogenesis, and 
remodelling of primitive vascular networks. Knockout mice genetically engineered to be 
deficient in VEGF receptors die of abnormal angiogenesis (Carmeliet et al, 1996, Ferrara et al, 
1996).  
This is why most likely VEGF A is an essential pre-requisite to angiogenesis and is the main 
focus here, although the other members of family will be discussed. This is a member of a 
family of dimeric glycoproteins that belong to the platelet-derived growth factor (PDGF) family 
of growth factors. Other members of the family include VEGF B, VEGF C, VEGF D, VEGF E 
and placental growth factor (PlGF). VEGF A is the most studied and mediates its effects by 
interacting with two tyrosine kinase receptors VEGFR-1(FLT-1) and VEGFR-2 (KDR). 
Recently, a non-kinase recetor, neuropilin (NRP-1), which is less selectively expressed on 
vascular endothelium was found to potentiate VEGF A binding to VEGFR-2. Disruption of the 
gene for VEGFR-2 interferes with the differentiation of ECs, leading to the death of embryo at 
day 8.5-9.5 (Shalaby et al, 1995). Disruption of the gene for VEGFR-1 permits differentiation 
of ECs but interferes with a later stage of vasculogenesis, resulting in thin walled vessels with 
larger than normal diameter and death of embryo at day 9 (Fong et al, 1995).  
There are three VEGF receptors for the family of VEGF ligands. VEGFR-2 is responsible for 
mediating microvascular permeability, ECs proliferation and migration but the signalling steps 
mediated through VEGFR-1 have been less characterised. VEGFR-2 is considered the main 
receptor involved in the proliferation of ECs after stimulation by VEGF but recent studies 
attributed significant roles to VEGFR-1, with independent role in cell motility and inhibiting 
signalling pathways mediated by VEGFR-2 (Dvorak, 2002). VEGFR-1 mRNA is expressed in 
both proliferating and quiescent ECs, suggesting a role for VEGFR-1 in the maintenance of ECs 
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(Peters et al, 1993).  VEGFR-1 is a potent antagonist of VEGF by binding VEGF with high 
affinity and reducing its interaction with other receptors (Bicknell et al, 2004). VEGF receptor 3 
(VEGFR-3 or FLT-4) becomes specific to lymphatic vessels in adults. The expression of Flt-1 
and KDR is largely restricted to vascular endothelium. All receptors are tyrosine kinases; they 
form dimers and exert their actions via secondary pathways. Each VEGF receptor is able to bind 
specific VEGF ligands (see diagram below).  
VEGF A has been shown to be a critical regulator of EC development and is essential for 
normal vasculogenesis and angiogenesis. VEGF A seems to have the ability to induce EC 
proliferation as well as migratory and sprouting activity, and to help promote ECs to form 
tubule-like structures. These effects seem to be mediated largely by the VEGFR-2 receptor. 
VEGF A is involved not only in the initial phases of vasculogenesis, but also in the later stages 
of vasculogenesis, in sprouting, and other aspects of angiogenesis, as well as in maintaining 
vessel survival (Carmeliet et al, 1996). VEGFR-1 interacts with VEGF B and may be involved 
in down-regulating VEGF activity to ensure that the right number of ECs is generated (Gale et 
al, 1999). VEGF is also known as vascular permeability factor (VPF) due to its property of 
inducing vascular leakage, which is considered an important step in angiogenesis and leading to 
the formation of extravascular fibrin gel. Induction of vascular permeability appears to be an 
essential first step in angiogenesis. Roberts et al (1995) suggested that VEGF may be able to 
induce fenestrations in ECs that may provide additional trans-cellular pathway. Recent studies 
suggested that VEGF-mediated angiogenesis requires a specific adhesion molecules pathway, 
mediated by the vascular integrin αVβ5 (Friedlander et al, 1995). Clauss et al (1990) reported 
VEGF may promote monocyte chemotaxis. The migration of monocytes in response to VEGF 
was shown to be mediated by Flt-1 (Barleon et al, 1996). VEGF expression is also detectable 
around microvessels in areas where ECs are usually quiescent (Brown et al, 1992). This would 
indicate the possibility that VEGF may be required not only to induce active vascular 
proliferation but also to maintain the differentiated state of blood vessels (Ferrara et al, 1992). 
The mechanisms relating VEGF receptor overexpression to that of their ligands are not known 
but there is evidence that chronic exposure to high levels of VEGF A stimulates the expression 
of both VEGF A receptors on ECs (Detmar et al, 1998). VEGF A has effects on cells other than 
ECs, such as lymphocytes, granulocytes, macrophages. 
It was suggested that VEGF B may participate in the regulation of angiogenesis, particularly in 
muscle (Olofsson et al, 1996).  
VEGF A is over-expressed in the majority of solid human cancers and is increasingly found in 
lymphomas and haematologic malignancies (Dvorak, 2002) Elevation in VEGF levels have 
been detected in the serum of some cancer patients and expression of VEGF receptors is known 
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to be up-regulated in tumours compared to normal vessels. VEGF expression was correlated 
with vessel involvement and metastases and patients with VEGF-positive tumours had a worse 
prognosis than those with VEGF-negative tumours (Maeda et al, 1996). VEGF up-regulation 
has been reported in other diseases such as rheumatoid arthritis, psoriasis, bullous disorders, 
endometriosis, Graves’ disease. Non-EC populations may express one or more VEGF receptors 
(Wang et al, 1998). Whether this is required for recruitment of other cells, specifically smooth 
muscle cells or pericytes or occurs as a consequence of cytokine synthesis by activated ECs, it is 
not known.  
VEGF A expression is subject to a number of control mechanisms. Oxygen tension is the major 
regulator of VEGF gene expression (Minchenko et al, 1994, Schweiki et al, 1992, Shima et al, 
1995, Brogi et al, 1994). Hypoxia has been proposed to play an important role in the regulation 
of VEGF receptor gene expression (Tuder et al, 1995). Hypoxia up-regulates expression of 
VEGF A by increasing m RNA transcription and stabilisation (Claffey et al 1996, Shih et al, 
1998, Levy et al, 1995, Forsythe et al, 1996). Its up-regulation is associated with up-regulation 
of both VEGF A receptors. Hypoxic up-regulation of VEGF A is mediated by hypoxia-
inducible factor 1 (HIF-1) and the details of this pathway are discussed in the hypoxia sub-
chapter. Hypoxia has been reported to up-regulate VEGFR expression independent of VEGF A 
(Gerber et al, 1997). 
The von Hippel-Lindau (VHL) tumour suppressor gene has been implicated in the 
regulation of VEGF gene expression (Siemeister et al, 1996).  
Cell differentiation has been shown to be important in the regulation of VEGF gene 
expression (Claffey et al, 1992).  
Several cytokines or growth factors up-regulate VEGF mRNA expression and induce 
release of VEGF protein in various tissues. Amongst those quoted in literature are: epidermal 
growth factor (EGF), TGF-β (Frank et al, 1995), TGF-α (Detmar et al, 1995), IL-1β (Li et al, 
1995), IL-1α, PGE2 (Ben-Av et al, 1995), IL-6 (Cohen et al, 1996), IGF-I, tumour necrosis 
factor (TNF), FGF-2 (Dvorak, 2002). Dexamethasone appears to down-regulate or to prevent 
cytokine-induced up-regulation of VEGF A expression (Nauck et al, 1998). Placental growth 
factor (PlGF), strongly expressed in placenta, has been suggested to play a vital role especially 
in pathological angiogenesis potentate the activity of VEGF A, and was shown to reconstitute 
haematopoietic stem cells via VEGFR-1 (Hattori et al, 2002).  
Tie-2/Angiopoietins 
Both VEGF/VEGF receptor system and the angiopoietin/Tie-2 system were identified 
as central regulators of embryonic angiogenesis (Breier, 2000).  
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Tie-1 and Tie-2/Tek represent the Tie family. Angiopoietin-1 and Angiopoietin-2 have 
been reported to be antagonistic and stimulatory ligands for Tie-2 Tyrosine kinase receptor 
(Maisonpierre et al, 1997, Suri et al, 1997). The four known Angiopoietins all bind to Tie-2, but 
it is not clear whether they utilise the closely related Tie-1, for which no ligands have been 
identified as yet. Both Tie receptors are required during embryonic development for the 
integrity and survival of ECs, especially in areas undergoing angiogenic sprouting of capillaries 
and later for EC maintenance (Dumont et al, 1994, Puri et al, 1995). Angiopoietins appear to 
influence how a simple EC-lined tube develops into a mature vessel (Folkman et al, 1996, 
Korpelainen et al, 1999). Unlike other well-known angiogenic factors, the angiopoietins are not 
mitogenic for ECs and their function is not well understood (Carlson, Feng et al, 2001). Defects 
in mice lacking Ang-1 or Tie-2 suggest that this system is critical for normal remodelling, 
maturation and stabilisation of the developing vasculature. Unlike VEGF, Ang-1 cannot 
promote mitogenic responses or tubule formation, but promotes vessel branching and 
remodelling, maturation and stabilisation of vessels. It has been suggested that Angiopoietins 
act in a ‘permissive’ way allowing for proper interactions between ECs and supporting cells, 
resulting in a system that can respond to other stimuli (Suri et al, 1996). Maisonpierre et al, 
1997 indicated that Ang-2 facilitates vascular remodelling in adults by blocking a constitutive 
stabilising action on Ang-1, allowing vessels to revert to a more plastic and instable state. 
Existing data suggest that VEGF A and angiopoietins not only have quite different roles during 
vascular development, but also very complementary and coordinating roles (Gale et al, 1999). 
All members of the VEGF family and their specific receptors are shown in the Figure 1.2.  
 
                              
                                       Figure 1. 2. VEGF family and their specific receptors 
                                             Diagram adapted from www.bioscience.org 
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1.10.3 Other molecules with implications in CVM related angiogenesis  
Integrins 
Adhesion of EC to one another and to the matrix is mediated by a variety of surface 
receptors that belong to several families of cell adhesion molecules such as cadherins, integrins, 
immunoglobulins and proteoglycans. There is evidence that EC adhesive structures might play a 
morphogenic role during blood vessel formation in both embryonic and postnatal life (Bazzoni 
et al, 2000). Targeted null mutation studies have supported the concept that EC-matrix and cell-
cell adhesionis involved in the formation and maintenance of the vascular tree (Bazzoni et al, 
1999). 
EC adhesion molecules of the integrin family have emerged as critical mediators and 
regulators of angiogenesis and vascular homeostasis (Ruegg et al, 2003). 
The integrins are a family of adhesion receptors involved in many physiological 
functions. They are adhesion molecules with well-established roles in angiogenesis as they were 
found to facilitate cell migration, proliferation and survival and the regulation of matrix 
degradation. They can also mediate cell-cell adhesion and influence the expression of 
differentiation related genes (Danen et al, 2003). They co-operate with growth-factor receptors 
to enhance signalling (Miyamoto et al, 1998). Integrins have both common and specific 
pathways for signalling into the cell (Ruoslahti, 1996).  The family of human integrins 
comprises 24 members, each of which is a heterodimer consisting of 1 of 18 α- and 1 of 8 β-
subunits (Carlson et al, 2001).  
                       
                                              Figure 1. 3. Integrin families and their ligands 
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The picture above is adapted from Morphogenesis of Endothelium, edited by Werner Risau and Gabor M. 
Rubanyi, 2000, p 49. 
Most integrin mediating cell adhesion to ligands is present in basement membranes, 
extracellular matrix, or plasma proteins. A subset of integrins binds receptors expressed on the 
surface of other cells, being involved in heterotypic cell-cell adhesion. Members of the β1, β3, 
β4 and β5 integrin families are expressed on EC, with significant heterogeneity in their 
expression dependant on the origin of ECs, species, etc.  
There is strong evidence to suggest that endothelial integrins might influence vasculogenesis 
and angiogenesis, as follows (Bazzoni et al, 2000): 
1. The integrin expression and function in ECs showed that integrins are not involved in 
providing attachment only, they mediate pro-angiogenic functions, such as cell migration, 
proliferation, survival and regulation of matrix degradation. 
2. Blocking integrin-mediated EC adhesion affects blood vessel formation.  
3. Gene targeting experiments in mouse indicated a role for integrins in vascular 
morphogenesis. 
Activation is key to integrin function in different processes and is termed dynamic 
regulation of integrin adhesive function or ‘inside-out’ signalling (Hughes et al, 1998). 
Integrins have permissive roles for angiogenic programme of ECs. Some integrins are 
known to be regulated by angiogenic growth factors and studies with inhibitors of integrin 
functions implicate some of these molecules in vasculogenesis and angiogenesis. So far it is 
unclear how angiogenic growth factors and integrin-mediated adhesive events cooperate in the 
process of angiogenesis.  
There is a large and growing body of evidence implicating various integrins and their 
ligands in vascular development but it is not clear which integrins are the most important or 
what exactly each of them does. From the vast family of integrins of which some have been 
studied on animal tissues, αVβ3 and αVβ5 merit attention as potential important regulators of 
angiogenesis. αVβ3 is a widely expressed integrin with a broad range of ligands and it is often 
called vitronectin receptor, although it can also bind fibronectin, von Willebrand factor, 
thrombospondin and fibrinogen (Dejana et al, 1990). αVβ3 is expressed on both abluminal and 
luminal surfaces of EC and it can bind both matrix components and plasma proteins (Conforti et 
al, 1992). Endothelial αVβ3 also binds circulating leukocytes through the receptor PECAM-1 
(Piali et al, 1995). αVβ3 is constitutively expressed on EC but it can be up-regulated by TGF-β 
(Defilippi et al, 1995) and bFGF (Boudreau et al, 1997). ECs can express at least αVβ3 and 
αVβ5 and perhaps αVβ1, although resting ECs express little or no αVβ3. 
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αVβ3 has several functional properties which indicate that this integrin might have a 
permissive role for the angiogenic program of EC.  αVβ3 co-localises with vitronectin at the 
basal surface of newly formed vessels (Drake et al, 1995) and promotes EC migration on 
vitronectin (Leavesley et al, 1993). αVβ3 regulates matrix degradation by binding MMP-2 and 
co-localising it at the surface of invading EC in an active form (Brooks et al, 1996). αVβ3 
mediated adhesion also promotes EC survival and maturation and induces apoptosis (Brooks et 
al, 1994). αVβ3 was found to be markedly up-regulated on vessels undergoing angiogenesis. In 
the process of building up focal adhesions, it was shown that a necessary cross talk should occur 
between αVβ3 and VEGFR2, in order to transduce the necessary VEGF signals. (Masson-
Gadais et al, 2003). 
Angiogenesis requires cell-extracellular matrix interactions, which are mediated in part 
via integrins αVβ3 and αVβ5 (Nisato et al, 2003). They were found to be involved in the EC 
invasion and capillary-like tube formation. αVβ5 was also found to bind vitronectin and to 
promote angiogenesis. The two integrins identify different angiogenic pathways: αVβ3 is 
essential for PKC-independent angiogenesis induced by bFGF and TNF-α, whilst αVβ5 
mediates PKC-dependent angiogenesis induced by VEGF and TGF-α (Friedlander et al, 1995). 
It was noted that in spite of different mechanisms of action, αVβ5 might compensate for αVβ3 
and explain the normal vascular development in Glanzmann’s thromboasthenia, a disease 
characterised by mutations of the integrin β3 gene and defective αVβ3 expression. Cheresh et al 
have shown that different angiogenic stimuli rely on either αVβ3 (FGF-2, TNFα) or αVβ5 
(VEGF) and have shown that αVβ3 can bind the MMP-2 in a fashion that contributes to an 
invasive response and to angiogenesis. 
Previous research has tried to establish if αV integrins are as essential for 
developmental angiogenesis as they are for adult angiogenesis. Preliminary reports indicate that 
if null mutation of the αV gene abolishes the expression of nearly all vitronectin receptors, the 
vasculature develops normally, and around one fifth of the αV-null progeny is born alive (Bader 
et al, 1998). It was concluded that if not essential for blood vessel formation, αV integrins might 
become relevant at later stages for maintaining vascular integrity, as the αV-negative mice that 
develop to term die after birth with severe haemorrhages in brain and intestine. 
Brooks et al (1994) reported expression of αVβ3 in blood vessels of human wound 
granulation tissue but not in normal skin. A monoclonal antibody to αVβ3 blocked angiogenesis 
induced by bFGF and TNF-α, but had no effect on pre-existing vessels. The authors concluded 
that αVβ3 may be a useful therapeutic target for diseases characterised by neo-vascularisation. 
Antagonists of αVβ3 and αVβ5 disrupt angiogenesis in response to bFGF and VEGF (Berman 
et al, 2003). Antagonists of αVβ3 suppress angiogenesis in many experimental models and are 
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currently tested in clinical trials for their therapeutic efficacy against angiogenesis-dependent 
diseases, including cancer (Ruegg et al, 2003). 
Integrin activation provides a mechanism for VEGF to induce a broad spectrum of cellular 
responses (Hood et al, 2003). Byzova et al (2000) indicated that VEGF activates integrins. 
Shattil (1995) found that beta 3 integrins, including αVβ3, are prominently expressed on the 
surfaces of platelets and ECs. These locations place them in strategic positions to perform 
adhesive functions required in haemostasis, wound healing and angiogenesis.  
ET-1/ETA/ETB 
Endothelin (ET) is a potent vaso-constrictive peptide, initially isolated from cultured 
ECs medium, in 1988 (Masaki, 2004) and comprises 21 amino acid residues. Subsequently 
three endogenous isoforms were discovered: ET-1, ET-2 and ET-3. The predominant ET 
produced in ECs is ET-1. 
Endothelins which exert their effects by binding to two distinct cell surface receptors, 
ETA and ETB, are produced by a variety of normal cells, including ECs, vascular smooth 
muscle cells and act as autocrine or paracrine growth factors (Bagnato et al, 1998). Both 
receptors are transmembrane proteins with different molecular and pharmacological 
characteristics and functions based on their location. ET-1 promotes the growth of various kinds 
of cells, including ECs, smooth muscle cells, mostly via ETA receptors (Simonson). ET-1 
modulates various stages of neovascularisation, including EC proliferation, migration, invasion, 
protease production, tube formation (Salani et al, 2000).  ETA interaction with ET-1 results in 
vasoconstriction and cell proliferation. By contrast, ETB receptors are suggested to be involved 
in apoptotic mechanisms of cells (Masaki, 2004). Its activation results in nitric oxide induced 
vasodilatation. ETB plays a determinant role in the clearance of circulating ET-1(Attina et al, 
2005). The ETA receptor binds ET-1 and ET-2 with greater affinity than it does ET-3, whilst 
the ETB receptor binds all three isoforms with equal affinity (Masaki, 2004).  
In physiological states, ET-1 actions result in a complex modulation of vasomotor tone, 
tissue differentiation and cell proliferation driven by the interplay between effects on ETA and 
ETB receptors. In pathological states, ET receptors are differently regulated and there is a 
tendency towards vasoconstriction and ET alteration may be involved in diseases affecting both 
micro and macro-vasculature.  
The increased expression of ET-1 is related to increased micro-vessel density and 
VEGF expression in some tumours (Salani et al, 2000) suggesting that ET-1 and VEGF might 
have complementary and coordinating roles during neovascularisation in such tumours. In these 
tumours ET-1 increases VEGF mRNA, expression and induces VEGF levels increase, 
especially in hypoxic conditions. ET-1 is up-regulated by hypoxia and could promote 
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angiogenesis by increasing VEGF production through an HIF-1α dependent mechanism. In 
hypoxic conditions, ET-1 potentiates hypoxia by amplifying HIF-1α stability and VEGF 
production, data derived from research on tumours (Gupta et al, 2003). In the presence of 
oxygen, HIF-1α binds to the VHL tumour suppressor protein leading to its ubiquitination and 
rapid degradation. In tumours HIF-1α stability was analysed and results indicated that the 
increase in HIF-1α protein levels induced by ET-1 results from enhanced HIF-1α stability 
(Bagnato et al, 2003). 
In other tumours, ET increases αVβ3 integrin expression (Bagnato et al, 2004). ET-1 
was reported to be expressed by macrophages (Mencarelli et al, 2009) and clearly both 
macrophages and mast cells of human hyperplastic tonsils expressed ET-1( Niwa et al, 1999). 
ET-1 expression by these cells is postulated to play a pathogenic role with a possible pro-
inflammatory action on macrophages. ET-1 induced vasoconstriction was suggested to be 
increased by macrophages via stimulation of macrophage ET receptors (Magazine et al, 1994).  
The gene encoding ET-1 is on chromososme 6 (Treiber et al, 2003) and stimuli such as 
shear stress, thrombin, hypoxia, growth factors, cathecolamines, angiotensin II can induce 
transcription of ET-1 mRNA.  ET is not stored and released but instead generated in response to 
stimuli which vary between different tissues. ET is produced from a precursor named pre-
proendothelin. This is selectively processed by an enzyme to the biologically inactive 
intermediate named big-endothelin. Big-ET is converted into active ET by the endothelin-
converting enzyme (ECE). Two pathways have been described for clearance of ET: ETB 
receptor mediated uptake followed by lisosomal degradation (Burkhardt et al, 2000, Bremnes et 
al, 2000) and catabolism by extracellular neutral endopeptidase (NEP) (Vijayaraghavan et al, 
1990, Battistini et al, 1993). ET-1 production is stimulated by a variety of cytokines and growth 
factors, including IL-1β, TNF-α, TGF-β, PDGF, vasopressin, hypoxia and shear stress. Nitric 
oxide, prostacyclin and atrial natriuretic peptides are inhibiting ET-1 (Remuzzi et al, 2002). 
Soon after the ET discovery in 1988, researchers became interested in ET receptor 
antagonists, because of the unique pharmacological response initiated by ET (sustained 
contraction) and the possible involvement in the cardiovascular disease (Masaki, 2004). Many 
selective and non-selective ET antagonists are currently available and tested in trials in a series 
of cardiovascular diseases, with variable success.  
1.11 HYPOXIA AND HYPOXIA INDUCIBLE FACTORS (HIFs) 
In the context of CVM development, there is no hypothesis as to how initial insult of 
hypoxia could be brought about or whether hypoxia is a leading signalling pathway in these 
lesions or if this is just a pre-requisite of a leading process of exacerbated angiogenesis. It is 
possible that abnormal micro-circulation comprising abnormal blood vessels of CVMs may 
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cause blood stasis with subsequent ischemia and injury to the ECs of the vessel intima as well as 
tissue hypoxia. It is also possible that the blood within CVM vessels, supplying CVM tissue is 
well oxygenated as a result of arterio-venous shunting and its delivery to the tissue is altered or 
normal with normal oxygenation of CVM tissue. However, nothing is known about HIF 
expression in normoxia. Several stimuli have been reported to induce HIF stabilisation and 
transcriptional activity, including mechanical stress, hormones, cytokines and growth factors or 
alteration of HIF degradation pathways are present, such as loss of function of the von Hippel-
Lindau ubiquitin ligase complex (Gaber et al, 2005).This occurrence represents ‘pathological 
hypoxia’ and it has been described in relation to abnormal angiogenesis found in some tumours. 
The effects of hypoxia have been sub-divided by time span. Acute hypoxia 
activates ECs to release inflammatory mediators and growth factors which encourage 
neutrophil adherence to the endothelium (Wood et al, 2000), as opposed to chronic 
hypoxia, which is thought to increase the expression of specific genes that encode for 
growth factors such as vascular endothelial growth factor (VEGF) and other various 
cytokines (Tipoe et al, 2006, Semenza et al, 2006). These genes are modified by 
transcription factors, the most important being hypoxia inducible factors (HIFs).   
HIF is a ‘key regulator’ of the adaptive response to alterations of oxygen tension and 
contains two (α and β) sub-units. HIF molecules bind to hypoxia-responsive elements (HRE) in 
the promoter or enhancer regions of various genes, including VEGF. Under normoxic 
conditions, HIF-α sub-units have a short half-life, due to hydroxylation of proline residues by 
prolyl 4-hydroxylases, which require oxygen as a co-substrate. This allows binding of the von 
Hippel-Lindau ubiquitin ligase complex, which targets HIF-α for proteasomal destruction. 
Additional oxygen-dependant hydroxylation of asparaginase within HIF-α regulates recruitment 
of transcriptional co- activators. The dependence of prolyl and aspariginyl hydroxylation on 
oxygen means that, under conditions of hypoxia, HIF-α accumulates within the nucleus. Here, 
upon binding to constitutively expressed HIF-1β and recruitment of co-activators, it recognises 
HRE within target genes, leading to their transcriptional activation. 
In parallel to the oxygen-dependant pathway, HIF-1α is also regulated by receptor-
mediated signals, although this pathway is less well understood. Hypoxia induces expression of 
numerous pro-angiogenic mediators as a result of stabilisation of hypoxia inducible factor-
1alpha. The specific involvement of the HIF transcription factors 1 and 2 in the angiogenic 
response of ECs is not clear. These more subtle changes in HIF-1α levels and/or transcriptional 
activation are stimulated by growth factors and cytokines.  
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1.11.1 Carbonic anhydrase IX (CA IX) 
Carbonic anhydrase is a transmembrane glycoprotein, which belongs to a family of at 
least 13 different carbonic anhydrases and also acts as an enzyme. CA IX is strongly induced by 
hypoxia and therefore can be considered an endogenous marker of hypoxia. CA IX catalyses the 
reversible inter-conversion between CO2 and HCO3‾, one of the most fundamental reactions in 
cells. This reaction is essential for organisms and influences respiration, pH regulation, 
exchange of electrolytes, and many metabolic pathways. 
A HIF binding site was found on CA IX and previous authors (Beasley et al, 2001) 
showed that a hypoxia responsive elements and HIF-1α were essential for CA IX transcription 
under hypoxia. CA IX expression is induced as early as two hours after HIF activation and 
persists for several days, meaning that CA IX reflects both previous and present hypoxia in 
cells.  
CA IX it is not present in most normal tissues but is known to be overexpressed in 
VHL-defective tumours and under hypoxic conditions (Wykoff et al, 2000, Loncaster et al, 
2001, Mandriota et al, 2002). In tumours, CA IX was noted to be involved in maintaining 
extracellular acidic pH, which resulted in tumour growth and spread (Ivanov et al, 2001). These 
facts prompted the investigation of expression of CA IX in CVMs, since one of the aims of this 
study is to investigate hypoxia in CVMs. 
1.11.2 Interaction of HIFs with NEP and ET-1 signalling pathway 
Activation of the hypoxia inducible pathway is a well-established potentiator of 
angiogenesis. Stabilised HIF-1α leads to the transcription of target genes including ET-1, which 
binds to its receptors enhancing HIF-1α stability (details in Chapters 6 and 7). 
1.11.3 Neutral endopeptidase (NEP)/CD10 
NEP (neprilysin) is a metallopeptidase known to degrade ET-1 and it has been shown to 
modulate the bioavailability of peptide mediators and growth factors. NEP exerts an important 
role in controlling inflammatory responses. Details are given in Chapter 6. 
1.11.4 Measurement of blood gases 
Measurement of blood gases or blood gas analysis or arterial blood gas analysis is a test 
which measures the amounts of oxygen and carbon dioxide in the blood, as well as the pH 
(acidity) of the blood. Further details are provided in the Appendix section. 
1.11.5 Blood-tissue gas exchange  
This term represents the movement of oxygen from the blood stream into the tissues and 
additional information is given in the Appendix section.  
Chapter 1 – Introduction 
 60 
1.11.6 Account of ventilation-perfusion inequality 
The rate at which oxygen reaches an alveolus is determined by its ventilation and the 
inspired pO2. The rate at which O2 leaves the alveolus is determined by its perfusion. pCO2 in 
the alveolus will depend on the delivery of CO2 to the alveolus by the venous blood and the 
ventilation. All these factors could influence the results of this study attempting to assess CVM 
oxygenation. More details are available in the Appendix section.  
1.11.7 Oxygen delivery to tissues and oxygen consumption 
The quantity of the oxygen made available to the body in one minute is known as the 
oxygen delivery. The pO2 results from the balance between oxygen delivery and its 
consumption. Additional explanations related to this matter can be found in the Appendix 
section. 
1.11.8 Hypoxia as a cause for CVMs – relationship to angiogenesis 
It is well established that the angiogenic mechanisms are stimulated in response to a hypoxic 
environment. It is not known whether CVMs are hypoxic lesions or not and this is part of the 
aim of this research work (see Chapter 6). Should CVM prove to be hypoxic lesions and express 
HIFs, then the question is whether CVMs are primarily hypoxic or the hypoxia is secondary. 
Theoretically it is possible for CVMs to represent hypoxic tissues because of potentially 
decreased oxygen delivery to the tissues as a result of blood shunting. On the other hand dis-
regulated angiogenesis could be the original culprit and hypoxia may accompany the angiogenic 
process. Further details as to the possible hypoxia and angiogenesis signalling pathways 
involved in the CVM pathogenesis are given in Chapter 7. 
1.12 HYPOTHESIS 
CVMs result from aberrant blood vessel development due to altered pro-angiogenic 
markers and their interaction with abnormal stromal cellular constituents and/or stimulation by 
hypoxia. 
1.13 OBJECTIVES OF STUDY 
1. To investigate the histological morphology of CVMs by histochemistry and 
immunohistochemistry. 
2. To determine the immunohistochemical expression of the following pro-angiogenic markers 
in CVMs: VEGF A, VEGF-R1, Tie2, αVβ3, αVβ5, and ET-1. 
3. To identify hypoxia-mediated responses relevant to CVMs by establishing whether hypoxia is 
a feature of CVMs measuring oxygen pressures within abnormal blood vessels of these lesions 
and by correlating expression of HIFs with hypoxia and with the expression of the selected pro-
angiogenic markers in CVMs. 
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2. MATERIALS AND METHODS 
2.1 SELECTION OF PATIENTS 
 Ethical approval has been granted for the collection  of vascular malformations and 
control tissue as well as blood samples, for all studies comprising this project by the 
Hammersmith Research Ethics Committee: 04/Q0406/37 – ‘Immunocytochemical studies of 
congenital vascular malformations’, and 064/Q04064/29 – ‘Study of partial oxygen pressures 
within blood vessels in congenital vascular malformations’. The study 04/Q0406/37 was 
subsequently amended to add additional immunohistochemical work (histochemistry, new 
antibodies to be tested and children’specimens to be included) and this was approved in January 
2006.  Data collected from recruited subjects were anonymised and protected according to the 
rules set out in the Human Tissue Bill (2004).  
Patient selection, inclusion and exclusion criteria 
Part of this proposed study involved tissue analysis and comprised two elements: one 
was prospective and one was retrospective. Both elements concern non-CVM control tissue as 
well as diseased tissue from patients with CVMs.  
Only the prospective element of this study involved research participants. These 
participants were assessed, investigated and recruited in two ways: from a consultant led 
vascular clinic at Hammersmith Hospital and from the hospital (Charing Cross, Hammersmith 
or, on rare occasions from Chelsea and Westminster Hospitals) prior to their surgical 
intervention. 
Prospectively, diseased tissue was obtained from participants with planned 
interventions, independent of this study. For collection of vascular malformation tissue, patients 
were seen by a Consultant Surgeon in the vascular outpatient clinics before appropriate surgery 
was decided. CVMs were operated for symptomatic reasons only. Those patients with lesions 
causing bleeding, ulceration/gangrene, mass pressure effect, functional impairment, 
cardiomegaly, severe pain or a combination of these problems, were offered surgery when 
location of the lesion made surgical intervention feasible. Patients undergoing operation to 
excise or debulk (serial removal without complete excision) CVMs were chosen for the study.  
Inclusion and exclusion criteria for patients undergoing vascular malformation surgery 
were established to avoid faulty results. Those patients suffering from any form of malignancy or 
those diagnosed with or suspected to have atherosclerotic disease, connective tissue diseases or 
any other conditions known to alter angiogenesis were excluded from this study. Also patients 
with respiratory diseases, acute or chronic, musculoskeletal conditions or conditions causing 
depression of the brain’s respiratory centre were also excluded from the blood gases analysis 
study.  
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Clinical details were obtained for all retrospective participants in the study, from the 
archived medical notes and all clinical data was recorded. The purpose of investigation was to 
exclude from the study those retrospective participants suffering with malignancy or 
inflammatory conditions such as rheumatoid arthritis, connective tissue disorders, atherosclerosis 
and systemic diseases that could result in stromal infiltration by inflammatory cells. 
Arteries and veins for comparison with vascular malformation vessels were harvested 
from control participants. Other control tissue for this study consisted of normal skin taken from 
patients undergoing other surgical resections; abdominoplasty, limb amputation, reconstruction 
using flaps and breast reduction.  A clinical history was taken from all control participants and 
care was taken that none of the control patients had known malignancy, advanced 
atherosclerosis or any other disease process that could alter angiogenesis within the peripheral 
vessels.   
Informed consent for participation in the study was obtained usually when patient was 
seen in clinic, prior to operation, or in some cases, on the day of the operation. Details of the 
study, the type of tissue collected and the experiments planned were provided in an information 
sheet that was given to all participants along with an invitation letter. Separate consent forms 
were obtained prospectively from agreeing participants to have photographs taken by the 
Medical Illustration Department at Charing Cross Hospital or by authors, with the purpose of 
using them for publications, presentations and other teaching opportunities. Reassurance was 
provided regarding protection of data and tissue disposal after experiments.  
Patients, from whom control tissue for this study was obtained, were approached for 
consent during their hospital stay before the operation. They were invited to participate in this 
present study and they were provided with an information sheet. Details of the study, tissue 
collection and disposal were provided as patients were given an information sheet and an 
invitation letter and informed consent was obtained. 
 A very small amount of tissue was necessary for the purpose of this study and this was 
delivered to us in the form of redundant tissue after a preliminary assessment of the whole 
specimen sent to histology as a routine, to confirm the diagnosis (see collection of tissue 
section).  
CVMs were identified from a retrospective surgical cohort (1993 – 2003) consisting of 
20 patients but 3 patients were represented by blocks of tissue for more than one specimen.  All 
samples were formalin fixed and stored as paraffin blocks within the Histopathology archive, 
Hammersmith Hospitals NHS Trust (using local standard protocols).   
Prospective cases were collected from theatre (2004 – 2009) and tissues were both snap 
frozen (when enough tissue was available) and formalin fixed.  The prospective tissue samples 
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from patients recruited in this study consisted of 16 new patients and 2 patients initially 
identified from the retrospective cohort; further surgical debulking of their CVM allowed fresh 
tissue accrual.  All tissues were collected and stored through the Human Biomaterials Resource 
Centre (Tissue Bank). All of these 33 samples had fixed tissues to allow immunohistochemical 
studies, but frozen tissue was limited to a variable number (7 - 20) of patients due to surgical 
limitations. In four patients normal skin away from the CVM was sampled. During this study the 
process of recruiting patients continued throughout its duration, averaging 7 new patients per 
annum. By the end of this research work, there were a total number of 20 new CVM patients 
agreeing to participate in this study but it was possible to consider 16 patients.  All patients were 
initially adults but ethics has been altered to include specimens from children increasing 
recruitment to 11 CVMs per annum (see ethics approval section).   
Ten control participants were recruited for most analyses in this study although by the 
end of this research work control tissue was obtained from 55 patients who agreed to participate 
in this study. The control samples represented a variety of specimens including skin from healthy 
areas (following operations like breast reductions, abdominoplasties, and amputations) and 
sometimes macroscopically normal skin adjacent to the excised CVMs, arteries and veins from 
pedicles, redundant at surgery involving flaps and varicose veins. After the initial morphological, 
histochemical and immunohistochemical analysis of the ten control specimens considered, given 
the uniformity of results, it was considered unnecessary to include more control participants. 
Pre-operative MRI Scans and angiography 
 All the patients who had CVMs included in this study had either MRI scans or 
angiography when dealing with HF CVMs, or both investigations. Duplex scans, although 
feasible and generally used to define the type, location and extent of the lesions, were not used 
routinely in the institution where this research was performed. They were not considered as 
useful and accurate as MRI scans, due to their limitations associated with the small field of view, 
and restricted depth of penetration.  
MRI scanning included T1- and T2- weighted imaging in multiple planes, fat-saturated 
T1-weighted imaging with intravenous administration of a gadolinium-based contrast agent. 
Dynamic contrast-enhanced MRI scan was used to distinguish between HF and LF vascular 
malformations, as well as to establish the extent of the CVM and any potential involvement of 
vital/important structures. The main feature in characterising vascular malformations on 
conventional MRI is represented by a mass/soft tissue abnormality and the presence or absence 
of flow-voids (HF vessels). 
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                                          Figure 2. 1. MRI scan of a left thigh LF AVM                                                                                                                                         
                                           
                          Figure 2. 2. Left thigh LF AVM following a first debulking operation 
Chapter 2 – Material and Methods 
 
 66 
                                       
                           Figure 2. 3. Left thigh LF AVM following more debulking surgery 
The Figure 2.1 is the MRI scan of a LF vascular malformation included in this study. This 
represents a young woman with a large left thigh AVM. Coronal images (Philips 1.5T) through 
the lower extremity showed an extensive left thigh LF vascular malformation, which is 
involving the vastus lateralis and the superficial fat overlying the lateral and posterior aspect of 
the thigh. Vastus medialis appeared un-involved; Figure 2.2 is a clinical picture of the vascular 
malformation described in Figure 2.1 following a limited debulking operation at the lower part 
of the lesion (arrow). Figure 2.3 represents the clinical picture of the same lesion, following a 
third debulking operation (original photographs). 
Angiography, which includes arteriography, venography and direct intralesional 
contrast agent injection, was used as standard criteria to evaluate HF CVMs pre-operatively. In 
addition, those lesions suitable for embolisation were embolised 24 -72 hours prior to the 
surgical intervention.  
Figure 2.4 is an example of angiography performed in an extensive HF vascular 
malformation involving left medial thigh in a young female with recurrent ulcerations and 
bleeding from overlying skin, participating in this study. The associated clinical pictures are 
also provided. The AVM nidus (arrows) is deriving its supply mostly from branches of the 
profunda femoris and anterior division of the left internal iliac artery. The radiologist reported 
extremely rapid arteriovenous shunting into dilated veins, which communicate with the 
superficial femoral vein. This patient had multiple femoral embolisations for a period of 4 years 
before she had the first debulking operation. The figure 2.5 is a clinical picture of the HF AVM 
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with intramuscular and soft tissue components as described in figure 2.4, obtained following the 
first debulking operation. Figure 2.6 is a clinical picture of the same patient, obtained after the 
second debulking operation showing that most of the lesion was removed (original 
photographs). 
 
        
                                          
                                         Figure 2. 4. Angiography of a thigh HF AVM 
                                                              
                                         
                                         Figure 2. 5. HF AVM following first operation     
    
nidus 
Surgical scar 
AVM 
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                                 Figure 2. 6. Same HF AVM as in fig 2.5 after more surgery 
 
2.2 COLLECTION OF TISSUE 
2.2.1 Operations for CVM and collection of CVM tissue 
The principle behind the operation for CVMs is to excised the lesion completely or, if 
this is not possible, to remove as much as possible from the lesion (‘debulking’), process which 
is often limited by the amount of the blood loss or by the involvement of vital adjacent 
structures by the CVM. Further debulking operations can be performed, usually spaced at 
minimum six months interval, to give patient the chance to fully recover and to assess the result 
of previous operation. The extent and location of incision for these lesions varies extensively 
with the location and extent of the lesion itself. 
Information about the risks of anaesthesia and surgery, the success and the failure rates 
of treatment, complications, recurrence rates and the follow up management were discussed 
with each prospective participant before the procedure. 
Patients were given general anaesthesia and their position on the operating table varied 
with the location of the lesion. The exposed operating area was cleaned using antiseptic solution 
and draped. The length of the incision varied from about 4-5 cm in limited lesion to more than 
30 cm in extensive CVMs. As the skin incision was already made, in most studied CVMs, the 
lesions could immediately be seen or they would announce they presence through extensive 
bleeding. Careful control of haemostasis is taken during all operation using diathermy forceps 
or suture-ligation of the bleeding vessels. The aim of the operating surgeon is to get around the 
whole lesion, or at least a good bulk of it, getting into a plane of normal, bloodless tissue and 
avoiding other structures such as nerves, important feeding vessels or vital organs. The length of 
operation varied considerably from under one hour to more than six hours, depending on the 
technical difficulties. Usually the surgical specimen will represent one main bulk of tissue, 
which is removed from the patient once all dissection around the CVM mass is performed. 
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When this was about to happen, the tissue biologist (AF) working in close relation to the 
consultant pathologist with a special interest in CVMs (AS), was called to the operating theatre 
to collect the specimen in a sterile recipient. This fresh tissue was immediately analysed by the 
consultant histopathologist, who confirmed the macroscopic appearance and supported the 
suspected clinical diagnosis of vascular malformation. Part of the fresh tissue collected, which 
was redundant to that necessary for the confirmation of histological diagnosis, was snap frozen 
and kept for research.                             
                                               
                                        
                          Figure 2. 7. Patient with HF AVM on operating table prior to surgery 
                                       
                                            Figure 2. 8. HF AVM exposed at surgery 
                
The CVM tissue retained for research purpose was divided in two parts (when enough 
tissue was available) using a sterile surgical blade under sterile precautions. One part of tissue 
was placed in formalin (4%), while the other part was snap frozen in liquid nitrogen and placed 
in -80°C freezer for biochemical analysis, after coding the tissue. At this stage, the tissue 
segments were assigned code numbers to protect participant identity and to blind the 
investigator. When research tissue was scanty, the specimen available was formalin fixed and 
subsequently embedded in paraffin. 
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The average recorded blood loss varied significantly from 50mls to 25L. In spite of this, due to 
the fact that majority of participants were young, their hospital stay was an average of nine days 
and this was mainly related to the required length of time to keep drains within the wound. 
2.2.2 Collection of control tissue 
Normal arteries and veins from location with similar provenience as CVM tissue were 
sampled for this research work in order to compare the morphological and 
immunohistochemical properties of CVMs with standard vessels. Control vessels were carefully 
chosen after detailed discussion between all involved in this study, and peripheral vessels were 
selected, as all CVMs we considered in this study were peripheral CVMs. The vessels in CVM 
include a mix of arteries and veins embedded in stromal tissue. Therefore, skin vessels were 
considered appropriate as control tissue for CVMs. Skin controls used in this study were 
obtained from patients undergoing operations such as: breast reduction surgery, abdominoplasty 
or leg amputations, where the tissue removed was redundant. None of the control patients had 
any other known disease process; tumour malignancy, advanced atherosclerosis or any other 
condition that could alter angiogenesis.  All types of control tissue were treated as a 
homogenous, singular reference control for the CVM tissue. The tissue bank scientist was 
informed when an appropriate operation took place and once the tissue was about to be removed 
from the participant, this was collected in sterile containers. As described above for the CVM 
tissue, the control tissue was also divided in two pieces, one piece was preserved in formalin 
(and subsequently embedded in paraffin) and the other was snap frozen in liquid nitrogen.  
2.3 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
2.3.1 Histological analysis of CVMs 
Paraffin embedded CVMs tissue was used for histological analysis with H&E 
(haematoxylin and eosin), Masson Trichrome, Elastic Van Gieson and Toluidine blue. 
Histological morphological analysis of CVM vessels and comparison to control vessels were 
undertaken using these special histological stains.  H&E stained tissue was used for general 
assessment and screening of sections, to assess quality of tissue and staining, presence of 
artefacts, to study the distribution of inflammatory cells of interest and as a reference for 
immunostained tissue. Masson’s Trichrome stained connective tissue green and muscle in red. 
This stain helped studying the assessment of architecture of CVMs in comparison with control 
tissue and was used to calculate percentage of collagen tissue present in average sections in 
CVMs in comparison to controls. EVG stained tissue was used to assess disruption of elastic 
lamina in comparison to control vessels. The EVG stain colour the elastin in black and the 
muscles in red. Toluidine blue showed mast cells in blue and this stain was used to count 
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average number of mast cell present per/field (1 mm
2
 section of CVM tissue) in comparison to 
control tissues.  
All staining techniques used in this research work were standardised and performed 
according to the protocols established by the Pathology Department at Charing Cross Hospital, 
London (described in a later section). The CVM and control tissues preserved in formalin and 
set in paraffin blocks were routinely cut into 3μm sections with a microtome. The special 
stainings were obtained following the stages described in the Appendix section. 
2.3.2 Immunohistochemistry (IHC) 
This method was used to localise specific antigens in the CVM sections and compare it 
with their presence in control sections. The methods IHC are linked to Alfred H Coons and his 
colleagues (Coons and Kaplan, 1950) who were the first to label an antibody with a fluorescent 
dye and use it to identify an antigen in tissue sections with a fluorescence microscope. This 
technique has been expanded by introducing enzyme labelling with peroxidase (Nakane and 
Pierce 1967) and alkaline phosphatase (Mason and Sammons 1978), as well as other enzymes. 
IHC was chosen in this project to study specific antigens in the CVM and control tissue in 
preference to immunofluorescence (IF), because it better allows the visualisation of cytological 
details and tissue architecture. 
2.3.3 Computer assisted microscopy and IA of CVMs and control vessels  
Microscopy and part of the quantitative IA was performed using a computerised IA 
system. This was represented by an Olympus Optical BH2 microscope (Olympus Optical; 
Tokyo, Japan). The microscope was connected with a JVC KY-F55BE video camera (Victor 
Company of Japan, Tokyo, Japan) linked to a Gateway 2000 computer (Gateway 2000, North 
Sioux City; USA). The digital images were acquired at low and high power as required and 
were processed using the AnalySIS IA software (Soft Imaging Software GmbH, Munster, 
Germany). This software was used for: 1) Blood vessel count, 2) Blood vessel diameter, 3) Cell 
count, 4) Nerve fibre count, 5) Collagen percentage, 6) Quantification of immunopositivity to 
antibodies, 7) General description of CVM morphology. The detailed protocols for all these 
measurements and assessments are given in the  Appendix section. 
2.4 WESTERN BLOT FOR HIFs PROTEIN ANALYSIS 
This technique was used in this study in the attempt to analyse the HIFs pathways and 
confirm the presence of HIF downstream proteins in CVM tissue, as HIFs were 
immunohistochemically expressed in CVMs (see Chapter 6). Details of the protocol are 
provided in the Appendix section. 
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2.5 BLOOD GASES ANALYSIS 
This component of the research  aim to determine if hypoxia is an element of CVMs, by 
measuring partial oxygen pressures (pO2) in the abnormal blood vessels comprising CVMs 
(during their operative management) and comparing it with the arterial oxygen pressure, as well 
as venous oxygen pressures from ipsi-lateral and contra-lateral veins to the CVM. Subsequently, 
markers of hypoxia such as HIFs were quantified immunohistochemically and analysed in 
respect to oxygen pressures in the CVM tissue. The protocol of this part of the study is provided 
in the appendix section. 
2.6 STATISTICAL ANALYSIS 
The morphological analysis of CVMs was performed in two stages. Initially, a pilot 
study was carried out, to determine the optimal method of assessment, followed by a more 
comprehensive study, in order to support initial findings. The aim of both studies was to 
compare numbers of vessels, nerve fibres, vessel diameters, collagen percentage, disruption of 
elastic lamina/fibres and stromal cells in CVMs to those in control tissue.  
The demographic data of the population in the pilot group of the morphological study 
was analysed using Mann-Whitney U test. The same test was used to analyse the difference in 
the number of cells, blood vessels, nerve fibres, vessel diameters, collagen percentage, degree of 
elastic fibres disruption and cells number between the groups studied as data could not be 
assumed to be parametric. 
In the pilot study, macrophages and mast cells were counted by two independent 
assessors (NM and AF) using a microscopic grid under light microscopy, as well as image 
analysis. Therefore one of the objectives was to examine the difference between microscopic 
grid method and image analysis when compared with controls and between themselves. 
Wilcoxon Signed Ranks was used to investigate the difference between microscopy and the 
image analysis method for both macrophages and mast cells. 
The other objective of the morphological study was to assess if there was any 
significant correlation between morphological findings in CVMs and control tissue and in 
different clinical patterns of CVMs (based on flow characteristics, i.e. HF and LF). Spearman's 
rho correlation coefficient was used to establish the relationship between clinical categories and 
any of variables that will show significant difference between the CVM group and the control 
group. SPSS for windows was used as statistical package to analyse the pilot data, two-sided 
test was used with 5% and 1% level of significance. 
Furthermore, analyses were performed on data obtained from 33 vascular malformation 
specimens obtained from 33 patients and ten controls using the Stata 8 statistical software (Stata 
Corporation, Texas, USA). Data were analysed according to a pre-defined statistical analysis 
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plan. Mann-Whitney test was used to examine the difference between the CVM group and the 
control group for all variables as data could not be assumed to be approximately normally 
distributed. In this case, as ten outcomes have been analysed on the same dataset, a Bonferroni 
correction was applied such that p<0.005 indicates significance. Data are quoted as median 
[interquartile range] as the group sizes are small. Data assessed within the CVM group was 
given as median without being statistically analysed, due to small numbers. 
In the angiogenesis markers immunohistochemical expression study, all 
immunostaining was quantified by two independent assessors using a scoring system from 0 to 
3, depending on distribution and intensity of stain. Data obtained was analysed for agreement 
using kappa coefficient analysis. The demographic data of CVM participants and controls in 
this study was given as means±SD. 
 The immunostaining scores for CVM tissue were compared for each antibody with the 
immunostaining scores of control tissue using the Mann-Whitney U test. Correlations were 
made between expression of each angiogenesis mediator by CVM tissue and the stromal 
infiltrate of macrophages and mast cells present using Spearman's rho correlation coefficient for 
non-parametric data. 
 Similar methods of interpreting results were used for the analysis of hypoxia markers in 
Chapter 6. HIFs and CD 10 were also quantified by two independent observers using the 
scoring system from 0 to 3 and results were analysed for agreement with kappa coefficient 
analysis. HIFs and CD10 demographic data was similarly reported as means±SD. HIF-1α, HIF-
2α and CD10 staining scores for CVM tissues were compared to the staining scores in control 
tissue using Mann-Whiney U test. HIFs staining scores in CVMs were correlated with those of 
each angiogenic marker studied as well as with the staining score of CD10 and the numbers of 
macrophages and mast cells per field, in the corresponding tissues, using Spearman's rho 
correlation coefficient. 
For the blood gases analysis study (Chapter 6, sub-chapter 6.3), it was noted that for 
95% power and a confidence interval of 27, 13 subjects were required for analysis. Two main 
comparisons were made in patients with CVMs: 1) paired comparison of arterial pO2 in the 
radial artery and the CVM blood vessel in patients undergoing surgical correction of their 
CVM; 2) paired comparison of venous pO2 in the venous systemic blood (on the same side as 
well as on the opposite side to the CVM) and the CVM blood vessel in patients scheduled for 
surgical correction of their CVM.  
Unpaired t-test and Wilcoxon matched-pairs signed-rank test (assuming non-parametric 
data) was used to compare the difference in pO2 between the radial/venous systemic and CVM 
vessels.  
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All comparisons and correlations in the angiogenesis, hypoxia and blood gases analysis 
studies were performed using GraphPad Prism version 4.03 statistics package. 
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3. HISTOLOGICAL ANALYSIS OF MORPHOLOGICAL CHANGES IN CVMs 
3.1 INTRODUCTION 
There are few recognised histologic features specific to haemagiomas or vascular 
malformations and these two entities are often difficult to distinguish using routine histology. 
Some lesions have features applicable to both categories, which imply that present 
classifications may not reflect the in vivo situation and are clinically less than satisfactory. The 
exact histological morphology of vascular malformations and the clinical relevance is unclear. 
They appear as an abnormal proliferation of blood vessels of variable calibre and wall thickness 
with variable density. Complete destruction of the confluence point of the abnormal vessels in 
CVMs (‘nidus’) is considered by some authors to be the only cure for CVMs. Specific histology 
of the ‘nidus’ is not described. The stroma between blood vessels may show fibrosis and 
calcification and Mulliken and Glowacki noted normal endothelium and normal mast cell count 
within vascular malformations. Proliferation and leakage of capillaries interpreted as a 
consequence of raised intra-capillary pressure, was sometimes noted by histopathologists. All 
features described are largely non-specific. Percutaneous sclerotherapy and trans-catheter 
embolisation are often used to treat these lesions and both involve the injection of a foreign 
material that can further alter the histological morphology. Published data has described 
hyperplasia of elastic fibrils in the arterial wall and inflammation and necrosis in the venous 
wall at   2-3 weeks after the injection of sclerosant material.  
3.2 OBJECTIVES 
There is limited description in the literature of the morphological changes in CVMs and 
the main problem is recognising whether the lesions described are truly CVM, given the still 
existent controversies regarding their nomenclature and classification. On the other hand, 
different clinical categories of CVMs are not distinguishable histologically and features 
described in the literature are non-specific. Even more, there is no correlation described between 
the clinical behaviour of CVMs and their histological appearance and immunohistochemical 
profile. 
The purpose of this part of the study was to compare the structural features of CVMs 
with those seen in control tissue (i.e. normal vessels, which were skin vessels from breast tissue, 
abdomen or lower limbs). An understanding of the potential morphological changes specific to 
CVMs, for example increased number of blood vessels per power field, increased vessel 
diameter, was essential for the subsequent studies of cellular infiltration (Chapter 4) and 
alteration in angiogenesis markers (Chapter 5).  
Counting the blood vessel number per power field and measuring the blood vessels 
diameter was performed in this analysis, they were easily recordable, reproducible and 
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comparable characteristics. In addition, descriptive morphology was provided for the specimens 
of CVMs, analysed as part of the initial pilot study. This study was performed to elucidate 
histology of these uncommon but often aggressive lesions and to gain insight into possible 
mechanisms involved in their aetio-pathogenesis.  
3.3 MATERIALS AND METHODS 
3.3.1 Selection of patients and tissue collection 
This part of our proposed study was both retrospective and prospective. A pilot study 
was initially performed and this was followed by a larger study, incorporating more participants 
and validating the data obtained in the pilot study. Both studies involved CVM and control 
participants. A total number of 33 CVM and 10 control participants were included. Whilst CVM 
specimens were obtained both retrospectively from archive and prospectively, control 
specimens were all obtained prospectively. All participants included in the pilot study had 
oestrogen and progesterone receptors (ER beta and PR) immunostaining to assess if these 
results would permit further morphological stratification. This initiative was supported by the 
clinical finding that CVM become clinically active during times of hormonal variation such as 
pregnancy or puberty. Therefore, differences in hormonal immune-stain may give indications of 
the CVM activity.  
Details of patient selection criteria, consent forms and tissue collection are given in 
Chapter 2.   
3.3.2 Assessment of blood vessel numbers and diameter in CVMs and controls 
Factor VIII stained CVM and control tissue were used to delineate blood vessels for the 
purpose of both counting the blood vessels and measuring their diameters in CVMs and control 
tissue. These techniques were thoroughly described in the Appendix. 
3.3.3 Histological and immunohistochemical studies 
CVM and control non-diseased tissue, were stained with Haematoxylin and Eosin 
(H&E), Elastic von Gieson (EVG), Masson’s Trichrome. In addition to the above histochemical 
stains, immunohistochemical stains for S100 and SMA 1-α were used to further characterise the 
morphological changes in CVMs. All histochemical and immunohistochemical techniques used 
in this part of the study were performed on formalin fixed and paraffin embedded tissues and 
they are described in the Appendix.   
The aim of this study was to analyse the morphological changes within the vascular 
malformation in comparison with the normal/non-diseased vessels.  
The H&E stained slides were used to identify the vascular malformation and ensure the tissue 
was representative and screen for various tissue artefacts, which may have affected the 
interpretation of proposed stains. 
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     x25/x200 
                                Figure 3. 1. Typical appearance of H&E slide of a HF AVM  
 
                                 x25 
                               Figure 3. 2. H&E slide of a CVM showing thrombus formation 
 
The following figures demonstate smooth muscle actin 1-α in CVMs. 
                                       x25                                                                                                                                                                            
                                      Figure 3. 3. Positive expression of SMA 1-α in an AVM 
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                                     x40 
                                      Figure 3. 4. Positive expression of SMA 1-α in a VM 
There is a similar appearance of SMA 1-α stain in both CVMs, demonstrating thick and thin 
vessels of variable calibre. 
S100 
In the analysis of the morphological changes in CVMs, account was taken of presence 
of nerve fibres within CVM tissue and they were visualised using S100 immunostain. 
                                        
                 Figure 3. 5.  Positive expression of S100 stain showing nerve fibres in an AVM 
3.4 RESULTS 
All CVM lesions analysed in this section (33 lesions) were negative for GLUT-1, therefore they 
were vascular malformations, not haemangiomas. All vascular malformations (17 lesions) 
analysed in the pilot part of this study for ERβ and PR receptors were negative for both 
receptors. Therefore, no comments can be further made regarding any association of ERβ or PR 
with the CVMs morphology or level of clinical activity. Most likely more specific hormonal 
stains need to be performed but this issue was not pursued further in this work. 
  
 
                                   
                                                     
Chapter 3 – Results 
 
 80 
The H&E stains of vascular malformations consistently showed large and small, thick 
and thin vessels lined by ECs, as well as a significant cellular infiltrate within the perivascular 
and extravascular space. Based on this stain, different clinical categories of CVMs cannot be 
distinguished, they appear similar. 
In the EVG stained sections, both internal and external lamina of blood vessels were 
clearly visualised as black fibres, within control tissue (Figure 3.6). The external elastic lamina 
formed a well demarcated layer around the tunica media of the vessel wall, with no features of 
disruption. These features were similar in all control specimens studied and represented normal 
variant for the types of vessels analysed. 
       x40                                                                   
      Figure 3. 6. Elastic von Gieson stain of a skin control  
Elastic Van Gieson stain, demonstrated disruption of the elastic fibres within a large 
proportion of AVMs. This finding was difficult to quantify, but EVG stain was used to assess 
the degree of disruption of the elastic fibres within the vascular wall, using a grading system 
from 0 to 3 (0 = no disruption, 1 = mild, 2 = moderate, 3 = severe). Beside this, it was noted that 
some CVM specimens contained a considerable amount of elastic tissue, sometimes in multiple 
layers, which was difficult to localise due to the nature of the specimen, containing really large 
blood vessels and at the same time giving the impression that the elastic fibres were localised 
outside the vessels, within the stromal tissue. This was thought to be due to the fusion of 
external elastic laminae of a number of adjacent vessels. The observation of dis-organised 
elastic fibres in some of the CVMs studied here could be associated an imbalance of pro-
angiogenic mediators such as metalloproteinases (Marler, Fishman, et al, Nikkari, Hoyhtya et al, 
1996). 
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                                        Figure 3. 7. Elastic von Gieson stain of an AVM      
                                         
                                           Figure 3. 8. Elastic von Gieson stain of a VM 
The figures 3.7 and 3.8 show dis-organisation of the elastic laminae (arrows), with no much 
difference between AVMs and VMs.  
The Masson’s Trichrome stained slides clearly identified the layers of the vessel wall, the 
presence of smooth muscle (purple) in the media, and the collagen (green) forming the 
adventitia and staining in variable proportion of inter-vascular space.  
                                       x40 
                          Figure 3. 9. Masson Trichrome stain of a section from skin control  
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The figure 3.9 shows circular SMC in tunica media and connective tissue, some in 
between muscle fibres but most of it forming the adventitia. 
 
         x40                                                                                               
            Figure 3. 10. Masson Trichrome stain of aVM    
                                       x25 
                                       Figure 3. 11. Masson Trichrome stain of an AVM 
 
Figures 3.10 and 3.11 demonstrate the smooth muscles and the proportion of connective 
tissue within the lesion, which was calculated using image analysis. This stain clearly showed 
the variable proportion of SMCs and connective tissue present in each specimen. As it can be 
seen in the VM specimen above, the SMCs are very scarce within the vessel wall, there were 
SMCs outside the vessel wall as this lesion was invading a muscle layer. The connective tissue 
predominates amongst the large, thin abnormal vessels of the CVM lesion. Sometimes vessels 
are so thin that it is difficult to clearly distinguish all three layers characteristics of a blood 
vessel. Within the next specimen (HF), the muscle layer is better represented, there are more 
thick vessels and they are appeared to be overall smaller in diameter comparing to the previous 
specimen. These represent simple observations but Masson’s Trichrome stain allowed 
calculation of the collagen percentage present in CVM specimens in comparison to that found in 
controls. 
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3.4.1 Pilot study results 
Demographic data of the population studied 
The data consisted of 17 CVM patients and 10 control patients. The CVM population 
were represented by patients who underwent operations at Hammersmith Hospital between the 
years 1993-2003. The control patients underwent operations at Charing Cross Hospital between 
2003 and 2007. The CVM group (n=17) consisted of both genders: 9 (52.9%) female and 8 
(47.1%) male. The control group (n=10) were all female (100%). The mean age was 35.06 and 
43.40, for the CVM and the control group respectively.  
 
Tabel 3. 1. Descriptive statistics of age for CVM and control groups 
Group N Median Minimum Maximum 
CVM 17 33 3 74 
Control 10 42 25 84 
 
Mann-Whitney Test showed that there was no significant difference in age (p = 0.20) 
between the CVM and the control group. This may indicated that both groups are well matched. 
The CVM tissue analysed corresponded clinically and histologically to different CVM 
categories. This information was obtained from patient’s medical records and histopathological 
reports. Twelve (70.6%) of the CVMs were LF malformations, 2(11.8%) were HF 
malformations, 2(11.8%) were lymphangiomas and one (5.8%) was glomangioma. The control 
tissue analysed was represented by normal skin vessels of which 4(40%) samples were obtained 
following breast reduction surgery, 3 following abdominoplasty (30%) and 3 following limb 
amputations (30%).  
Table 3.2 showed there was significant difference in number of blood vessels (p < 
0.001) between the CVM and the control groups. 
 
Tabel 3. 2. Number of blood vessels in CVM and control groups 
Variable Group N Median P-value 
Number of  blood vessels 
  
CVM 17 7.60 < 0.0001** 
Control 10 4.50 
Mann-Whitney Test, ** Significant at 1% level 
 
Table 3.3 showed that there was only significant difference (p=0.05) in diameter of 
blood vessels (field1) between the CVM group and the control group. 
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Tabel 3. 3. Diameters of blood vessels in CVM and control groups 
Variables Group N Median P-value 
Diameters of blood vessels (average of field 1) 
  
CVM 17 65.85 0.05* 
Control 10 35.59 
Diameters of blood vessels (average of field 2) 
  
CVM 17 72.77 0.45 
Control 10 37.86 
Diameters of blood vessels (average of field 3) 
  
CVM 17 52.46 0.82 
Control 10 47.00 
Diameters of blood vessels (average of field 4) 
  
CVM 17 51.22 0.86 
Control 10 57.27 
Diameters of blood vessels (average of field 5) 
  
CVM 17 50.93 0.45 
Control 10 36.86 
Diameters of blood vessels (averages per 
specimen) 
  
CVM 17 73.18 0.31 
Control 10 65.36 
Mann-Whitney Test, * Significant at 5% level 
 So far, the only significant results in the comparison between the CVMs and control 
vessels were concerning the number of blood vessels/field with magnification 40 and the 
diameter of blood vessels assessed at the same magnification. Spearman's rho correlation 
coefficient was used in the attempt to correlate these significant findings with the clinical 
categories of the CVM tissue analysed, as described earlier. 
 
Tabel 3. 4. Vessel number and diameter and clinical types of CVMs - correlation 
 Variable 
N Correlation 
coefficient  P-value 
Number of  blood vessels 17 -1.00 0.71 
Diameters of blood vessels  
(average of field 2) 
17 0.41 0.12 
# Spearman's rho correlation coefficient 
Spearman's rho correlation coefficient showed that there was no significant correlation 
between clinical categories and any of variables that showed significant difference between the 
CVM and the control groups. However, it is interesting to note that the highest correlation (r = 
0.41) was between clinical categories and diameters of blood vessels (average of field 2). This 
finding was not statistically significant and it may be just by chance, due to the small numbers 
in this pilot study. 
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Tabel 3. 5. Collagen in CVM and control groups 
 
 Collagen percentage showed no significant difference when CVM and control tissue 
were compared. This assessment considered stromal collagen found around the vessels within 
CVM and normal control tissue respectively.  
 Tabel 3. 6. S100 and EVG immune-staining score in CVM and control groups 
 Mann-Whitney Test, ** Significant at 1% level 
Table 3.6 showed S100 and EVG score between the CVM and the control groups, 
demonstrating no significant difference between the two groups. 
3.4.2 Results of morphological analysis of CVMs 
 Following the results of the pilot study, further numbers were added to increase the 
power of this morphological analysis. Therefore, an additional 16 prospective participants were 
added to the pilot study to make up a total of 33 CVM samples. As the results within the control 
group were uniform, the same number of 10 control samples was kept for comparison of the two 
groups. 
Demography of the studied population is detailed in table below. 
Within the CVM group we have looked at the significant findings in relation to the 
clinical confounding factors (i.e. type of flow – HF or LF, location of the lesion, previous 
interventional treatment of the lesion and presence of an ulcer in the vicinity of the lesion at the 
time of operation), in addition to the usual confounding factors such as age and sex. A more 
detailed analysis was performed on these data comparing to the basic analysis in the pilot study. 
 
 
Variable Group Median P-value 
Collagen (%) 
  
CVM 19.82 0.47 
Control 16.07 
Collagen (Micro meters square) 
  
CVM 850.55 0.13 
Control 408.51 
Variable Group N Median P-value 
 control 10 408.51  
S100 CVM 17 1.60 0.82 
control 10 1.70 
EVG score 
  
CVM 
17 1.00 
 
0.09 
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Tabel 3. 7. CVM morphological study - patient demographic and clinical data 
Patients Age/sex Site Clinical  
diagnosis 
High flow/ 
low flow 
Previous  
Endovascular 
therapy 
Presence of 
ulcer at 
operation 
1 51/F torso VM* LF˜   
2 41/M Lower limb VM LF   
3 28/F Upper limb VM LF   
4 19/F Upper limb VM LF   
5 49/F Lower limb VM LF   
6 23/F head VM LF   
7 3/M Lower limb LM** LF   
8 25/M Lower limb LM LF   
9 20/F Lower limb VM LF   
10 31/M Head  AVM° HF
+
  yes 
11 43/M Head  AVM HF yes  
12 40/F Upper limb AVM HF yes  
13 74/F Head  VM LF  yes 
14 33/M Head  VM LF   
15 31/F Upper limb VM LF   
16 36/M Upper limb VM LF   
17 49/M Lower limb VM LF   
18 20/M Lower limb VM LF   
19 27/F Upper limb VM LF   
20 26/F Upper limb VM LF   
21 73/F Upper limb AVM HF yes  
22 64/M Upper limb AVM HF   
23 24/F Lower limb AVM HF yes yes 
24 20/M Lower limb AVM HF yes  
25 28/F Upper limb AVM HF yes yes 
26 31/F Lower limb VM LF   
27 18/M Lower limb VM LF yes  
28 32/M head VM LF   
29 54/F Lower limb VM LF   
30 19/F Upper limb VM LF   
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31 24/F Upper limb VM LF yes  
32 19/F Lower limb AVM HF  yes 
33 45/M Lower limb VM LF   
* = venous malformation; ** = lymphatic malformation; ° = arteriovenous malformation; ˜ = LF; += HF 
Vessel number (p=0.0004) and vessel diameters (p=0.0005) were significantly higher in 
the CVM group compared to controls. There was no correlation between the statistically 
significant morphological parameters resulted in this study, and any of the clinical parameters.  
Comparison of histological findings in CVMs to control tissues 
The control and test samples were matched in number although the control tissues have a higher 
female to male ratio; 3:1 than the CVM 3:2. 
 
Tabel 3. 8. Demography and clinical data in CVM and control groups 
Variable Control group 
N=10 
CVM group 
N=33 
P-value from Mann-
Whitney U test or Chi-
squared test* 
Age 
(Years) 
42 
[34-50] 
31 
[23-43] 
0.064 
Gender 
Number male (%) 
0/10 
(0%) 
14/33 
(42%) 
0.012* 
Number of vessels  
(mean of 5 fields 
x40/ mm
2
) 
3.3 
[2.4-3.6] 
4.8 
[3.8-5.6] 
0.0004 
Vessel diameter 
(mean of 5 fields 
x40/ mm
2
) 
334 
[258-419] 
627 
[508-734] 
0.0005 
Data quoted as median [interquartile range] 
 
 Tabel 3. 9. Vessel number and diameter, CVM demography and clinical data 
Significant morphology parameters on 
comparing CVMs and controls* 
Vessel Number/mm
2
 Vessel Diameter µm 
Demographic and clinical data CVMs  
Sex Male 
female 
5 
4 
594 
643 
Type of flow  High 
Low 
6 
5 
628 
625 
Chapter 3 – Results 
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Location  Lower limb 
Upper limb 
Head 
torso 
5 
4 
4 
3 
591 
657 
613 
475 
Previous 
endovascular 
therapy 
Previous therapy 5 
 
5 
661 
 
624 
No previous therapy 
Presence of 
ulcer at 
operation 
Ulcer 
No ulcer 
6 
5 
643 
625 
*Data quoted as median 
 
3.5 DISCUSSION 
This series of 33 ‘true’ vascular malformations (meeting the diagnostic clinical, radiological and 
histological criteria), is one of the largest recorded in the world literature. Currently, there is no 
correlation between accepted clinical classifications and morphology of these lesions. 
The aim of this part of the study was to identify morphological features characteristics 
to CVMs by comparing CVM tissue with similar normal control skin vessels.  
Secondly, this study allowed morphological examination of a variety of CVM, which 
permitted more insight into the reasons as to why is still impossible to match these 
lesions to the recognisable clinical categories. 
Since CVMs represent abnormal proliferation of blood vessels, we decided to assess the vessels 
present within CVMs specimens and objectively, the number of vessels present per field and the 
average vessel diameter, which were chosen as indicators of vessel proliferation. There are no 
similar studies in literature reporting figures for these chosen parameters, for morphological 
assessment of CVMs. The most important microscopic changes we demonstrated in this part of 
the study were related to the blood vessel as a whole since we have shown that CVMs contain 
considerably more blood vessel per field and they have a greater diameter in comparison with 
skin controls. It has been suggested that abnormal local concentrations of angiogenesis 
mediators are responsible for increased blood vessel diameter (Nakatsu, Sainson et al, 2003) but 
this possibility needs to be investigated in vascular malformations. Increased expression of 
angiogenesis markers such as VEGF, VEGFR-1, Tie-2, αVβ3 were found in this study (see 
results in chapter 5). The abnormal expression of these cytokines may be responsible for the 
increased blood vessel diameter within CVMs. Vessel size also changes following alterations in 
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smooth muscles proliferation – not demonstrated in CVMs - or matrix protein synthesis, which 
remains to be investigated.  
CVMs vessels consist of three definable layers as seen in other vessels. Some of the 
morphological changes observed in a variety of CVMs specimens in this study appear to be 
located within the tunica media and adventitia. Although there were presumptions in the 
literature that CVMs have at the origin an abnormality of the ECs composing the abnormal 
vessels of CVMs, we could not demonstrate any microscopic abnormality or disruption of the 
endothelial lining, based on Factor VIII immunostaining. Certainly, the ECs in vessels 
comprising the vascular malformations in our study were sufficiently differentiated to express 
Factor VIII antigen and similar findings have been previously reported. These results however, 
do not exclude intrinsic abnormalities of the ECs composing CVM, a matter which does not 
represent the direct aim of this study. 
Histological analysis of CVMs by comparison with controls demonstrated a deviation of 
the vessel morphology in CVM from what we considered normal vessel morphology in 
controls. Although both specimens had recognisable, demarcated vessel wall, CVMs 
varied considerably in respect to the presence of the circular layer of muscles in tunica 
media, the types of vessels (thick and thin, large and small), the amount of connective 
tissue forming the adventitia or interposing between the abnormal vessels. These 
features apart from confirming the pathological element of CVMs, also pointed out their 
wide variability, hence the difficulties in matching these variable but similar 
histological entities with a defined clinical lesion. Certainly, flow categories of CVMs 
cannot be distinguished by histological morphology so far. Many of the CVM 
specimens had the external elastic lamina disrupted, and the elastic fibres appeared to be 
multilayered and diffuse within the stromal tissue of the CVMs. Thrombus formation 
was noted within some CVM vessels. Leakage of capillaries or larger vessels was 
commonly observed. 
 Scanning all CVM specimens did not allow to confidently predict the site of the so 
called ‘nidus’, destruction of which would lead to a cure of CVMs. This ‘nidus’ is 
frequently reported by the interventional radiologists during embolization of AVMs and 
represents a cluster of prominent blood vessels. The ‘nidus’ is suspected to be amongst 
the most active parts of the specimens, featuring the common morphological elements 
described in relation to CVMs. However, morphology alone cannot establish exactly the 
location of the ‘nidus’ or whether this has been removed or not at the time of surgery.  
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The intralesional nerves noted in our study were also described in a study of 167 extracranial 
CVMs, of which 76 were vascular malformations. The nerve bundles were identified in 91% of 
the vascular malformations and it has been suggested as a diagnostic clue to differentiate 
vascular malformations from haemangiomas (Adegboyega and Qiu, 2005). The close 
relationship between the abnormal vascular channels and associated large nerve fibres may 
implicate the Ephrin family of molecules in the development of these lesions. Ephrins are 
known to have essential roles in both angiogenesis and neural crest cell and axonal growth 
guidance. Recent published work indicated expression of arterial markers ephrinB2 and EphB2 
by the venous ECs of the malformed veins in a series of seven venous malformations. Whether 
this can be interpreted as a cause or consequence remains to be established. 
CVMs are considered by some authors to represent focal persistence of primitive 
vascular elements but this statement remains unproven and this study found no results to 
support such a statement. 
CVM vessels are embedded into a stromal tissue, to which they are closely 
related and with which they interact. This stromal tissue appears to vary from specimen 
to specimen in quantity, although by analysing the quantity of connective tissue present 
in CVMs in comparison with control tissue, there was no significant difference. Another 
important feature of the CVM stroma was the presence of a cell infiltrate amongst most 
of CVMs. The nature of this cell infiltrate is still to be determined and this represents 
the objective of the next chapter. Interestingly, previous studies reported that stroma of 
these lesions was unremarkable (Mulliken et al, 1982). This remark may be associated 
with the difficulties over the years in clearly defining CVMs and differentiating them 
from haemangiomas. The access to CVM tissue is still very limited and this explains the 
paucity of studies in the literature on CVM tissue. This emphasises the difficulty in 
interpreting the available studies in literature, since authors may not have a clear 
understanding of CVMs nomenclature, and therefore the lesions described may not be 
classified correctly. 
To summarise, CVMs contained a higher number of blood vessels (p=0.0004) and these 
vessels had an average diameter higher that skin controls (p=0.0005). Alteration of 
vessel walls in CVMs was noted although, it is not possible to know whether these 
changes developed primarily within the vessels wall of CVMs or they are the result of 
the interaction between vessel wall and stromal constituents, which in our study points 
Chapter 3 – Results 
 
 91 
out towards a stromal cell infiltrate which became the object of our next phase of the 
study. 
This study demonstrates the necessity of: 1) finding a classification that is clinically 
reproducible and applicable and 2) establishing a common language for clinicians and 
histopathologists. It provides a basis for further work in understanding the aetio-pathology of 
vascular malformations. The morphological heterogeneity of the lesions studied here suggests 
that specific molecular patterns may exist within vascular malformations, which may result in 
further clinical sub-classification. Exploration of angiogenesis, hypoxia and related signalling 
pathways involved may further identify these patterns and may provide novel classifications, 
more therapeutically, and prognostically useful together with a common international 
terminology for all specialists dealing with these difficult lesions. 
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4. HISTOCHEMICAL AND IMMUNOHISTOCHEMICAL ANALYSIS OF 
INFLAMMATORY CELL INFILTRATION OF CVMs 
4.1 INTRODUCTION 
The morphological analysis described in Chapter 3 resulted in the observation of a 
stromal cell infiltrate within CVM specimens, which was clearly identified in most H&E 
sections of the CVMs.  
Among the variety of inflammatory cells, which could represent the cell infiltrate 
identified, mast cells and macrophages have been the most commonly studied in literature and 
they are frequently present where cell infiltrates are identified. There is data in literature 
indicating that leukocytes can attach firmly to ECs and transmigrate into surrounding tissue 
(Mozzam, DeLano et al. 1997; Marschel and Schmid-Schonbein et al. 2002). It is also known 
that inflammatory cells can respond to flow changes. Altered blood flow triggers an 
inflammatory response that facilitates remodelling (Bakker et al, 2008) and vascular tone 
appeared crucial determinant of the direction of the remodelling response. Little is known about 
the blood flow within the abnormal vessels of vascular malformations.  
CVMs are not considered inflammatory lesions but their natural course is complicated 
at times by elements involving inflammation such as ulcers and thrombosis. In addition, 
endovascular therapies, meaning introducing foreign bodies/substances within CVM vessels, 
could also introduce an element of local inflammation. In theory it is possible that these lesions 
may have an underlying chronic inflammatory process, which in certain conditions may become 
acute. However, in our series of 33 CVMs, only three CVMs had ulceration, six had 
endovalscular treatment and two had both ulcers and history of endovascular treatment. The 
abundant cell infiltrate was present in the majority of specimens and not to those described 
above. 
Whilst there is sufficient data in literature regarding the presence of mast cells and 
macrophages in haemangiomas, as described below, there is only one study referring to their 
presence in vascular malformations (Mulliken et al, 1982), implying their absence in these 
lesions. This is why further clarification is required as to the nature of the cellular infiltrate we 
identified on analysing vascular malformations. 
4.1.1 Mast cells in CVMs 
Mast cells circulate as immature cells and mature once they settle in a tissue. They are 
considered resident cells of connective tissue and have multiple functions as described in 
Chapter 1.  
The occurrence of mast cells in vascular tumours was observed by Dalion in 1965. 
Baroni in 1964 noted an increase of mast cells in haemangiomas, sclerosing haemangiomas 
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(dermatofibromas) and glomus tumours. Kim and Lee reported an increased number of mast 
cells within vascular tumours, particularly in capillary and mixed types of haemangiomas, 
whereas no significant increase was found in cavernous haemangiomas. Glowacki et al (1982) 
found abundant mast cells in the proliferating phase of haemangiomas, but very few in the 
involuting phase of haemangiomas as well as in vascular malformations and skin. They 
speculated that haemangiomas may arise or be maintained by very large concentrations of mast 
cells, but when stimuli from the mast cells disappear, the ECs and vascular channels may 
involute. The abundance of mast cells in the proliferating phase of haemangiomas suggests that 
they may play a role in the natural history of these lesions. Pasyk et al (1984) noticed the 
increase in the number of mast cells counts was associated with the formation of fibrous 
connective tissue, which appeared gradually within the stroma of these vascular tumours. The 
number of mast cells was proportional to the amount of fibrous tissue. In patients with 
intermediate or complete involution of strawberry haemangiomas, where haemangioma lesions 
in the majority of cases have been replaced by connective tissue, the number of mast cells was 
considerably decreased. The mast cell counts in lesions known to never spontaneously regress 
(port wine stains and AVMs) remained unchanged or were slightly increased in comparison 
with the number of mast cells in normal skin. Pasyk et al found a strikingly low number of mast 
cells in cellular haemangiomas that showed active growth as well as deficiency of the fibrous 
connective tissue inside the stroma of these vascular tumours. Therefore, they postulated that 
the concentration of mast cells in growing haemangiomas was connected with the gradual 
growth of fibrous connective tissue inside the tumour. Asboe-Hansen reported that mast cells 
occur during new connective tissue formation in pathological states. Since the lowest number of 
mast cells was found in cellular haemangiomas in which the ECs showed the largest 
proliferation, Pasyk (1983) suggested that mast cells are not responsible for the proliferation of 
the endothelium of blood vessels and that they are not the direct cause of the development of 
haemangiomas. This impression was further emphasized by the coincident appearance of 
increased mast cell counts and of fibrous connective tissue in growing stages of haemangiomas 
and the accumulation of mast cells in growing stages of haemangiomas prior to clinical 
regression.  
Woodrow et al (1997) described the entity of ‘enlarging congenital haemangioma’ in an 
adult with histological evidence of numerous mast cells suggesting an aetiological role of these 
cells in pathogenesis of haemangiomas.  
Enjorlas et al (2001) proposed the term ‘non-involuting congenital haemangiomas’, 
which may be a variant of common haemangioma of infancy or another hemangiomatous entity 
characterized by persistent fast-flow and associated with increased mast cells. These lesions 
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tested negative for GLUT-1, a marker for common haemangioma of infancy (North et al, 2000). 
Authors explained that this lesion does not carry a risk of excessive operative bleeding and 
recurrence and must be differentiated from vascular malformations because both exhibit fast-
flow. However, to date there is no histological criteria towards this differentiation or sufficient 
data to prove the two lesions are different.  
The roles of mast cells which are present in varying number in all stages of 
haemangiomas have not yet been defined but clearly they appear to be implicated in the patho-
physiology of these lesions. Mast cells have been indicated as a source of various inflammatory 
cytokines, chemokines and growth factors. Certain effectors produced by mast cells may 
participate in the development of haemangioma. Mast cells may secrete both pro-angiogenic 
and anti-angiogenic mediators, some of them already quantified in haemangiomas and 
considered to be implicated in their development (see ‘angiogenesis and CVMs’). The roles of 
mast cells in the life cycle of haemangioma are likely to be complex and may involve 
stimulators of angiogenesis in the proliferative phase and inhibitors in later phases (Tan et al, 
2004). Histamine which is a mast cell product may stimulate angiogenesis through its direct 
effect on EC proliferation by acting on the histamine-1 receptors. 
4.1.2 Macrophages in CVMs 
Macrophages are monocytes differentiated on migration into tissue and they share a 
number of cell markers and features. Their life time varies between 6 and 16 days and they are 
two types: resident (normal) and inflammatory (activated).  
Isik et al (1996) found macrophages to infiltrate haemangiomas during the proliferative phase 
but they were not found in vascular malformations. Macrophages have the potential to display, 
at different times, both inflammatory and anti-inflammatory activities. They have diverse 
functions, including phagocytosis, antigen presentation, antimicrobial cytotoxicity, and tissue 
remodelling as well as secretion of a wide range of growth factors, cytokines, complement 
components, prostaglandins and enzymes (Burke et al, 2002). They have the potential to initiate 
angiogenesis by release of proteases, growth factors (basic FGF, GM-CSF, TGF-alpha, IGF-I, 
PDGF, VEGF, TGF-beta), and other cytokines (IL-1, IL-6, IL-8, TNF-alpha, substance P, 
prostaglandins, interferons, thrombospodin 1). Activated macrophages have the capability to 
influence each phase of the angiogenic process, such as alteration of the local extra-cellular 
matrix, induction of ECs to migrate or proliferate, and inhibition of vascular growth with 
formation of differentiated capillaries (Boye et al, 2001). Monocytes recruitment to various 
tissues has been shown to be controlled by various chemokines including monocyte chemotactic 
protein (MCP-1)
 
(Sunderkotter et al, 1994) which Isik et al (1996) found to be significantly 
raised during haemangima growth. However, no explanation as to the role of macrophages 
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infiltrates in proliferating haemangiomas has been given to date. 
In summary, to date there is no knowledge about the composition or significance of the 
cell infiltrates in the stroma of CVM. This information could provide more insight into the 
pathophysiology of these lesions. 
4.2 OBJECTIVES 
Previous morphological analysis of CVMs demonstrated evidence of a cellular infiltrate 
within the CVM stromal tissue. This study aimed to identify the nature of infiltrate by 
investigating the constituent cells using markers for mast cells, macrophages, B lymphocytes, T 
lymphocytes, and a marker for cell proliferation. The cell infiltrate within CVMs was compared 
with that in control skin tissue. 
4.3 MATERIALS AND METHODS 
4.3.1 Selection of patients and tissue collection 
CVM specimens were obtained retrospectively from archive and prospectively as 
participants were subjected to surgery for their CVMs. Control specimens were all obtained 
prospectively. Details of patient selection criteria, consent forms and tissue collection are given 
in Chapter 2. 
  All CVM lesions analysed in this section were negative for GLUT-1, therefore 
supporting the clinical observation that they were vascular malformations, not haemangiomas. 
4.3.2 Assessment of cell infiltrate in CVMs 
Mast cells were assessed histochemically using Toluidine blue dye as described in 
Chapter 2. Paraffin sections of CVMs and controls were stained with Haematoxylin and Eosin 
staining (H&E) and Toluidine blue. Toluidine blue identified mast cells by demonstrating the 
metachromatic substances found in their cytoplasm. CD68, CD3, CD20 and Ki67 were assessed 
in addition, using the ABC technique for immunostaining of tissue, described in detail in 
Chapter 2 and Appendix. Primary antibodies were applied to the sections for 1 hour at room 
temperature, at the following concentrations: CD68 (M0876-Dako) (1:200), CD3 (VP-C316-
Vector Laboratories) (1:200), CD20 (M0755-Dako) (1:600), ki67 (VP-K542-Vector 
Laboratories) (1:200). For visualisation, the peroxidase reaction was developed using 
diaminobenzidine (Vector Laboratories). 
4.3.3 Measurement of mast cell and macrophage count on a field (1mm
2
) of CVM 
Once the tissue was stained for all markers, the numbers of cells was counted using 
AnalySIS software and expressed as cells per field, technique described in Chapter 2. 
In addition to this technique, for the preliminary study detailed below, based on 17 
CVM specimens obtained retrospectively, light microscopy method was used to count 
macrophages and mast cells by 2 observers. A 1mm
2 
microscopic grid under light microscopy 
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was used to count the cells on high power, over 5 different fields as described in the image 
analysis technique. This second technique was employed to assess the quality of data collected 
by analysing the inter-observer agreement.  
The selected variables (cell infiltrates), histological and immunohistochemical were 
analysed within the CVMs group and compared with their values in the control group. Within 
the CVM group, the significant findings in relation to the clinical confounding factors (i.e. type 
of flow, location of the lesion, previous interventional treatment of the lesion and presence of an 
ulcer in the vicinity of the lesion at the time of operation) were considered. Preliminary results 
were obtained as a result of analysing data obtained from the 17 CVM samples found in the 
archive, which were compared with the data obtained from control tissues. This study was 
performed concurrently using consecutive sections of tissue from blocks used for the pilot 
morphological analysis described in Chapter 3. As more prospective CVM samples became 
available, a database of 33 CVM specimens was consolidated. Below, the preliminary results 
are given in the first instance, followed by the results of the more comprehensive study based on 
the 33 CVMs. 
4.4 RESULTS 
  x100                                                 
                          Figure 4. 1. Toluidine Blue stain showing mast cells in a HF AVM 
                                    x200 
                            Figure 4. 2. Toluidine Blue stain showing mast cells in a LF AVM 
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                                 x100 
                           Figure 4. 3. Toluidine Blue stain showing mast cells in a skin control 
 
 
                        
                                                 Figure 4. 4. Mast cells in CVMs and controls 
 
The figure above shows there was a higher number of mast cells per microscopic field in CVMs 
comparing to skin controls, by both microscopy and image analysis as methods of 
quantification. 
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                                 x200 
Figure 4. 5. Immuno-staining expressed in stromal histiocytes (brown) in a HF AVM 
                                  x200 
                                   Figure 4. 6. Positive expression of CD68  in a LF AVM 
 
                       
                                              Figure 4. 7. Macrophages in CVMs and controls 
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The figure above shows there was a higher number of macrophages per microscopic field in 
CVMs comparing to skin controls, by both microscopy and image analysis as methods of 
quantification.  
 
Tabel 4. 1. Macrophages and mast cells in CVM and control groups               
Mann-Whitney Test, ** Significant at 1% level 
 
The table 4.1 shows highly significant difference in macrophages (p <.001) and mast cells (p 
< 0.001) between the CVM and the control groups. 
 
Tabel 4. 2. Macrophages and mast cells in CVMs by microscopy and IA  
Variables Median P-value 
Macrophages CVM (microscopy) 29.20 0.83 
Macrophages CVM (image analysis)) 32.40 
Mast cells (microscopy) 5.60 0.45 
Mast cells (image analysis) 6.20 
Wilcoxon Signed Ranks Test 
 
Wilcoxson test demonstrated no significant difference in CVM macrophages (p=0.83 > 0.05) 
between the microscopy and the image analysis method. No significant difference in mast cells 
(p=0.45 > 0.05) between the microscopy and the image analysis method was also proven. 
 
 
 
 
 
Variables Group Count Median P-value 
Macrophages CVM (microscopy) 
 
CVM 17 29.2 < 0.001** 
Control 10 8.5 
Macrophages CVM (image analysis)) 
 
CVM 17 32.4 < 0.001** 
Control 10 8.5 
Mast cells (microscopy) 
 
CVM 17 6 < 0.001** 
control 10 3 
Mast cells (image analysis) 
 
CVM 17 6.2 < 0.001** 
Control 10 2.8 
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Tabel 4. 3. CD3, CD20, ki67 in CVM and control groups 
Variable Group Median P-value 
CD3 
  
CVM 4.00 0.57 
Control 6.90 
CD20 
  
CVM 5.40 < 0.0001** 
Control .20 
KI67 
  
CVM .60 0.41 
Control 1.30 
Mann-Whitney Test, ** Significant at 1% level 
 
Tabel 4. 4. Correlations between significant variables and HF-LF types of CVMs 
Variable Correlation coefficient P-value 
Macrophages (microscopy) -0.14 0.58 
Macrophages (image analysis) 0.04 0.88 
Mast cells (microscopy) -0.06 0.82 
Mast cells (image  analysis) -0.06 0.81 
 CD20 0.05 0.86 
Spearman's rho correlation coefficient 
There was no significant correlation between clinical categories and any of variables that 
showed significant difference between the CVM group and the control group. Highest 
correlation (r = 0.41) was between clinical categories and diameters of blood vessels.  
 
Tabel 4. 5. Results of comparison between CVM and control groups 
Variable Control group 
N=10 
CVM group 
N=33 
P-value from Mann-
Whitney U test or Chi-
squared test* 
Age 
(Years) 
42 
[34-50] 
31 
[23-43] 
0.064 
Gender 
Number male (%) 
0/10 
(0%) 
14/33 
(42%) 
0.012* 
Macrophages 
(Number/mm
2
) 
8.5 
[7.4-9.4] 
26.2 
[18.8-32.8] 
<0.0001 
Mast cells 
(Number/mm
2
) 
2.8 
[2.0-3.4] 
5.4 
[4.4-7.0] 
<0.0001 
B-cells 0.2 2.2 0.003 
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(Number/mm
2
) [0-0.6] [0.4-6.6] 
T-cells # 
(Number/mm
2
) 
6.9 
[4.2-7.6] 
4.0 
[1.4-12.2] 
0.547 
Proliferating cells 
(Number/mm
2
) 
1.3 
[1.0-1.6] 
0.4 
[0-1.4] 
0.057 
Data quoted as median [interquartile range] 
# T-cell calculation based upon N=17 in CVM group and N=10 in control group. 
 
Tabel 4. 6. Macrophages, mast cells, demography and clinical data in CVMs 
Significant  parameters on CVMs and controls* comparison Macrophages 
N   number/mm
2 
 
Mast cells 
N   number/mm
2 
 
CVM demographic and clinical variables 
Sex Male 
female 
26 
26 
 6 
 5 
Type of flow  High 
Low 
27 
25 
27 
 5 
Location  Lower limb 
Upper limb 
Head 
torso 
23 
24 
34 
23 
5 
5 
8 
4 
Previous endovascular therapy Previous therapy 20 
 
26 
5 
 
5 
No previous therapy 
Presence of ulcer at operation Ulcer 
No ulcer 
27 
25 
5 
5 
*Data quoted as median 
 
4.5 DISCUSSION 
CVMs are not considered to be inflammatory lesions and therefore, there is no research data 
available in this respect. Previous morphological study indicated the presence of an 
inflammatory infiltrate within the stroma of these lesions and this study aimed to to clarify the 
nature of the cellular infiltrate.  
In this study the nature of the stromal cell infiltrate within CVMs was investigated using a 
panel of histochemical and immunohistochemical markers such as Toluidine blue for mast cells, 
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CD68 for macrophages, CD3 for T lymphocytes, CD20 for B lymphocytes, and Ki67 for 
proliferating cells. For the pilot study, two methods were used to count the mast cells and 
macrophages, light microscopy and image analysis, to determine the most precise and accurate 
method. There was no difference between the two methods as they rendered similar results 
(Wilcoxon Signed Ranks, p = 0.45 for mast cells respectively p = 0.83 for macrophages). Mann-
Whitney test showed a significant increased infiltrate of mast cells and macrophages in CVM 
stroma when compared to control tissue with a p<0.001 for both mast cells and macrophages. 
There were no significant increase in numbers of T lymphocytes or proliferative cells in CVMs 
when compared to controls by Mann-Whitney test, p = 0.57, respectively 0.41). Although 
results indicated there was a significant infiltrate of B lymphocytes within CVM stroma, it 
appears that the data is skewed by a few CVM specimens involving lymph nodes, and therefore 
containing more B lymphocytes than the rest of the samples.  
The majority of mast cells and macrophages were found to be clustered in close vicinity of 
the abnormal CVM channels or even within the vessel adventitia. This raises the possibility that 
these cells are not resident in the stromal tissue of the lesions and that they migrated from the 
vessel lumen into the stromal tissue. What attracted these cells to the stromal CVM tissue, what 
triggered and favoured their migration from the vessel vessel lumen through the endothelial 
lining and what actually is the role they fulfil within the CVM stroma, are all questions for 
which there are no answers available at present.  
The finding of mast cell and macrophage infiltrates in CVMs has not been reported previously. 
On the contrary, there was a report suggesting that the number of these cells was not raised in 
vascular malformations and the stroma of these lesions was unremarkable (Mulliken et al. 
1982). 
Macrophages and mast cells have been shown to have important roles in angiogenesis 
and response to hypoxia. Their presence within CVMs is not accidental and suggests an 
aetiological or pathogenic role. This infiltrate, when active, could also act as a promoter for 
progression of the CVMs. Mast cell chemotaxis is stimulated by angiogenic factors like VEGF 
and bFGF (Gruber, Marchese et al. 1995). Given the accepted role of mast cells in angiogenesis, 
scientists looked at the parallel development of blood vessels and mast cells in the lateral 
geniculate nuclei and concluded that both exhibited similar developmental time course 
(Michaloudi, Grivas et al, 2003). Human mast cells are a recognised source of cytokines as 
detailed in Chapter 1. The importance and role of mast cell-derived cytokines in diseases is 
uncertain, but it is understandable that they might play an important role in both physiologic and 
pathologic conditions. The function of mast cells in tissues is still generally unknown, but most 
likely involves both homeostatic controls of nerves and blood vessels, as well as host immunity. 
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Mast cell mediators also are known to affect ECs by inducing vasodilatation and are capable of 
initiating the recruitment of inflammatory cells and possibly the recruitment of macrophages in 
this case.  
The finding of a significant mast cells and macrophages infiltrate does not help with the 
classification of these lesions or help to improve communication between histopathologists and 
clinicians. There was no correlation between number of mast cells or macrophages found in 
CVMs with the clinical type of malformation, i.e. HF or LF, using Spearman's rho correlation 
coefficient.  
In summary, there was a significant increase in mast cell and macrophages (CD68) cell 
infiltration in association with CVMs compared to control skin vessels. This finding could 
account for the morphological vascular changes observed in CVMs, described in previous 
chapter. On the other hand, the accepted role of these cells in angiogenesis raises the possibility 
that their presence may be the result of altered angiogenesis markers in CVMs or, the abnormal 
expression of such markers. As the following chapter describes, there appear to be increased 
expression of VEGF, VEGF-R1, Tie2 and αVβ3 within CVMs. Whether there is a direct link 
between the expression of these markers and the presence of an inflammatory infiltrate, it is not 
known and further research is required. However, we performed a correlation analysis between 
the cytokines found to be over-expressed in CVMs and mast cells and macrophages infiltration. 
The results of these analyses are detailed in Chapter 5.  
To gain more insight into these mechanisms it is necessary to explore the complex 
signalling pathways associated with angiogenesis and hypoxia. This may identify patterns of 
disease and may provide novel useful classifications, which may act as therapeutic and 
prognostic indicators. 
 
 
  105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
 
 
 
 
 
 
 
 
Chapter 5 – Results 
 
 106 
5. ANGIOGENESIS MARKERS EXPRESSION IN VASCULAR 
MALFORMATIONS 
5.1 INTRODUCTION 
CVMs are composed of abnormal vessels and are associated with an inflammatory cell 
infiltrate represented by mast cells and macrophages within the stroma, cells which have a 
recognised role in angiogenesis. In addition, the morphological findings in CVMs such as 
increased number of vessels per field, increased vessel diameter, along with changes in vessel 
wall, may all be related to abnormal angiogenesis which may be implicated in the aetio-
pathogenesis of these lesions. 
5.1.1 VEGF in CVMs 
Very little is known about factors which regulate VEGFR expression in vascular ECs. 
High levels of VEGF have been associated with several disorders, including CVMs. Elevated 
levels of VEGF have been found in the proliferative phase of haemangiomas (Mulliken et al, 
2000). Takahashi et al (1994) stated that vascular malformations do not express VEGF. There is 
no research data quoting VEGF levels in peripheral vascular malformations but there is some 
data in relation to cerebral AVMs. The recurrent childhood cerebral AVMs have increased EC 
expression of VEGF, whilst non-recurring lesions have a low expression of VEGF (Sonstein et 
al, 1996). There is increased expression of VEGF mRNA in the parenchyma adjacent to brain 
AVMs with increased levels of VEGF protein in the AVM endothelium, compared to those in 
normal brain tissue and vessels (Hatva et al, 1996). Cutaneous and leptomeningeal vascular 
malformations were also reported to have increased expression of VEGF A, VEGFR-1 and 
VEGFR-2 (Comati et al, 2007). These data may not be applicable to peripheral CVMs for which 
no similar data exist. The expression of angiogenic cytokines such as VEGF in the vicinity of 
CVM could explain their tendency to recur when abnormal vessels are left behind after 
embolisation or debulking of the lesion. 
5.1.2 Tie-2/angiopoietins in CVMs 
Vikkula et al, 1996 reported venous malformations occurring in two families where a 
mis-sense mutation in the Tie-2 receptor resulted in an arginine to tryptophan substitution. They 
indicated that patients carrying this mutation develop vein-like structures that are deficient in 
non-ECs, mainly SMCs. Therefore, these malformations are comprised of vein-like lumina 
lined by a monolayer of ECs, with reduction in the smooth muscle layers, compared to normal 
vessels with similar sized lumina. There is a proportional increase in the number of smooth 
muscle cell layers as the diameter of the normal vessels increases but, venous malformations 
exhibit wide variation in luminal size without a complementary increase in smooth muscle 
layers with increasing vessel diameter. The abnormally large lumina in venous malformations 
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suggest that there must have been EC proliferation. Vikkula et al, 1998 stated that it would be 
interesting to determine whether sporadic venous malformations are caused by the same Tie-2 
mutation, as in the familial cases or whether other Tie-2 mutations can have the same functional 
effects. Folkman et al, 1996 suspected that the increased EC proliferation in the venous 
malformation is secondary to absence of SMCs. Vikkula speculated that the Tie-2 receptor-
ligand system is coupled with chemotaxis and proliferation of mesenchymal cells and with their 
differentiation into smooth muscle cells. Mutations result in ‘uncoupling between proliferation 
and differentiation of ECs and SMCs’ and to a ‘disproportionate number of ECs and SMCs in 
VMs’. Tie-2 was reported to have an increased immunohistochemical expression in the blood 
vessels of cerebro-vascular malformations (Comati et al, 2007).  
5.1.3 Integrins αVβ3 and αVβ5 in CVMs 
αVβ3 is reported to be expressed on blood vessels in human wound granulation tissue 
but not in normal skin (Brooks, Clark et al, 1994). αVβ3 is prominently expressed on the 
surface of ECs and platelets (Shattil, 1995).  Expression of αVβ3 is known to be up-regulated on 
ECs involved in the new blood vessel formation such as quiescent ECs lining blood vessels 
express minimal amount of αVβ3, whilst angiogenic vessels show increased expression. 
Complex formation of integrins and MMPs is crucial for wound healing and angiogenesis. In 
ECs αVβ3 induces the production of MMP-2 and subsequently interacts with the synthesized 
MMP-2 to stimulate vascular invasion (Brakebusch, Bouvard et al, 2002). 
EC interactions with the surrounding ECM are mediated by the integrin family of 
adhesion receptors as detailed in the Introduction chapter. ECs have been shown to express a 
variety of integrins, including αVβ3 and αVβ5.  
Whilst αVβ3 is frequently reported to be critically important in angiogenesis (Nisato, 
Tille et al, 2003), there is surprising data in the literature reporting normal vascular development 
in absence of all αV integrins (Bader, Rayburn et al, 1998). This raises the question whether 
different angiogenic processes have differential dependency on integrins. Tumour angiogenesis 
could be different from developmental angiogenesis and CVM angiogenesis. In conditions 
where angiogenesis process is dependent on integrins, these mediators may be a useful 
therapeutic target for those conditions. αVβ3 antagonists downregulate αVβ3 expression and 
inhibit ECs and vascular proliferation (Singh, Fu et al, 2000). A lot of integrin data in literature 
is derived from studies on tumour angiogenesis. Studies on rat lung implicated the αVβ3 
integrin in the inflammatory responses by increasing the capillary permeability (Singh, Fu et al, 
2000). 
There are no studies in the literature assessing any of the integrins in CVMs. However, 
there is data reporting αVβ3 expression (Lim, Guccione et al, 2005) or both αVβ3 and αVβ5 
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expression (Askn, Ozlem et al, 2006)  in cerebral vascular malformations, suggesting these 
molecules contribution to cerebral AVM pathology and indicating αVβ3 as a potential target for 
treating CVMs.  
Thus αVβ3 together with αVβ5 appear to be important mediators to be investigated in 
CVMs, given the abnormal angiogenesis theories surrounding CVMs pathogenesis. In addition 
an understanding of integrin activation mechanisms is crucial to the understanding regulation of 
cell adhesion in CVMs.  
5.1.4 Endothelins in CVMs 
 ET-1 is one of the most potent vasoconstrictor peptides, produced and released by ECs. 
It has many roles in the homeostatic mechanisms in different organs as modulator of vascular 
tone, tissue differentiation and development, cell proliferation and hormone production 
(Bagnato et al, 2004). 
  The role of ET-1 in pathological states is unclear. Experiments have shown animals 
with ET-1 mutations develop cardiovascular mutations (Kurihara et al, 1995). Multiple sources 
data suggests that ET plays a crucial role in cardiovascular diseases such as chronic heart 
failure, ischaemic heart disease, hypertension, atherosclerosis, pulmonary hypertension among 
others. In these diseases the circulating level of ET-1 is usually high. Data also suggests that 
ET-1 participates in the growth and progression of a variety of tumours. Chronic hypoxia has 
been shown to be an important stimulus for ET-1 release.  
5.2 OBJECTIVES 
As discussed, extensive data in the literature has suggested that CVM may be the result 
of disregulated angiogenesis. In order to support this statement it is necessary to demonstrate 
what chemical mediators are participating in CVM angiogenesis. A whole array of mediators 
plays a crucial role in the process of angiogenesis. It was impossible to analyse all of them, 
within the scope of this project, so a few markers for angiogenesis mediators were selected to be 
assessed in this work. This selection was based on an extensive literature review with respect to 
vasculogenesis, angiogenesis and the known chemical mediators involved in these processes. In 
addition, the morphological analysis detailed in chapter 3 demonstrated a potential role of an 
abnormal stromal cellular infiltrate found in CVMs. That may alter the expression of various 
chemical mediators with angiogenic roles.  VEGF A, VEGFR-1, Tie-2, αVβ3, αVβ5, and ET-1 
were chosen to be analysed in this project as each of them in part were considered to play key 
roles in the blood vessel development and, represented different pathways. The purpose of this 
component of my research work was to determine if the presence of abnormal stromal cellular 
constituents altered immunohistochemical expression of the following pro-angiogenic markers 
in CVMs: VEGF A, VEGFR-1, Tie-2, αVβ3, αVβ5, and ET-1. 
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5.3 MATERIAL AND METHODS 
5.3.1 Selection of patients and tissue collection 
CVM specimens were obtained retrospectively from archive and prospectively as 
participants were subjected to surgery for their CVMs. Control specimens were all obtained 
prospectively. This tissue was selected based on the same criteria as discussed in Chaper 2 and 
originated in the same blocks of tissue as those used for the studies detailed in Chapters 3 and 4.  
All CVM lesions analysed in this section were negative for GLUT-1, which supported the 
diagnosis of vascular malformations, rather than haemangiomas.  
The following table gives the number of CVM and control specimens used in this 
component of research for each proposed immunostain. 
 
Tabel 5. 1.  Immunostaining for angiogenesis markers and number of specimens analysed 
Antibody VEGF A VEGFR1 Tie2 αVβ3 αVβ5 ET-1 
Tissue 
CVM 29 11 11 11 11 10 
Control 10 7 7 7 7 x 
 
ET-1 immunohistological stains were also performed on additional 3 haemangioma specimens 
selected randomly from the Tissue Bank. Two of these were capillary haemangiomas and one 
was cavernous haemangioma. There were no additional demographic or clinical data known for 
these patients.  
5.3.2 Immunohistochemical analysis 
The immunostaining with VEGFR-1, Tie-2, αVβ3, αVβ5 antibodies required frozen 
tissue technique and this explains why these stains were fewer in comparison to VEGF A 
immunostain, which could be performed on paraffin embedded tissue. Frozen tissue was 
available only those prospective cases where sufficient tissue was available. The 
immunostaining for VEGF A and ET-1 were performed on fixed paraffin embedded tissue.  
The ABC peroxidase technique and immunostaining protocol used here has been 
described in Chapter 2.  
CVM tissue immunostained for VEGF A, VEGFR-1, Tie-2, αVβ3, αVβ5, and ET-1 was 
analysed by 2 observers for the distribution of expression of all markers expression using image 
analysis and light microscopy. The immunopositive slides were quantified using a simple 
scoring system from 0 to 3 as described in Chapter 2. On interpreting and reporting the data, the 
mean score of the two observers was considered. The staining was assessed as to whether this 
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was diffuse or focal, confined to ECs or within the vessel wall. The data obtained was 
interpreted for agreement using the kappa coefficient analysis. 
The results of the analysis of immunostaining of CVM tissue for each antibody 
considered was compared to the results from control tissue using the Mann-Whitney test for un-
paired non-parametrical data as this could not be assumed to have a Gaussian distribution. 
Correlations were made between the expression of each mediator in CVMs and the significant 
stromal constituents represented by macrophages and mast cells using Spearman’s coefficient 
for non-parametrically distributed data. 
 
5.4 RESULTS 
Tabel 5. 2. Demographic data for angiogenesis markers in CVMs study 
Antibody Control CVM  
 
Control  
 
CVM 
 
 Age (Years) 
Mean±SD 
 
 
Gender Number male (%) 
VEGF A  43±17 30±17 0(0%) 13(45%) 
VEGFR-1  
Tie-2 
αVβ3  
αVβ5 
ET-1 
42±20 
42±20 
42±20 
42±20 
x 
39±19 
39±19 
39±19 
39±19 
32±17 
0(0%) 
0(0%) 
0(0%) 
0(0%) 
x 
3(27%) 
3(27%) 
3(27%) 
3(27%) 
4(40%) 
 
Tabel 5. 3. Angiogenesis markers in CVMs and relationship to clinical features 
Antibody Flow type  
LF:HF 
CVM location Number (%) 
Embolised 
CVMs 
VEGF A 3.8:1 Upper limb 11 (38%) 
Lower limb 11 (38%) 
Abdomen 1(3%) 
Head and neck 6 (21%) 
4 (14%) 
VEGFR-1 
Tie-2 
αVβ3  
αVβ5 
1.2:1 
1.2:1 
1.2:1 
1.2:1 
Upper limb 4 (36%) 
Lower limb 6 (55%) 
Abdomen 1 (9%) 
 
4 (36%) 
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ET-1 9:1 Upper limb 4 (40%) 
Lower limb 3(30%) 
Head and neck 3(30%) 
3 (30%) 
 
 
 
Figure 5. 1. Staining score for angiogenesis markers in CVMs 
The figure above shows the scoring distribution (from 0 to 3) for all angiogenesis markers 
analysed by the two independent observers. 
Inter-observer agreement was acceptable (kappa=0.33). For perfect agreement kappa=1 and for 
no agreement better than chance, kappa=0. The p-value of <0.0001 indicates that this agreement 
is not occurring by chance. 
 
Tabel 5. 4.  Kappa coefficient data analysis    
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Tabel 5. 5. Results of kappa coefficient analysis   
                           Expected 
Agreement        Agreement          Kappa        Std. Err.              Z           Prob>Z 
---------------------------------------------------------------------------------------------- 
  51.38%             27.81%              0.3265         0.0557             5.86          0.0000 
 
5.4.1 VEGF A/VEGFR-1 
5.4.1.1 Immunohistochemical localisation of VEGF A/VEGFR-1 
CVM specimens and control tissue were immunostained for VEGF A and VEGFR-1 
using the ABC technique described previously. The stained slides were analysed using light 
microscopy and image analysis software. Both VEGF A and VEGFR-1 were localised to EC of 
abnormal blood vessels comprising the CVM. VEGF A was expressed in all categories of 
CVMs. VEGFR-1 was present in most CVMs and was highly expressed by the ECs of the 
clinical category of CVMs known as HF, which are a more aggressive entity.  
5.4.1.2 Image analysis of of VEGF A/VGFR-1 immunostained sections of CVMs 
                                       x100 
                                   Figure 5. 2. Positive VEGF A Immuno-staining in a CVM 
                                     x40 
                         Figure 5. 3. Negative VEGF A Immuno-staining in a skin control 
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Fourteen % of cases showed moderate expression of VEGF-A (score 2). Twenty one % of 
CVMs showed focal expression of VEGF-A (scored 1) and 66% were negative for VEGF-A. 
VEGF-R1 was highly expressed by the ECs in some CVMs (18%). Eighteen % of lesions 
scored 2, 45% scored 1 and 18% were negative. Tie-2, which controls vascular remodelling, 
was moderately expressed by the ECs in all CVMs. All lesions expressed Tie-2.  Eighteen % of 
lesions scored 3, 64% scored 2 and 18% scored 1. From the adhesion molecules assessed, αVβ3 
was highly expressed by ECs in CVMs. Eighteen % of lesions scored 3, 18% scored 2, 45% 
scored 1 and 18% were negative for αVβ3.  αVβ5 which mediates angiogenesis induced by 
VEGF A was also expressed. Eighteen % of cases scored 3, 27% scored 2, 36% scored 1 and 
18% were negative for αVβ5. 
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Figure 5. 4. Comparison of VEGF A immuno-staining in CVM and control groups 
The figure 5.4 shows that there was no statistically significant difference between the 
immunohistochemical expression of VEGF A in CVMs and controls (p=0.226).  
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                                        x100 
                                Figure 5. 5. Positive VEGFR-1 Immuno-staining in a CVM 
                                   x100 
                            Figure 5. 6. Negative VEGFR-1 immuno-staining in a skin control 
 
 
Figure 5. 7. Comparison of VEGFR-1 immuno-staining in CVM and control groups 
Comparison of VEGFR-1 Immuno- staining
VEGFR-1 VEGFR-1 controls
0
1
2
3
Mann-Whitney test, p=0.011, *
CVM patients and control groups
V
E
G
F
R
-1
 I
m
m
u
n
o
-s
co
ri
n
g
Chapter 5 – Results 
 
 115 
The figure 5.7 shows that there was statistically significant difference between the 
immunohistochemical expression of VEGFR-1 in CVMs and controls (p=0.011).  
5.4.1.3 Correlation of VEGF A/VGFR-1 expression with the significant morphological 
stromal changes in CVMs 
 
Figure 5. 8. VEGF A immuno-scoring and macrophages number in CVMs 
The figure 5.8 shows that there was statistically significant correlation between the 
immunohistochemical expression of VEGF A and macrophages number in CVMs (p=0.0003).  
 
Figure 5. 9. VEGF A immuno-scoring and mast cells number in CVMs 
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The figure 5.9 shows that there was no statistically significant correlation between the 
immunohistochemical expression of VEGF A and mast cell number in CVMs (p=0.36).  
 
 
Figure 5. 10. VEGFR1 immuno-scoring and macrophages number in CVMs 
The figure 5.10 shows that there was no statistically significant correlation between the 
immunohistochemical expression of VEGFR-1 and macrophages number in CVMs (p=0.53).  
 
Figure 5. 11. VEGFR-1 immuno-scoring and mast cells number in CVMs 
The figure 5.11 shows that there was no statistically significant correlation between the 
immunohistochemical expression of VEGFR-1 and mast cells number in CVMs (p=0.41).  
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5.4.2 TIE-2 
5.4.2.1 Immunohistochemical localisation of Tie-2 
Tie-2 which controls vascular remodelling was moderately expressed in all CVMs and it was 
localised to EC. 
5.4.2.2 Image analysis of Tie-2 sections of CVMs 
 
 
                                       x100 
              Figure 5. 12. Positive expression of Tie-2 Immuno-staining in a CVM expressed in ECs 
 
 
                                     x40 
                      Figure 5. 13. Weak expression of Tie-2 on Immuno-staining in a skin control 
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Figure 5. 14. Comparison of Tie-2 immuno-staining in CVM and control groups 
The figure 5.14 shows that there was statistically significant difference between the 
immunohistochemical expression of Tie-2 in CVMs and controls (p=0.002).  
5.4.2.3 Correlation of Tie-2 expression with the significant morphological changes in CVMs 
(number of macrophages and mast cells per field). 
 
Figure 5. 15. Tie-2 immuno-scoring with macrophages number in CVMs 
The figure 5.15 shows that there was no statistically significant correlation between the 
immunohistochemical expression of Tie-2 and macrophages number in CVMs (p=0.94).  
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Figure 5. 16. Tie-2 immuno-scoring with mast cells number in CVMs 
The figure 5.15 shows that there was no statistically significant correlation between the 
immunohistochemical expression of Tie-2 and mast cells number in CVMs (p=0.07).  
5.4.3 Integrins αVβ3 and αVβ5 
5.4.3.1 Immunohistochemical localisation of  αVβ3 and αVβ5 
αVβ3 is known to be exclusively expressed on activated ECs. αVβ5 is also an 
endothelial integrin which promoted VEGF (but not FGF2) induced angiogenesis. αVβ3 was 
highly expressed in CVMs but αVβ5 was absent. 
5.4.3.2 Image analysis of  αVβ3 and αVβ5 sections of CVMs 
                                    x100 
                      Figure 5. 17. Positive αVβ3 immuno-staining in a CVM expressed in ECs  
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                                   x100 
                             Figure 5. 18. Negative αVβ3 Immuno-staining in a skin control 
 
                                     x100 
                                  Figure 5. 19. Negative αVβ5 Immuno-staining in a CVM 
 
                                 x40 
                                  Figure 5. 20. Weak expression of αVβ5 in a skin control 
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Figure 5. 21. Comparison of αVβ3 immuno-staining in CVM and control groups 
The figure 5.21 shows that there was statistically significant difference between the 
immunohistochemical expression of αVβ3 in CVMs and controls (p=0.011).  
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Figure 5. 22. Comparison of αVβ5 immuno-staining in CVM and control groups 
The figure 5.22 shows that there was statistically significant difference between the 
immunohistochemical expression of αVβ5 in CVMs and controls (p=0.044).  
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5.4.3.3 Correlation of αVβ3 and αVβ5 expression with the significant morphological changes in 
CVMs (number of macrophages and mast cells per field). 
 
Figure 5. 23. αVβ3 immuno-staining and macrophages number in CVM 
The figure 5.23 shows that there was no statistically significant correlation between the 
immunohistochemical expression of αVβ3 and macrophages number in CVMs (p=0.048).  
 
 
Figure 5. 24. αVβ3 immuno-staining and mast cells number in CVM 
The figure 5.24 shows that there was statistically significant correlation between the 
immunohistochemical expression of αVβ3 and mast cells number in CVMs (p=0.0033).  
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Figure 5. 25. αVβ5 immuno-staining and macrophages number in CVM 
The figure 5.25 shows that there was no statistically significant correlation between the 
immunohistochemical expression of αVβ5 and macrophages number in CVMs (p=0.46).  
 
Figure 5. 26. αVβ5 immuno-staining and mast cells number in CVM 
The figure 5.26 shows that there was no statistically significant correlation between the 
immunohistochemical expression of αVβ5 and mast cells number in CVMs (p=0.98).  
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5.4.4 ET-1/ETA/ETB 
Endothelin-1 and its receptors ETA and ETB have recognised roles in direct and 
indirect modulation of angiogenesis. As detailed in Chapter 1, ET-1 promotes EC proliferation, 
migration, protease formation, tube formation and invasion. Previous studies implied ET-1 
association with microvessel density and VEGF expression. Data in literature reports a 
pathogenic role for ET-1 in disease states. Interestingly, cerebral AVM vessels lacked ET-1 
although ET-1 expression was prominent in vessels distant from these lesions (Rhoten, Comair 
et al, 1997). This molecular phenotype was thought to be responsible for the lack of 
haemodynamic auto-regulation present in cerebral AVMs. The pattern of expression of ET-1 
has not been previously reported to be assessed in any of the CVMs. ET-1 presence or absence 
in CVMs would be informative in the context of the other angiogenic markers investigated in 
this chapter, as well as hypoxia markers and NEP investigated in Chapter 6. NEP is a 
metallopeptidase known to modulate bioavailability of peptide mediators and growth factors. 
NEP degrades ET-1 and controls inflammatory responses.  
5.4.4.1 ET-1 immunohistochemical expression in CVMs 
The immunohistochemical staining of CVM tissue was technically sub-optimal but the 
majority of vascular malformations were negative for ET-1. Ten vascular malformations were 
analysed immunohistochemically for ET-1 and 8 of them had negative expression of ET-1. One 
lesion which was ET-1 immuno-positive was embolised pre-operatively, had an intra-muscular 
component and it was located on the forearm. Another vascular malformation had equivocal 
expression of ET-1, but the corresponding slide had areas of technical errors (tissue has lifted) 
and it was difficult to interpret results accurately. It was interesting to note that from the 3 
haemangiomas (two capillary haemangiomas and one cavernous haemangioma) immunostained 
for ET-1, all of them showed positive expression of ET-1. ET-1 was localised in the ECs and 
inflammatory cells in haemangiomas. Small bowel was used as a positive control for ET-1 
immunostaining and the figure 5.27 shows ET-1 expression in the ECs and inflammatory cells 
in a section of small bowel.  
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                                   Figure 5. 27. Positive expression of ET-1 in small bowel 
 
5.5 DISCUSSION 
The first aim of this part of study was to determine the expression of angiogenic 
mediators in CVMs. Secondly the aim was to explore the relationship between the identified 
angiogenic markers and the CVM stromal inflammatory cell infiltrate represented by 
macrophages and mast cells. The immunohistochemical assessment of the chosen angiogenic 
mediators – VEGF A (p=0.22), VEGFR-1(p=0.01), Tie-2 (p=0.002), αVβ3 (p=0.01) and αVβ5 
(0.04) – indicated that there was increased expression of all these mediators in CVM tissue in 
comparison to normal control tissue. The exception was VEGF A which, although present in 
CVMs, showed no statistically significant difference in its expression in CVMs in comparison 
to control tissue, in the cases analysed. Also, ET-1expression in vascular malformations appears 
to be absent, although there is positive expression of ET-1 in haemangiomas. The statistical 
analysis was performed using the Mann-Whitney U test. The findings suggest that all the 
angiogenic mediators found to be up-regulated in CVM tissue could be implicated in the 
pathogenesis of these lesions. Clinical correlation showed the highest immuno -score was noted 
in lower limb CVMs for VEGFR-1, Tie-2 and αVβ3. The score for αVβ5 was similar in lower 
limb and upper limb lesions. There was no significant difference in the immuno-score for HF or 
LF lesions but the majority of embolised HF lesions were positive for all investigated markers, 
except in two instances: one where VEGFR-1 was negative in an embolised upper limb HF 
lesion and, one where αVβ5 was negative in a lower limb HF lesion with a history of multiple 
embolisations. All these clinical parameters (location of lesion, type of flow and history of 
embolisation) could influence the expression of the angiogenic mediators in CVMs. The 
embolic material introduced at the time of embolisation theoretically could lead to tissue 
hypoxia, which in turn could act as a stimulus for the angiogenic mediators. The shear stress 
caused by the pattern of flow or even location of the CVM could potentiate any hypoxic effects.  
x400 x40 
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There was a statistically significant negative correlation between the immunohistochemical 
expression of αVβ3 and the number of mast cells per microscopic field with a Spearman 
correlation ratio r= – 0.81 and p=0.0033. The highest number of mast cells per microscopic field 
was found in CVMs where there was no expression of αVβ3. Similarly, there was a statistically 
significant negative correlation between the immunohistochemical expression of VEGF A and 
the number of macrophages per field, with a Spearman correlation ratio r= -0.64 and p=0.0003. 
Again, the highest number of macrophages per field was found in specimens of CVMs where 
there was no immunohistochemical expression of VEGF A. No other correlation was identified 
between any of the up-regulated angiogenic markers in CVMs and stromal macrophages or mast 
cells, although the numbers compared were small.  
HIF-1α activity is known to result in the transcriptional up-regulation of many 
angiogenic factors including VEGF A and VEGFR-1. VEGF induction may be secondary to 
activation of HIF-1α, either by inhibiting its degradation, or by increasing its rate of synthesis. 
HIF-1α and especially HIF-2α (see Chapter 6), were present in CVMs, although little is known 
about the HIF-2α signalling pathways in comparison to HIF-1α signalling pathways. Recently it 
has been shown that macrophage production of VEGFR-1 in response to hypoxia was 
dependent on HIF-2α, whilst HIF-1α specifically regulated VEGF production (Sumner et al, 
2011), by neutralising VEGF and inhibiting its biological activity.  
Macrophages are known to be capable of producing and expressing VEGF A along with 
other angiogenic factors as discussed previously. They are also reported to become angiogenic 
in conditions of hypoxia and respond to hypoxic conditions by up-regulating HIFs expression, 
with subsequent increase in VEGF A expression. In this study VEGF expression appears to be 
the result of hypoxia/HIFs up-regulation, rather than mediated by macrophages. The 
immunohistochemical localisation of the VEGF A was on the ECs of the CVM vessels and not 
on macrophages, although macrophages in many instances were intimately related to the 
abnormal vessels of CVMs. These results suggest at least two different categories of CVMs: 
those with higher number of macrophages and no expression of VEGF A and those with no 
macrophages or few numbers and increased expression of VEGF A. VEGF expression was not 
detected in macrophages themselves despite the accepted ability of macrophages to produce and 
express VEGF. This finding could represent a snap picture of the CVM disease status, meaning 
some lesions may be more active than others or simply, CVMs have different molecular 
mechanisms involved in their patho-physiology. All CVMs specimens were obtained at the time 
of surgery and as previously indicated, it was difficult to assess disease activity clinically, 
except in very few cases. Macrophages also have the ability to modulate angiogenesis by 
releasing factors that inhibit migration and mitoses of ECs and can down-regulate the formation 
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of new capillary blood vessels. CVMs with no expression of VEGF and increased number of 
macrophages may well represent a remission disease status or a pre-activation status or simply a 
quiescent status. Usually in tumours the increased number of macrophages is associated with 
on-going growth, neo-vascularisation and poor prognosis (see Introduction). These findings 
suggest that angiogenic pathways in CVMs may be different from those in tumours.  
A high number of mast cells in CVMs correlated with no staining for αVβ3 and absent 
or low number of mast cells in CVMs correlated with over-expression of αVβ3.  
Integrins mediate adhesion between cells and their surrounding matrices and transmit signals 
regulating cell survival, differentiation and migration. There have been studies reporting 
integrins to be mediators of mast cell inflammatory responses although, these reports were 
related to different integrins (α2β1) from those analysed in this study. It was postulated that 
mast cells express integrin and their co-stimulatory function may contribute to mast cell 
activation and cytokine production (Edelson et al, 2003). There are other studies confirming that 
mast cells express fibronectin-receptor integrins, which are involved in cell activation (Ra, 
Yasuda, et al, 1994) and other studies report that αVβ3 is expressed by most mast cells (Lorentz 
et al, 2002).  
αVβ3 expression in this study was localised to the CVM ECs and did not appear to be 
expressed by mast cells, although mast cells were very closely related to the CVM blood 
channels. Some categories of CVMs may have a ‘quiescent’ (asymptomatic) status and contain 
a significantly higher number of macrophages and mast cells. Eady et al, 1997 demonstrated a 
significant correlation between the number of mast cells and number of blood vessels in the 
dermis. CVMs are characterised by a significantly higher number of blood vessels/mm
2
 and this 
may also signify a higher number of macrophages and mast cells/ mm
2
 in quiescent states.   
To conclude, CVMs are not classified as inflammatory lesions but this study 
demonstrated increased stromal macrophages and mast cells (see Chapter 4). Although it is not 
possible to prove the role of this stromal infiltrate in the phase of active angiogenic process in 
CVMs it is plausible that the infiltrate must play some role in the pathogenesis of CVMs. There 
is heterogeneity in expression and up-regulation of the selected angiogenesis markers in CVMs 
and, this suggest an angiogenic pathway characteristic to CVMs.  Hypoxia or other mechanisms 
may be more important than the inflammatory cells in the up-regulation of angiogenic markers. 
However, this data supports the general statement that aberrant angiogenesis in CVMs appears 
to be the result of complex interactions between vessel EC and surrounding stroma. Different 
clinical categories of CVM appear to exhibit different angiogenic markers, which imply a 
different pathogenic mechanism and therefore a means for more accurate assessment and 
treatment.
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6.  ANALYSIS OF HYPOXIA IN CVMs 
6.1. HYPOXIA INDUCIBLE FACTORS EXPRESSION IN CVMs 
6.1.1 INTRODUCTION 
6.1.1.1 Hipoxia inducible factors and CVMs 
A variety of pathological conditions exists where the affected tissues are hypoxic or 
exhibit a low oxygen tension and CVMs may be amongst them, since these lesions appear to 
exhibit disregulated angiogenesis which is enhanced by hypoxia. Oxygen starved cells can 
recruit new blood vessels to their vicinity by the production of vascular endothelial growth 
factor (VEGF). Angiogenesis does not occur in normal adult tissue under normoxic conditions.  
Data in literature indicates that hypoxia-inducible factor 1 (HIF-1α) is a critical mediator of 
physiological responses to acute and chronic hypoxia. HIF-1α is required for the development 
of the systems that mediate these responses including the heart, blood and blood vessels.   
Studies have shown that hypoxia is marked during tumour development (Carreau et al, 
2011). Hypoxia develops in tumors because of the vascularisation with less ordered, chaotic and 
leaky vascular beds compared with that in normal tissues. In laboratory models, hypoxia has 
been shown to be associated with treatment resistance and increased malignant potential. 
Clinical studies have shown the presence and extent of tumor hypoxia as a negative prognostic 
indicator. Tumour-associated angiogenesis is partly regulated by the HIF pathway.  
CVMs are not vascular neoplasms and the significance of HIF expression in CVMs is 
still to be demonstrated.  
The association between hypoxia and inflammation is well established, and 
experimental models of ischaemia and reperfusion injury have proved the expression of certain 
inflammatory mediators is regulated by hypoxia. 
Recent experiments have shown that HIF-1α alters the expression of many of the key 
angiogenic growth factors that are produced by hypoxic cells in tissues including VEGF (Kelly 
et al 2003), and these bind to receptors on ECs and SMCs. In addition, HIF-1α also controls 
cell-autonomous responses to hypoxia in ECs by regulating the expression of hundreds of genes 
(Manalo et al 2005). Loss-of-function and gain-of-function studies indicate that HIF-1α plays a 
critical role in vascularisation both during development and in postnatal life (Carmeliet et al 
1998, Iyer et al 1998, Kelly et al 2003, Ryan et al 1998). 
There are some data to suggest that the prolyl hydroxylases (PHDs) increase during hypoxia. 
This would suggest that chronic hypoxia may cause reduced expression of HIF-1α. 
HIF-1α is universally expressed in all cell types, and coordinates responses to hypoxia 
in all tissues in which it is expressed. Wang and Semenza (1993) suggested that HIF-1α played 
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a more general role in oxygen homeostasis. HIF-1α also controls remodelling of pre-existing 
vessels in response to hypoxia. HIF-1α is required for embryonic survival (Carmeliet et al 1998, 
Iyer et al 1998, Maltepe et al 1997, Ryan et al 1998). The absence of HIF-1α activity results in 
lethality at mid-gestation with defective development of the heart, blood and vessels. HIF-1α 
protein levels and transcriptional activity were found to respond dramatically to cellular O2 
concentration (Jiang et al, 1997). O2-dependent hydroxylation of proline and asparagine 
residues in HIF-1α represent the mechanism for transducing changes in cellular oxygenation 
into changes in HIF-1α activity (Epstein et al 2001, Ivan et al 2001, Lando et al 2002, Yu et al 
2001). 
The HIF-2α subunit shows properties similar to HIF-1α, but is mainly expressed in 
stromal macrophages, and may mediate a different response to hypoxia. HIF-2α has a more 
specialized role, and appears to be much more cell-type specific (Talks et al, 2000). 
Arterial thrombosis is clinically linked to low or absent oxygen content within the 
thrombus and therefore, it could be argued that HIFs should be expressed. The process of 
arterial thrombosis may be acute or chronic but there are no reports in the literature regarding 
HIFs expression in thrombi in either situation. Many CVMs are characterised by thrombus 
formation.  
Animal experiments have shown that chronic hypoxia results in increased total vessel 
length, volume, endothelial surface area and number of endothelial cells in vivo, demonstrating 
a process of hypoxia-induced angiogenesis (Howell et al, 2003). 
Comati et al, 2007 reported markedly elevated nuclear immunohistochemical 
expression of HIF-1α and HIF-2α in cerebro-vascular malformations. It was emphasised that 
EC-specific HIFs activation provides a setting which supports and sustains angiogenesis and 
they could be used for developing therapeutic strategies aiming to treat incurable lesions.  
6.1.2. OBJECTIVES 
Whether or not hypoxia represents a permanent or intermittent feature of CVMs, is 
unknown.  Since it appears CVMs are lesions characterised by disregulated/active angiogenesis 
(see Chapter 5), it is logical to expect CVMs to express HIFs as hypoxia induces angiogenesis. 
Therefore, the possibility of hypoxia-mediated responses relevant to CVMs was explored 
assessing expression of HIFs in CVMs and correlating results with the expression of the 
selected pro-angiogenic markers in CVMs. 
6.1.3. MATERIAL AND METHODS 
6.1.3.1 Selection of patients and tissue collection 
To determine hypoxia-mediated responses in CVMs two techniques were used on CVM 
tissue: immunohistochemistry and Western blot analysis. In the immunohistochemistry part of 
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this study 12 and 20 CVM specimens for HIF-1α and HIF-2α respectively, were analysed, using 
tissue excised over a period of 3 years, as well as 10 control specimens. HIF-1α and HIF-2α 
expression were also assessed on 12 specimens of arterial thrombi (received from 8 patients). In 
addition, 22 CVM specimens (from prospective, newly acquired CVM patients) and 10 controls 
were immunostained for CAIX. Preliminary immunohistochemical analyses showed the 
selected HIFs antibodies did not work on paraffin sections from processed CVM tissue. They 
did work on thrombi.  The immuno- technique to assess HIFs did work on sections of frozen 
tissue. Therefore, all CVM cases in the HIF immunohistochemistry part of this study were 
prospective and staining was performed on frozen tissue. 
For the Western blot analysis samples from 7 patients were suitable for HIF-1α analysis and 
8 patients for HIF-2α analysis. The Western blot analysis was also performed on frozen tissue 
only.  
All tissue specimens were selected, collected and stored as described in Chapter 2.  
6.1.3.2 Immunohistochemical analysis 
Sections of CVM and control non-diseased tissue were stained with H&E, and 
immunohistochemical stains for HIF-1α and HIF-2α were used to determine whether HIF 
regulated hypoxia is a feature of CVMs. Additional stains were done for CAIX. A routine ABC 
peroxidase protocol used for surgical pathology specimens at Charing Cross Hospital was 
followed (described in Chapter 2 and Appendix). The immunostained slides were analysed for 
the distribution and expression of HIF-1α and HIF-2α and the immunopositivity was quantified 
using both image analysis and light microscopy.  
6.1.3.3 Immunohistochemical localisation of HIF-1α and HIF-2α 
HIF stained slides were analysed for localisation of staining by two independent assessors and a 
simple scoring system was used to interpret data. Slides were scored for the intensity and 
distribution of the staining using the traditional scoring system from 0 to 3 (as described in 
Chapter 2). On interpreting and reporting the data, the mean score of the two observers was 
considered. The staining was assessed as to whether this was diffuse or focal, localised to 
endothelial, within the vessel wall, stromal or within the macrophages.  
6.1.3.4 Western Blotting 
This study was to determine the presence or absence of downstream proteins in the HIF 
pathway in CVMs using Western Blot analysis. The protocol is described in detail in Chapter 2 
and it was optimised in the Renal Research Laboratories at Hammersmith Hospital, London. 
HIF immunostaining has been very difficult technically but with optimal tissue fixation the 
protocol has proven reliable and reproducible for the renal research team at Hammersmith 
Hospital. The Western blot analysis of CVM samples was done in collaboration with the team at 
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Hammersmith Hospital. The ‘in house’ HIF-2α monoclonal antibody was also used in this 
work, as described in Chapter 2. 
The protein levels of HIF-1α and HIF-2α are determined mainly by their rate of 
proteasomal degradation. Although other mechanisms, including positive and negative 
regulation of co-activator recruitment, phosphorylation, cellular redox state, and intracellular 
compartmentalization may also have a role in determining HIF activity, the dominant mode of 
regulation is HIF-1α stabilisation. 
 
6.1.4 RESULTS  
The following table presents the number of CVM and control specimens, analysed 
immunohistochemically categorised clinically according to site, whether there was pre-operative 
embolisation and the type of flow within CVM vessels, i.e. HF or LF.   
 
Tabel 6. 1. HIFs staining of CVMs and clinical data 
Immunostaining Number 
specimens 
Type of CVM 
flow 
 
Location CVM Location control 
HIF-1α 12 CVMs 
10 Controls 
High flow 2 
Low flow 10 
Lower limb 6 
(2 embolised) 
Upper limb 4 
(1 embolised) 
Head and neck 2 
Breast 4 
Amputation 3 
Abdomen 3 
HIF-2α 20 CVMs 
10 Controls 
High flow 5 
Low flow 15 
Lower limb 8 
(3 embolised) 
Upper limb 8 
(3 embolised) 
Head and neck 3 
Abdomen 1 
Breast 4 
Amputation 3 
Abdomen 3 
 
Western blot analyses for both HIF-1α and HIF-2α were performed on two HF lesions 
and five LF lesions. Westen blot for HIF-2α was also performed on a skin control specimen. 
The HF lesions and two of the LF lesions had been previously embolised or underwent previous 
sclerotherapy. Four specimens analysed originated in lower limbs, one in upper limb, one was 
abdominal and one was located in soft tissue of the head.  
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The next table gives a summary of the localisation of HIF-1α and HIF-2α staining for 
the samples analysed immunohistochemically. 
Tabel 6. 2. HIFs staining of CVM specimens and localisation of staining 
Immunostaining Number 
specimens 
Predominant staining area 
CVMs 
Predominant staining area 
controls 
HIF-1α 12 CVMs 
 
EC  Focal 1 
(8%) 
 
EC – Focal 0 (0%) 
      – Diffuse 4 (40%) 
 
Macrophages – Focal 0 (0%) 
           – Diffuse 4 
              (40%)   
 
No staining – 6 (60%) 
Diffuse 7 
(58%) 
8 Controls Macrophages Focal 1 
(8%) 
 
Diffuse 6 
(50%) 
No staining – 3 (25%) 
HIF-2α 20 CVMs EC Focal 1 
(5%) 
EC – Focal 4 (50%) 
      – Diffuse 2 (25%) 
Macrophages – Focal 0 (0%) 
                       – Diffuse 3    
                          (37%) 
Vessel wall – Focal 1 (13%)  
 
No staining – 2 (25%) 
Diffuse 
17 
(85%) 
8 Controls Macrophages Focal 1 
(5%) 
Diffuse 
15 
(75%) 
No staining – 2 (10%) 
 
The figures above do not add up because in most specimens HIF was expressed by both 
EC and macrophages. The most common overlapping picture of HIF expression seen in CVMs 
or controls was either focal or diffuse HIF expression by EC and diffuse expression by 
macrophages.   
The mean age ± SD of the patients recruited for immunohistochemical analysis was 
27.42 ± 11.80 for HIF-1α and 32.65 ± 11.80 for HIF-2α. The median age for HIF-1α group was 
Chapter 6 - Results 
 134 
24 with a minimum of 13 and maximum of 54 and the median age for HIF-2α group was 26.5 
with a minimum of 13 and maximum of 73. The sex ratio was 3:1/female: male in the HIF-1α 
group and 2:1/female: male in the HIF-2α group.  
The mean age ± SD of the patients recruited for Western blot analysis was 28.14 ± 13.83 for 
HIF-1α and 27.88 ± 12.82 for HIF-2α. The median age for both groups was 24 with a minimum 
of 18 and maximum of 58. The sex ratio was 6:1/female: male in the HIF-1α group and 
7:1/female: male in the HIF-2α group. 
Within the HIF-1α group on the scoring scale from 0 to 3 (as described in the Methods sub-
chapter), three lesions scored 0, seven lesion scored 1, one lesion scored 2 and one scored 3. 
Within the HIF-2α group, one lesion scored 0, three lesions scored 1, ten lesions scored 2 and 
six lesions scored 3.  These represented the mean score assessed by two independent observers. 
The kappa coefficient analysis of the data showed that the inter-observer agreement was 
acceptable (kappa 0.33) and the p value of <0.0001 indicated that this agreement was not 
occurring by chance. 
6.1.4.1 Image analysis of HIF-1α in CVMs 
The following slides demonstrate the immunostaining results for HIF-1α of various types of 
CVMs. HIF-1α was present in the ECs of abnormal channels of CVMs. HIF-1α was also 
expressed to a less extent in some of the control tissue samples.  
 
                                  x100 
                       Figure 6. 1. Weak expression of HIF-1α immuno-staining in a skin control  
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                                      x200 
                                            Figure 6. 2. HIF-1α immuno-staining in a CVM 
 
                                 x200 
                      Figure 6. 3. Weak expression of HIF-1α immuno-staining in a skin control 
 
 
Chapter 6 - Results 
 136 
Comparison of HIF-1  Immuno- staining
HIF-1  CVMs HIF-1  controls
0
1
2
3
Mann-Whitney test, p=0.66, NS
CVM patients and control groups
H
IF
-1
 I
m
m
u
n
o
-s
c
o
r
in
g
 
Figure 6. 4. HIF-1α immuno-staining in CVM and control groups 
The figure 6.4 shows that there was no statistically significant difference between the 
immunohistochemical expression of HIF-1α in CVMs and controls (p=0.66).  
6.1.4.2 Absence of immunohistochemical staining for carbonic anhydrase IX 
CA IX has been shown to be induced by hypoxia. HIF-1α has a binding site on CA IX. 
Previous reports indicated HIF-1α to be essential for CAIX transcription under hypoxia. CX IX 
was negative in all 22 CVM specimens analysed. 
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6.1.4.3 Correlation of HIF-1α and pro-angiogenic markers expression in CVMs 
 
Figure 6. 5. HIF-1α and angiogenesis markers immuno-staining in CVMs 
The figure 6.5 shows that there was no statistically significant correlation between the 
immunohistochemical expression of HIF-1α and VEGFR-1, Tie-2, αVβ3 and αVβ5 in CVMs 
(p=0.14; p=0.27; p=0.21; p=1).  
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Figure 6. 6. Correlation of HIF-1α and VEGF A immuno-staining in CVMs 
The figure 6.6 shows that there was no statistically significant correlation between the 
immunohistochemical expression of HIF-1α and VEGF A in CVMs (p=0.29).  
 
Figure 6. 7. Correlation of HIF-1α and macrophages number/field in CVMs 
The figure 6.7 shows that there was no statistically significant correlation between the 
immunohistochemical expression of HIF-1α and macrophages number in CVMs (p=0.76).  
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Figure 6. 8. Correlation of HIF-1α and mast cells number/field in CVMs 
The figure 6.8 shows that there was no statistically significant correlation between the 
immunohistochemical expression of HIF-1α and mast cells number in CVMs (p=0.35).  
 
6.1.4.4 Image analysis of HIF-2α 
 HIF-2α was even more prominent in CVMs and mostly absent in controls. HIF-2α was 
demonstrated in macrophages and co-localisation of CD68 and HIF-2α positive cells in serial 
sections was confirmed. HIF-2α stained EC nuclei. 
 
                                      x40 
                          Figure 6. 9. Positive expression of HIF-2α immuno-staining in a CVM  
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                                      x200 
                         Figure 6. 10. Positive expression of HIF-2α immuno-staining in a CVM 
                                x100 
                    Figure 6. 11. Negative expression of HIF-2α immuno-staining in a skin control 
       
HIF-1α x100                                                                    HIF-1α X200 
      
HIF-2α x100                                                                  HIF-2α X200 
Figure 6. 12. Positive HIF expression in CVMs – macrophages and EC nuclear staining 
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The picture above brings together HIF-1α and HIF-2α staining and suggests that although both 
are expressed in CVMs, HIF-2α is more extensively expressed than HIF-1α.  
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Figure 6. 13. Comparison of HIF-2α immuno-staining in CVM and control groups 
The figure 6.13 shows that there was statistically significant difference between the 
immunohistochemical expression of HIF-2α and in CVMs and controls (p=0.0004).  
6.1.4.5 Correlation of HIF-2α and pro-angiogenic markers expressions in CVMs 
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The figure 6.14 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and VEGFR-1 in CVMs (p=0.0043).  
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Figure 6. 15. Correlation of HIF-2α and Tie-2 immuno-scores in CVMs 
The figure 6.15 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and Tie-2 in CVMs (p=0.03).  
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Figure 6. 16. Correlation of HIF-2α and αVβ3 immuno-scores in CVMs 
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The figure 6.16 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and αVβ3 in CVMs (p=0.029).  
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Figure 6. 17. Correlation of HIF-2α and αVβ5 immuno-scores in CVMs 
The figure 6.17 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and αVβ5 in CVMs (p=0.045).  
 
 
 
Figure 6. 18. Correlation of HIF-2α and VEGF A immuno-scores in CVMs 
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The figure 6.18 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and VEGF A in CVMs (p=0.0001).  
 
Figure 6. 19. HIF-2α immuno-scoring and macrophages number in CVMs 
The figure 6.19 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and macrophages number in CVMs (p=0.02).  
 
Figure 6. 20. HIF-2α immune-scoring and mast cells number in CVMs 
The figure 6.20 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and mast cells number in CVMs (p=0.01).  
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6.1.4.6 HIFs expression in thrombi 
HIF-2α co-localised with CD68 staining for macrophages in CVMs.  
HIF-2α expression was negative in 5 out of 12 specimens and the rest of 7 specimens had little 
and few areas of staining. 
                                         
            Figure 6. 21. Positive expression of HIF-2α immuno-staining in a RCC specimen 
                                         
                 Figure 6. 22. Positive expression of HIF-2α immuno- staining in thrombi 
                                         
      Figure 6. 23. Positive expression of CD68 showing macrophages in the same thrombi specimen 
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Western Blot analysis results in CVMs 
The analysis was technically difficult because of the tissue composition of CVMs. 
The two HF specimens analysed (originating from lower limbs) were strongly positive for both 
HIF-1α and HIF-2α. In addition, one LF specimen (originating from upper limb) was strongly 
positive for both HIF-1α and HIF-2α. All these specimens have in common the fact that they 
have been embolised pre-operatively. One LF specimen (originating in the lower limb) was 
negative for HIF-1α and strongly positive for HIF-2α. One LF lesion (abdominal) was negative 
for HIF-1α and weakly positive for HIF-2α. Another LF lesion (head and neck) was weakly 
positive for HIF-1α and strongly positive for HIF-2α. The seventh lesion was weakly positive 
for both antibodies and this lesion in particular underwent pre-operative sclerotherapy. The HIF-
2α was negative in the skin control. The positive control was represented by RCC, known to be 
positive for HIFs. These results indicate variability in HIF-1α and HIF-2α presence in CVMs 
specimens, with a clear tendency for the specimens to show a stronger positivity for HIF-2α 
rather than HIF-1α, results similar to those obtained by immunohistochemistry. There was 
correspondence between HIFs expression on immunohistochemistry and HIFs positivity on 
Western blot as showed in the following table. These results have not been analysed statistically 
given the small numbers.  
 
Tabel 6. 3. HIFs immune-scoring and Western blot analysis results in CVMs  
Immuno-scoring 
HIF-1α  
Western blot  
HIF-1α 
Immuno-scoring 
HIF-2α 
Western blot  
HIF-2α 
1 
x 
0 
1 
1 
3 
1 
Strong 
0 
0 
Weak 
Strong 
Strong 
Weak 
2 
2 
3 
2 
3 
3 
2 
0 
Strong 
Weak 
Strong 
Weak 
Strong 
Strong 
Strong 
0 
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                              a)                        
                Figure 6. 24. Western blot analysis of CVMs showing results of HIF-1α in CVMs 
 
                           b) 
         Figure 6. 25. a) and b)-Western blot analysis of CVMs showing HIF-2α results in CVMs 
 
 6.1.5 DISCUSSION 
Both HIF-1α and HIF-2α were found to be present in CVM tissue analysed both 
immunohistochemically and using the Western blot. The expression of HIF-2α was significantly 
higher in CVM tissue than in control tissue (p=0.0004) but, there was no significant statistical 
difference between the immunohistochemical expression of HIF-1α in CVMs and control tissue.  
In theory these results are expected in CVMs, which are considered ‘highly angiogenic’ lesions. 
CVMs in which angiogenesis is taking place are said to be ‘active’. This phase is variable 
between lesions. Areas of hypoxia are common in places of active angiogenesis. HIF-1α 
component has a short half-life, but it is stabilised by hypoxia. HIF-1α has a low expression in 
HIF-2α 
HIF-1α 
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normal tissues. HIF-1α also directly potentiates migration and tube formation in ECs with 
potency similar to FGF2 (Eccles, 2004). Less is known about the contribution HIF-2α makes to 
the angiogenesis process. The contribution of HIF-1α versus HIF-2α to VEGF expression and 
other HIF regulated target genes under different conditions is also unclear. HIF-1α is known to 
regulate the transcriptional activation of VEGF in response to hypoxia. HIF-2α appears to 
enhance HIF-1α mediated VEGF expression in response to hypoxia (Carroll et al, 2006). The 
later authors also reported that in RCCs that constitutively express HIF-1α and HIF-2α due to 
loss of VHL function, high basal VEGF expression was predominantly dependent on HIF-2α. 
Other studies have shown that HIF-2α regulates a variety of hypoxia-inducible genes suggesting 
that its function is not restricted to the EC as it was initially thought (Hu, Wang et al, 2003). 
Another recent study showed opposing roles for HIFs in regulation of angiogenesis by 
tumour associated macrophages, suggesting that administration of GM-CSF induced VEGFR-1 
and inhibited tumour growth and angiogenesis in patients with melanoma (Sumner et al, 2011). 
I have shown a statistically significant correlation between the immunohistochemical expression 
of HIF-2α and VEGF A (p=0.0001), VEGFR-1 (p=0.0043), Tie-2 (p=0.03), αVβ3 (p=0.029) 
and αVβ5 (0.045) suggesting a direct or indirect connection between HIF-2α expression and the 
up-regulated angiogenesis markers. HIF-2α appears to be up-regulated in CVMs when the 
angiogenesis process is ‘active’ and it is possible that HIF-2α could up-regulate the expression 
of VEGF A, VEGFR-1, Tie-2, αVβ3 and αVβ5 in CVMs. HIF-1α was diffusely localised on 
ECs in 58% of cases and diffusely localised on macrophages in 50% of CVMs analysed here. 
HIF-2α was diffusely localised on ECs in 85% of case and diffusely localised on macrophages 
in 75% of cases. 
There was a positive correlation between HIF-2α and the number of stromal macrophages and 
mast cells in CVMs. Recently, the connection between hypoxia and inflammation has been 
demonstrated to be mediated by HIFs (Imtiyaz et al, 2011). In macrophages, HIFs regulate 
glycolytic energy generation, optimize the innate immunity, control pro-inflammatory gene 
expression, mediate bacterial killing and influence cell migration. In mast cells HIFs contribute 
to inflammatory functions (Imtiyaz et al, 2011). Macrophages themselves are known to be 
responsive to hypoxia leading to the up-regulation of HIFs. 
The angiogenic markers in our study (Chapter 4) did not correlate with the stromal 
inflammatory infiltrate in CVMs, although they did correlate with HIF-2α expression which in 
turn correlates with the stromal inflammatory infiltrate.  Other studies (Sluimer et al, 2008) 
demonstrated that hypoxia correlated with the presence of macrophages, angiogenesis, thrombus 
formation, and the expression of HIF and VEGF in human atherosclerotic lesions. It was 
speculated that hypoxic macrophages stimulate HIF and angiogenesis as well as the increase in 
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cytokine production. In other studies (Chen, et al, 2005) no correlation was found between HIF 
and angiogenesis in coronary intraplaque, and there was an inverse correlation with carotid and 
femoral intraplaque angiogenesis (Vink et al, 2007). The results from these studies contradict 
the well known positive correlation between HIF and angiogenesis in tumours (Semenza, 2003).  
Furthermore, in this study we also tested 12 thrombi for HIFs expression and 58% of specimens 
were positive with HIF staining co-localised with CD68. All studies so far indicate that the HIF 
signalling pathway and its involvement in angiogenesis and inflammatory processes may be 
different in different tissues/organs. 
In this study hypoxia related markers were expressed in macrophages but not all 
macrophages were hypoxic. Hypoxia may develop from an increased oxygen demand, resulting 
from the high oxygen demand of metabolically active inflammatory cells (Murdoch et al, 2005). 
On the other hand, hypoxia causes macrophages to accumulate in affected areas. It is not clear 
what the chronology of events in CVMs is but the likely possibility is that macrophages are 
attracted to CVM stroma, the lesion becomes active. Two facts point towards this possibility: 1) 
macrophages and mast cells are present in the stroma of CVMs (Glowacki, 1982); 2) 
inflammatory cells were close to the abnormal vessels in CVMs, suggesting they have migrated 
there from the blood vessel lumen. There are some clinical features of CVMs (as described in 
the introductory chapter) which may indicate an active CVM but they are not always accurate.  
In this study, there was variability in the HIFs expression in different clinical types of 
CVMs (HF or LF), with different locations. There was up-regulation of both HIF-1α and HIF-
2α in all HF lesions analysed by both, immunohistochemistry and Western blot. HF lesions are 
the most challenging clinically and notorious for exacerbation after any trauma including 
surgical intervention. HIF-1α and HIF-2α were also strongly expressed in a LF arm lesion 
which was previously embolised. Weak expression of both antibodies was noted in a LF lesion 
subjected to sclerotherapy pre-operatively. Another LF VM was negative for HIF-1α and 
strongly positive for HIF-2α. This lesion had no history of embolisation or sclerotherapy. 
Taking into account these pre-operative interventional techniques is important as the embolic 
material or the sclerosant would locate into the CVM blood vessel, occluding the vessel and 
subsequently depriving the CVM tissue from O2. Therefore, it is expected that lesions with 
previous radiological intervention would be hypoxic and express HIFs. Overall, all HF lesions 
analysed in this work and all CVMs with pre-operative radiological intervention over-expressed 
HIFs. In this case, HIFs and especially HIF-2α, which was more widely expressed could 
represent an index of activity of the CVM lesion and could possibly aid in predicting operative 
outcomes or simply to aid in the selection of which lesions would be most suitable for operative 
treatment. All patients from whom the CVM tissue in this study was derived had surgical 
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management and they had an excellent outcome from their operative management. However, 
the two lesions that were negative for HIF-1α and positive for HIF-2α required repetitive 
interventions and suffered exacerbations of symptoms between operations. How best to interpret 
these findings is difficult but it could be argued that more chronically hypoxic lesions tolerate 
better external intervention, even if these lesions are HF. The lesions that express less HIFs or 
no HIF-1α may be more vulnerable to external intervention. Looking at our clinical results, it is 
possible that even lesions less tolerant to external intervention may become more tolerant in 
time with successful repetitive interventions. This hypothesis cannot be proven as no tissue is 
available from lesions assessed to be high risk for surgery or inoperable and their immuno- 
profile cannot be ascertained. There may be other stimuli influencing HIFs expression, 
particularly HIF-2α expression in CVMs, which were not addressed in this study.  
The results suggest that HIF-2α expression may play an important role in CVM related 
angiogenesis and that the combined expression of HIF-1α and HIF-2α may be significant in 
CVM progression and prognosis. There was no expression of CAIX, although CAIX is also a 
marker of hypoxia. However, absence of CAIX may be significant. HIF-1α is part of the 
signalling pathway for CAIX, and the absence of CAIX may indicate a less important role for 
HIF-1α in CVM pathogenesis in comparison to HIF-2α. 
The results suggest HIF expression could be a useful target for therapeutic intervention and thus 
provide a route to cure these lesions and to avoid what may be life-threatening surgery. 
 
6.2 NEP/CD10 EXPRESSION IN CVMs 
6.2.1 INTRODUCTION  
Neutral endopeptidase (NEP, neprilysin), also known as common acute lymphoblastic 
leukemia antigen, represents  a cell surface zinc metallopeptidase involved in the extracellular 
metabolism responsible for the regulation of a variety of biologically active vasoactive peptides. 
Therefore, the presence of NEP may contribute to the regulation of vascular tone and local 
inflammatory responses in the vascular endothelium and surrounding stroma. Recent studies 
suggest that NEP may possess anti-angiogenic activity (Sumitomo et al, 2004). 
NEP is a membrane protein consisting of three domains: an N-terminal short 
cytoplasmic domain, a hydrophobic transmembrane domain and a large extracellular domain, 
which is responsible for the catalytic activity (Sumitomo et al, 2004). NEP has various functions 
depending on cell type or tissue origin. NEP is implicated in the regulation of the cardiovascular 
system and is protective in a number of cancers. NEP can influence signal transduction 
pathways that regulate cell growth (Ganju et al, 1996, Angelisova et al, 1999) and apoptosis 
(Cutrona et al, 1999).  The regulation of NEP expression is not well characterised at the cellular 
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level but studies suggest a cell type-specific event (Graf et al, 1995). These studies report that 
NEP is inducible by thrombin via activation of the PKC pathway.  NEP is constitutively 
expressed in a variety of human EC types (Graf et al, 1995) suggesting a systemic as well as a 
local regulatory role.  
In the vascular system, ET-1 is amongst the well known and best researched bioactive 
peptides reported to be degraded by NEP. ET-1 has an important role in vascular diseases as 
well as angiogenesis (see sub-chapter 5.4.4) but ET-1 expression or role in CVMs is unknown, 
as is the expression or role of NEP in CVMs. The cellular concentration of NEP is critical to 
tissue homeostasis (Turner, 2003). NEP up or downregulation can favour a range of 
pathological conditions such as cardiovascular, neurodegenerative or malignant, depending on 
the availability of the peptides acting as NEP substrate. 
Another reason to examine NEP expression in CVMs is the growing evidence that up-
regulation of NEP expression may relate to tumour progression. Loss or decrease in NEP 
expression has been reported in a variety of malignancies. Reduced NEP may promote peptide-
mediated vascular proliferation by allowing accumulation of higher peptide concentrations, with 
angiogenic roles (Sumitomo et al, 2004). Tumour progression is based on active angiogenesis, 
and disregulated angiogenesis appears to be the underlying cause of CVMs. ET-1 absent 
expression in CVMs was demonstrated in this study (chapter 5) and this could represent a 
substrate for NEP. NEP is a membrane bound enzyme and can be detected with CD10 
antibodies.  
 
6.2.2 OBJECTIVES 
The expression of NEP in CVM specimens was investigated using immunostaining 
techniques with CD10 antibodies. The aim was to elucidate the role of NEP in CVM 
pathogenesis.  
 
6.2.3 MATERIALS AND METHODS 
6.2.3.1. Selection of patients and tissue collection 
CVM specimens were obtained retrospectively from archive and prospectively as 
participants were subjected to surgery for their CVMs. Control specimens were all obtained 
prospectively. Details of patient selection criteria, consent forms and tissue collection are given 
in Chapter 2.   
In this study, 38 CVM specimens and 16 control specimens excised over a period of 15 
years were immunostained for NEP with CD10 antibodies. 
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Twelve CVM specimens were also stained for HIF-1α and 20 specimens for HIF-2α as 
described previously and the specimens used to assess HIFs expression were prospectively 
collected. The majority of these specimens showed expression of HIF-1α and HIF-2α in ECs 
and stromal cells.  
6.2.3.2. Immunostaining for NEP with CD10 antibodies 
All specimens were analysed immunohistochemically using standard methods as 
described in Chapter 2 with the difference that all immunohistochemistry for CD10 was 
performed using an automated immunostaining machine (see Methods, Chapter 2), which 
helped to standardise the results. CD10 immunostaining was performed on formalin fixed and 
paraffin embedded tissue samples. Glomus tumor was used as negative control for 
immunostaining. For HIFs, the staining technique was developed for frozen sections as it did 
not work on paraffin embedded tissue. 
CD10 stained slides were analysed for localisation of staining and were scored using the 
traditional scoring system from 0 to 3 as described in Chapter 2. Scoring was based on the 
proportion of cells with positive surface membrane and cytoplasmic staining. The staining was 
assessed as to whether was diffuse or localised to endothelial cells, within the vessel wall, 
stroma or adventitia. Descriptive statistics were calculated for baseline demographic and clinical 
characteristics of CVMs.  
 
6.2.4 RESULTS 
6.2.4.1 NEP/CD10 in CVMs 
All CVM specimens analysed in this section were vascular malformations as they did not 
express GLUT-1 on immunostaining. 
 
Tabel 6. 4. Demographic data of participants in NEP/CD10 analysis 
Variable Control group 
N=16 
CVM group 
N=38 
Age (mean±SD) 
(Years) 
42±18 31±17 
Gender 
Number male (%) 
5/16 (31%) 18/38 (47%) 
 
Endothelial cells lining the abnormal vessels of CVMs consistently expressed CD10. 
This marker was mostly absent or weakly expressed focally by the EC or vessel wall in our 
control tissues. CD10 was expressed in different types of CVMs regardless of their location (see 
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table 6.5). Sixteen % of cases scored 3, 16% scored 2, 63% scored 1 and 5% of cases were 
negative for CD10. 
 
Tabel 6. 5. NEP/CD10 number and location of specimens analysed 
Immunostaining Number specimens Location CVMs and 
numbers 
Location controls and 
numbers 
CD 10 38 CVMs Lower limb 16  
Upper limb 14 
Head and neck 7 
Abdomen 1 
Breast  4              
Amputation 4 
Abdomen 3 
AVM 3 
Flap 2 
Varicose veins 1 17 control specimens 
 
In three cases the CD10 staining appeared different from the majority of CVMs, where 
the CD10 was located at the EC, either diffuse or focal. In these aberrant CVMs the CD10 was 
located at the vessels adventitia and the vessel itself had no staining.  
The expression of CD10 in CVMs was correlated with the number of stromal macrophages 
(expressing CD68 immunostain) and mast cells (demonstrated with Toluidine Blue stain) but 
the results were not statistically significant. 
 
                                       x200 
                    Figure 6. 26. Positive expression of NEP/CD10 Immuno-staining in a CVM 
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                                     x40 
              Figure 6. 27. Negative expression of NEP/CD10 Immuno-staining in a skin control 
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Figure 6. 28. CD10/NEP immuno-staining in CVM and control groups 
The figure 6.28 shows that there was statistically significant difference between the 
immunohistochemical expression of CD10 in CVMs and controls (p=0.0002).  
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6.2.4.2 Correlation of HIFs with CD10/NEP in CVMs 
 
Figure 6. 29. Correlation of HIF-1α with CD10/NEP in CVMs 
The figure 6.29 shows that there was no statistically significant correlation between the 
immunohistochemical expression of HIF-1α and CD10/NEP in CVMs (p=0.065).  
 
Figure 6. 30. Correlation of HIF-2α with CD10/NEP in CVMs 
HIF-1 / CD10 Immuno-score
0 1 2 3
0
1
2
3
Spearman r=0.50, p=0.065, NS
HIF-1
C
D
1
0
/N
E
P
HIF-2 / CD10 Immuno-score
0 1 2 3
0
1
2
3
Spearman r=0.64, p=0.0002, ***
HIF-2
C
D
1
0
/N
E
P
Chapter 6 - Results 
 156 
The figure 6.30 shows that there was statistically significant correlation between the 
immunohistochemical expression of HIF-2α and CD10/NEP in CVMs (p=0.0002).  
6.2.4.3 Correlation of CD10/NEP with the significant stromal inflammatory cells in 
CVMs 
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Figure 6. 31. CD10/NEP immuno-scoring and macrophages number in CVMs 
The figure 6.31 shows that there was no statistically significant correlation between the 
immunohistochemical expression of CD10/NEP and macrophages number in CVMs (p=0.51).  
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Figure 6. 32. CD10/NEP immuno-scoring and mast cells number in CVMs 
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The figure 6.32 shows that there was no statistically significant correlation between the 
immunohistochemical expression of CD10/NEP and mast cells number in CVMs (p=0.22).  
6.2.5 DISCUSSION 
The results from this study indicated NEP over-expression in CVMs, implicating NEP 
in the pathophysiology of CVMs and possibly suggesting a role for NEP inhibitors in CVM 
treatment. Recently, there has been a considerable interest in NEP inhibitors due to 
physiological importance of NEP in the modulation of nociceptive and vasoconstrictor 
responses. 
The over-expression of CD10 coexisted with a prominent stromal inflammatory 
infiltrate and expression of HIFs, especially HIF-2α in CVMs. 
It is not known if hypoxia is the cause of HIF expression in CVMs. HIFs could also be 
expressed as a result of tumor suppressor gene inactivation or other conditions inducing 
expression (Talks et al, 2000). The results of the analysis of blood gases in CVMs are given in 
the sub-chapter 6.3. If hypoxia is a feature of CVMs, this is more likely to be chronic or at most, 
acute on chronic, given the chronicity of these lesions. Recent studies have shown the effect of 
chronic hypoxia on the expression of HIF-1α and HIF-1α target genes in various tissues (Tipoe 
et al, 2006). HIF-1α regulates the gene expression of several vasoactive substances, including 
ET-1. Since the transcriptional regulation of several genes involved in angiogenesis induced by 
hypoxia is mediated by HIF-1α, it is conceivable that ET-1 expression might be regulated by the 
same oxygen-dependent mechanism. Chronic hypoxia may be an important stimulus for ET-1 
release (Ferri et al, 1995) and this study has demonstrated ET-1 negative expression by CVMs 
(see Chapter 5). This raises the possibility that NEP may have a role in ET-1 degradation in 
CVMs but this is unknown and NEP may have more than one function in these lesions.  
NEP/CD10 expression has been shown to be absent in some poorly differentiated 
tumours, allowing mitogenic peptides to drive cell division. In absence of NEP in malignant 
tumors is linked to poor outcomes. This would suggest that angiogenesis in CVMs is controlled 
by specific signalling pathways, which are different from those governing angiogenesis in 
tumours.   
NEP up-regulation in CVMs in the presence of a pro-inflammatory infiltrate, expression 
of HIFs and absent expression of ET-1 in CVMs implies that the hypoxia/NEP pathway may 
play a part in the physio-pathology of CVMs. Stimulation of NEP expression by thrombin, 
which is produced during acute vascular events, may limit the local effects of pro-inflammatory 
or other vasoactive peptides, within CVMs.  
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It is clear that further work is necessary to establish clearer pathways. Animal studies in 
the literature have shown that hypoxia may down-regulate NEP (Wang et al, 2010) but clearly, 
this is not the case in CVMs. 
At present it is not possible to judge whether NEP has a positive or negative effect or 
not. NEP expression may be in response to the need for ET-1 degradation, so that one of the 
angiogenesis signalling pathways is blocked and thus the CVM is maintained in a quiescent or 
less active status. If this is the case NEP has a positive role in CVM pathophysiology and its 
inhibitors will have no place in the management of these lesions. The importance of ET-1 in 
CVM angiogenesis in comparison to other pro-angiogenic markers is not known. The outcome 
of prevention of ET-1 degradation by NEP in CVMs is also unknown.  NEP expression may be 
part of a different signalling pathway in CVMs and its effect whether advantageous to benefit 
the patient or not is unknown. The physiological relevance of NEP in CVMs is speculative.    
 
6.3 BLOOD GASES ANALYSIS IN CVMs 
6.3.1. INTRODUCTION 
Oxygen is necessary for cells/tissue to survive. It is transported by arterial blood to the 
peripheral tissue after gas exchange at the pulmonary level following ventilation and diffusion 
of the oxygen from the atmosphere into the arterial blood. Oxygen is delivered to the tissue (by 
a process dependent on many local factors) usually following a gradient at the capillary level. 
Therefore, venous blood transported from periphery to heart and lungs will contain less oxygen. 
The exchange will take place again at the lungs level and the process is continuously repeated. 
In AVMs there is shunting of the capillaries. From the arterioles, blood is drained directly 
through the abnormal communications to the venules. Therefore, it is possible that oxygen 
extraction by the peripheral tissues does not take place, nor the usual gradient. Random 
sampling over the years of the CVM blood during their operative treatment and as part of their 
management, by the surgeon supervising this study (NJS), indicated that the blood within the 
vessels of a CVM has an arterial pattern. This observation was valid even in VMs where there is 
no apparent blood shunting from the arterial to the venous system to explain such findings. 
Blood from the abnormal vessels of CVMs, showed results within the normal range for arterial 
oxygen pressure (10.7-14kPa). This occurred even when blood was obtained from 
predominantly venous lesions, where oxygen pressure will be expected to be reduced at 5.3-6.7 
kPa. Furthermore, the blood from CVMs had the macroscopic features of bright red colour 
associated with arterial blood. 
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This finding may be explained by blood shunting capillaries where gas exchange normally takes 
place or oxygen delivery is hampered in abnormal blood vessels of CVMs (perhaps CVMs are 
well oxygenated lesions and there is no oxygen gradient to facilitate diffusion to the tissues, etc)  
There are no studies in the literature assessing how well oxygenated is the blood within 
the CVM vessels or to assess the degree of oxygenation of CVM tissue. Presuming that CVMs 
have an underlying mechanism of disregulated or ‘increased’ angiogenesis, one would expect 
CVMs to have hypoxic features since angiogenesis and hypoxia are directly linked.  
It is not known if hypoxia is a feature of CVMs, if blood within CVM vessels is 
oxygenated or whether hypoxia-regulated molecules such as HIFs are expressed by all CVMs.  
This work aimed to establish if hypoxia is an element of CVMs by directly measuring the 
oxygen pressure within abnormal blood vessels of CVMs during their operative management.  
This information was correlated with the expression of hypoxia-regulated transcription   factors 
(HIF-1α and HIF-2α) and with the expression of the selected angiogenesis markers (VEGF A 
/VEGFR-1, Tie-2, ET-1, and the integrins αVβ3 and αVβ5), detected immunohistochemically. 
 
6.3.2 OBJECTIVES 
1) To identify hypoxia-mediated responses relevant to CVMs by establishing whether hypoxia 
is a feature of CVMs by measuring oxygen pressures within abnormal blood vessels of these 
lesions and as well as arterial and venous systemic blood.  
2) To correlate oxygen pressures within CVMs with the expression of HIFs by CVM tissue. 
Three comparisons were made in patients with CVMs: 
a) Paired comparison of arterial oxygen pressure in the radial artery and the CVM blood vessels 
in patients undergoing surgical correction of their CVM. 
a) Paired comparison of venous oxygen pressure in the venous systemic blood (ipsilateral to the 
CVM as well as from the contra lateral side to the CVM) and the CVM blood vessel in patients 
scheduled for surgical correction of their CVM. 
 
6.3.3 MATERIALS AND METHODS  
6.3.3.1. Selection of patients and blood sample collection 
This was a prospective study involving blood samples collected from subjects affected 
by CVMs between 2006 until 2009.  A total number of 13 participants were recruited for this 
study. All details regarding selection of patients, consent forms and blood samples collection are 
given in Chapter 2. 
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6.3.3.2. Partial oxygen pressure (pO2) comparisons 
Comparisons were made between the partial oxygen pressures within CVM blood and 
controls represented by systemic blood from the same patient from an artery and two veins with 
different locations – one on the same side as the CVM and one on the opposite side. The pO2 
does not reveal how much O2 blood contains but only the pressure exerted by dissolved O2 
molecules against the measuring electrode. The pO2 compared were considered in mmHg and 
therefore the results obtained in kPa were converted in mmHg (760mmHg = 101.325kPa). The 
pO2 were measured for each patient at different fractions of inspired oxygen (FiO2), due to 
anaesthetics protocols. Therefore, the pO2 were adjusted for a fraction of inspired oxygen of 
100% knowing that each 10% increase in the fraction of inspired oxygen wil increase the partial 
oxygen pressure with 50-60mmHg. At any altitude, the FiO2 is 0.21. 
 
6.3.4 RESULTS 
The demographic data of the patients recruited in this study is given in the following table. 
Tabel 6. 6. Demographic data of patients recruited in blood gas analysis study 
 
Tabel 6. 7. pO2* within CVM and systemic blood and HIFs staining 
Variable CVM group N=13 
Age (mean±SD) (Years) 41±23 
Gender Number male (%) 9/13 (69%) 
Patient CVM 
type 
pO2 
CVM 
 
pO2 
arterial 
blood 
 
pO2 venous 
blood same 
side with 
CVM 
 
pO2 venous blood 
opposite side with 
CVM 
HIF-2α 
 
HIF-
1α 
 
CAI
X 
1 LF 74 207 170 85 +  0 
2 HF 506 577 371 509   0 
3 HF 200 344 369 206 +++  0 
4 LF 462 402 316 418 +++ 0 0 
5 LF 410 339 186 292   0 
6 HF 412 374 311 330   0 
7 HF 485 568 374 363   0 
8 HF 451 479 434 413   0 
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* Normal pO2 at FiO2 100% is 500-600mmHg; * pO2 are calculated / adjusted at FiO2 of 100%.  
The comparisons between the adjusted pO2 within CVM blood vessels and arterial blood as well 
as venous blood on the same side as CVM and venous blood on the opposite side to CVM are 
given in the following three graphs.  
 
Figure 6. 33. Comparison of CVM pO2 and arterial blood pO2 data 
The figure 6.33 shows there was no statistically significant difference between pO2 in CVMs 
and arterial blood (p=1) 
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9 LF 449 324 375 321   0 
10 LF 419 487 451 388   0 
11 LF 453 369 246 241 + + 0 
12 LF 425 277 288 260   0 
13 HF 385 290 214 196   0 
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Figure 6. 34. pO2 CVM and venous blood on the same side with CVM 
The figure 6.34 shows there was statistically significant difference between pO2 in CVMs and 
venous blood ipsilateral to CVMs (p=0.0034). 
 
 
Figure 6. 35. pO2 CVM and venous blood opposite side to CVM 
The figure 6.35 shows there was statistically significant difference between pO2 in CVMs and 
venous blood contra lateral to CVMs (p=0.039). 
6.3.4.1 Correlation of pO2 within CVM vessels with HIF-1α and HIF-2α immunostaining of the 
corresponding tissue.   
Since the numbers are small it was not possible to perform a statistical analysis of the 
correlation between pO2 within CVM vessels and HIF-1α and HIF-2α immunostaining. The two 
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studies were performed at different times and this allowed only 2 and 4 paticipants respectively, 
to have had HIF-1α and HIF-2α immunostaining as well as pO2 measured. However, the results 
are presented here. HIF-1α and HIF-2α immunostaining were interpreted using a scoring system 
from 0 to 3 as described earlier. HIF-1α was expressed in one of the two cases tested for both 
HIF and pO2 and scored 1. Both specimens tested were clinically LF vascular malformations. 
Overall HIF-1α was expressed by CVM tissue, although most specimens scored one. The 
corresponding pO2 within CVM vessels, for the two common specimens were similar (462 and 
453mmHg). Four cases tested in the oxygen study had HIF-2α immunostaining and the scores 
were 1, 3, 3 and 1. One specimen was clinically a HF CVM and the rest were LF vascular 
malformations. The corresponding pO2 for the four cases stained for HIF-2α varied between 74 
and 462 mmHg. There appeared to be no correlation between the intensity of the HIF-2α 
staining and pO2 within the CVM vessels. HIF-2α appeared to be over-expressed by CVMs, in 
HIF study, despite there being a pO2 range in these lesions comparable with arterial systemic 
pO2. These data indicate that there is no correlation between pO2 in CVM vessels and HIF-1α or 
HIF-2α expression on immunostaining or the clinical type of CVM.  
    
 6.3.5 DISCUSSION 
There was no statistical difference between the pO2 within CVM vessels and arterial 
vessels (p = 1). The CVM blood appears to be oxygenated even in LF vascular malformation 
where there should be no vascular shunting. The ratio LF: HF vascular malformations was 7:6, 
and the values of pO2 within CVM vessels were even. This supports the clinical suspicion that 
CVM blood resembles arterial blood. There appears to be no relationship between the pO2 
within CVM vessels and the clinical type of CVM, i.e. HF or LF due to similar values of the 
pO2 within CVMs. 
Comparison of pO2 within CVM vessels with that in venous blood ipsilateral and distal to the 
lesion, showed there was a statistically significant difference with p = 0.039. This difference 
was even higher when the comparison was made with the pO2 within the venous blood on the 
contra lateral side (p = 0.01). The further away the vein, from which the blood sample was taken 
the higher the difference between the pO2 within the CVM and the venous blood. This suggests 
hyper oxygenation of blood within the CVM as well as surrounding vessels. However, 
expression of HIF-2α in CVM tissue obtained from patients in whom the pO2 was measured, 
suggested the tissue was hypoxic. The HIF-1α was weak or absent. HIF-2α was tested in our 
study in CVM lesions from a number of sites and regardless of the location, patient’s age or sex, 
it was over-expressed in the majority of lesions. HIF-1α was also tested but this was generally 
weaker than HIF-2α or even absent. Since CVMs represent a network of abnormal blood 
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vessels, which are arguably the product of abnormal angiogenesis, it is theoretically possible 
that CVMs are hypoxic when active, given the close relationship between hypoxia and 
angiogenesis. All CVM lesions included here were clinically considered to be in their quiescent 
phase as surgery to active lesions could exacerbate the morbidity, especially in AVMs. The 
assessment of cell proliferation using ki67 immunostaining showed no significant expression in 
CVM, when compared to controls which supported the clinical assessment of the quiescent 
phase. The question arises whether the observed HIF expression in CVMs reflects the in vivo 
situation or not and whether CVMs are hypoxic lesions or not. HIF expression in CVM tissue 
could take place in absence of hypoxia if VHL gene expression is disregulated. VHL gene 
expression in CVMs is unknown. Blood shunting capillaries where the gas exchange normally 
takes place at tissue level could explain the discrepancy between high pO2 in CVM vessels and 
HIF expression in some CVMs where there is shunting, but not in all lesions. As CVMs are 
composed of abnormal blood vessels, the O2 delivery to the tissue could be deficient if CVMs 
are well oxygenated lesions, there may be no oxygen gradient to facilitate O2 diffusion to the 
tissues, which is the main mechanism of O2 delivery. It is not possible from these data to 
determine which mechanism if any applies to CVMs or whether multiple mechanisms are 
responsible. Nevertheless, HIF-2α overexpression in CVMs could be investigated further and 
possibly exploited as target therapy for CVMs.   
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7. FINAL DISCUSSION 
CVMs are rare lesions but they pose serious challenges in their clinical management 
and therefore, these patients are usually seen in specialist centres by consultants. The decision 
whether or not to treat CVMs and especially AVMs is crucial because if the lesion is 
inappropriately subjected to any treatment – radiological or surgical- symptoms may be 
exacerbated, leading to complications, increased morbidity and even mortality. This course of 
events occurs due to lack of experience with these lesions. Medical personnel specialised in the 
management of CVMs have learnt by experience which CVMs are ‘not to be touched’, although 
not with 100% accuracy. Better understanding of the biology of CVMs is required to achieve 
better therapeutic results and to find alternative management possibilities.  
The exact cause of CVMs is not clear but it is likely to be a multifactorial process. What 
signalling pathways are altered in the process of angiogenesis leading to CVMs or what is the 
primary causation it is not yet known. Most theories regarding the aetio-pathogenesis of CVMs 
(Chaper 1.8) are addressing haemangiomas and not the AVMs, which represent the real 
problem. It has been suggested the original defect involves the intrinsic properties of EC but no 
research has proven this theory. From our research data it resulted that the stromal infiltrate was 
associated with the imbalance of the angiogenic and hypoxia mediators, implicated in the 
development of vascular malformations. The paucity of AVM data in the literature is partly 
caused by the lack of AVM tissue available for research all over the world. This is due to the 
fact that true AVMs often rapidly progress when operated by un-skilled hands and there is a 
general acceptance, although not universal, amongst specialists that AVMs should be managed 
non-surgically. To avoid exacerbation or activation of AVM, the whole lesion has to be 
removed at one operation, or debulking in a few serial surgical procedures performed until the 
whole lesion is removed. This is often quite difficult as the lesion tipically invades important or 
vital structures. Torrential bleeding is one of the most fearful encounters for any surgeon when 
embarking on such surgery. Fig 7.1 illustrates the extent of haemorrhage surgeons encounter 
when operating CVMs, and represents ‘a sample’ of the clinical experience of one senior 
surgeon and expert in the field (NJS). In this series of 73 operated CVMs, 16 were complicated 
by major haemorrhage (Maftei et al, 2009).  
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                             Figure 7. 1. Report of a major haemorrhage group at surgery 
 
The use of cell-saver (equipment allowing patient own blood to be transfused back to the patient 
after a process of filtration) is common when operating on these lesions, as well additional 
transfusion of blood and blood products and the requirement of a very experienced anaesthetist 
with CVMs. 
                          
                                   Figure 7. 2. Cell-saver used during a CVM operation 
There was and still is confusion about the classifications of CVMs and what some authors 
describe in their papers as AVMs are in fact haemangiomas, which are usually self-limiting and 
do not pose as much clinical difficulties as AVMs. Previous research work has addressed mostly 
haemangiomas. The classification of CVMs has changed extensively over the years (see 
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Chapter 1.2) and although the Hamburg classification is now generally accepted and also the 
current ISSVA is increasingly accepted, many authors do not adhere to either of these 
classifications. Therefore, it is difficult to know what category of lesion they are referring to and 
often the terminology used for the lesions described is erroneous or mis-leading, leading to mis-
interpretation of research work.  
The samples analysed for this study came from CVM tissue carefully collected through 
the Tissue Bank at Hammersmith Hospitals NHS Trust over many years. The results sustain the 
hypothesis that CVMs are most likely the result of aberrant vessel angiogenesis. The embryonic 
vascular system develops during the 3
rd
 week of foetal life from mesodermal cells and 
represents the field of complex interactions between pro- and anti-angiogenic factors, which are 
numerous. To date, there is no reported study investigating pathways of abnormal angiogenesis 
in CVMs. This work does not scientifically overlap with any work reported in the literature. 
The detailed histological analysis of CVM morphology clearly demonstrated that the 
number of blood vessels per mm
2 
and the vessel diameter (µm) in CVMs were significantly 
higher than in control tissue with  p=0.0004 and p=0.0005 respectively. These findings 
represent the effect of the prominent inflammatory infiltrate in the CVM stroma (Chapter 4) or 
may be due to the increased expression of various categories of pro-angiogenic mediators 
(Chapter 5). There were no morphological features to distinguish different clinical categories of 
CVMs but the morphological criteria continue to remain the basis for the confirmation of the 
clinical diagnosis of CVM.  This study demonstrates the necessity of a novel classification of 
CVMs that ideally will close the perceived gap between the histopathologist and clinician. This 
classification is likely to be a molecular one and it should also have prognostic value. 
Abundant macrophages and mast cells were found in the stromal tissues of CVMs, and 
both cells types have recognised roles in angiogenesis. Macrophages have an important role in 
sustaining angiogenesis partly by producing VEGF. They are likely to act as promoters of 
angiogenesis when exposed to a hypoxic environment, by interacting directly with HIF or with 
other angiogenic pathways such as the VEGF pathways. Previous studies have shown that mast 
cells accumulate at sites of angiogenesis and this study showed increased number of mast cells 
in close vicinity to abnormal blood vessels constituting the CVM. Changes in the mast cells 
density at the time of capillary proliferation indicate a special role for these cells in the 
formation of new vessels. Angiogenic mediators secreted by mast cells such as VEGF have 
been implicated as mast cells chemotactic factors.  
CVMs are represented by dilated abnormal blood vessels and they may be more permeable 
vessels, allowing cells and chemical mediators to escape from the blood stream. The leaky 
vessels may also be the reason for the increased oxygen pressure (demonstrated in Chapter 6) 
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within the CVM vessels. The presence of the stromal inflammatory infiltrate may be reactive in 
response to hypoxia or tissue expression of HIFs. It is also possible that areas of hypoxia in 
CVM stroma develop as a result of increased metabolism associated with the inflammatory 
cells. The vessels of the CVM and the infiltrate of mast cells and macrophages in the stroma 
must be related. The following figure suggests a possible relationship between the inflammatory 
infiltrate, tissue hypoxia and blood vessel morphology.  
 
Figure 7. 3. Vessel morphology, inflammation and hypoxia in CVMs 
Hypoxia induces expression of numerous angiogenic mediators as a result of stabilisation of 
HIFs. The distribution of specific angiogenesis markers and their relationship to hypoxia 
markers HIFs in CVMs and controls were investigated using immunohistochemistry.  VEGF-
R1, Tie-2 and αVβ3 and αVβ5 were over-expressed by ECs in CVMs. The immuno-expression 
of all these angiogenic markers was significantly higher in CVMs than in control tissues. All 
these mediators were localised on the EC of the CVMs. 
VEGF-A, one of the most important regulators of angiogenesis, was expressed by the ECs in all 
categories of CVMs but not in every lesion (see results Chapter 5). 
 Despite the increased number of vessels in CVMs, the majority of the cases examined, 
Chapter 7 – Final Discussion 
 
 170 
showed nuclear expression of HIF-1α and more widespread expression of HIF-2α which was 
observed in the ECs as well as in the stromal macrophages. Normal control tissue showed only 
very focal expression of HIF in relation to adnexal structures or macrophages. There was a 
significantly higher immuno-expression of HIF-2α in CVMs comparing to controls (p=0.0004), 
although there was no significant difference between the expression of HIF-1α in CVMs 
comparing to controls (p=0.66).  HIF-2α appears to play a more important role in CVM 
pathogenesis than HIF-1α. HIF-2α is related more to a pathological hypoxia and HIF-1α is 
related more to physiological responses to hypoxia.  
These data demonstrate that HIF activation is present in CVMs and hypoxia may be a 
key feature of CVMs and may regulate important inflammatory and angiogenic cytokines. This 
statement is supported by the positive correlations found between HIF-2α and VEGF A 
(p=0.0001), VEGFR-1 (p=0.0043), Tie-2 (p=0.03), αVβ3 (p=0.029) and αVβ5 (p=0.045) 
immunohistochemical expression in CVMs as well as the positive correlations between the 
immuno-expression of HIF-2α and the number of stromal macrophages and mast cells within 
the CVM stroma. The question is whether hypoxia as indicated by expression of HIF is part of 
the adaptative processes secondary to other changes such as inflammatory cell extravasations in 
CVMs, or whether hypoxia is a primary feature of CVMs that triggers all other changes. The 
first hypothesis seems more likely with the current available data. Physiological hypoxia in 
CVMs could not be demonstrated and high partial oxygen pressures were found within CVM 
vessels. CVMs contain a higher number of blood vessels per mm
2
. As discussed, other 
mechanisms could be responsible for primary hypoxia/HIFs expression in CVMs such as a 
defect in the oxygen delivery mechanisms to tissue or even a mutation of VHL, the regulatory 
gene for HIFs. Experiments to explore these hypotheses were outside the scope of this study. 
The expression of NEP was assessed by immunohistochemistry, on CVM tissue 
sections and controls. NEP was identified using the CD10 marker. NEP is a metallopeptidase 
known to modulate bioavailability of peptide mediators and growth factors in hypoxic 
conditions. NEP has been shown to degrade endothelin ET-1, which has important roles in 
angiogenesis, as well controlling inflammatory responses. We have observed over-expression of 
CD10 in all CVMs analysed. The expression of CD10 was associated with a prominent stromal 
inflammatory infiltrate and expression of HIFs, especially of HIF-2α, in CVMs. There was a 
positive correlation between the immunohistochemical expression of HIF-2α and CD10 in 
CVMs (p=0.0002). 
From these results, hypoxia/NEP/ET-1 emerges as possible signalling axis implicated in 
pathophysiology of CVMs.  
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Figure 7. 4. Hypoxia/NEP/ET-1 signalling pathways in CVM pathophysiology  
Neutral endopeptidase indirectly interacts with HIF pathways, when HIF is up-
regulated. This interaction is known to involve HIF-1α and it is not yet known whether 
HIF-2α is also implicated. Stabilised HIF-1α leads to the transcription of target genes, 
including ET-1 and VEGF genes showed in the diagram above. NEP degrades ET-1 and 
therefore, inhibits its pro-angiogenic pathway. 
CD10 expression has been reported as decreased or absent in some poorly differentiated 
tumours. This would suggest that angiogenesis in CVMs is controlled by specific signalling 
pathways which are different from those ruling angiogenesis in malignant tumours. 
It had been observed clinically that CVM blood even in LF lesions such as VMs 
demonstrated high oxygen pressures (Prof. Standfield personal communication). Therefore, the 
pO2 within the abnormal CVM blood vessels was compared with the pO2 within veins in close 
proximity to CVM and, ipsilateral as well as with the pO2 in veins distal to CVM, usually contra 
lateral to the CVM. This study confirmed the clinical observation and proved that there was no 
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statistical difference between the partial oxygen pressure within CVMs vessels and arteries. It 
was not possible to prove an influence on the nearby venous oxygen pressure because the 
oxygen pressure within CVM vessels was statistically significantly different to venous blood 
both on the same side as CVM (p=0.01) and on the opposite side to CVM (p=0.03). It was not 
possible to compare pO2 and HIF-1α and HIF-2α immunohistochemical staining for four 
patients included in this study. Whilst HIF-2α was positive in all four cases with variable 
intensity of expression, HIF-1α was weakly positive in one case only. The cases positive for 
HIF-2α comprised HF and LF lesions from both upper and lower limb. 
The data of HIF-1α and HIF-2α expression generated by this study suggests at least two 
categories of CVMs. The majority of lesions were positive for both HIF-1α and HIF-2α but 
HIF-2α was more prominent. Other lesions were HIF-2α positive and HIF-1α negative. These 
categories were confirmed by the results of Western blot analysis in a group of participants. 
There was one lesion which did not express either marker but this may represent processing 
artefact as the case came from the archive. Both HIF categories of CVMs showed heterogeneity 
in the expression of different angiogenic markers, although in the majority of specimens all 
markers were up-regulated. All specimens expressed Tie-2, although with different intensity. 
One particular HF lesion located in the upper part of the lower limb was notoriously difficult to 
manage. This lesion diffusely expressed all the angiogenesis markers tested and expressed HIFs, 
but αVβ5 was absent. This lesion had multiple embolisations prior to each surgical intervention. 
A clinically quiescent status was achieved after many years and repetitive interventions. Two 
other lesions, which clinically were similar, did not express αVβ3. These were intra-muscular 
CVMs and they both had pre-operative sclerotherapy. One was located in the upper limb and 
one was in the lower limb. One other lesion that was extremely difficult to manage clinically did 
not express VEGFR-1 and HIF-2α was over-expressed but there was insufficient tissue 
available to assess HIF-1α expression. This patient achieved quiescent status after multiple 
upper limb resections. One patient did not survive surgery and the resected tissue was strongly 
positive for HIF-2α.  
To summarize the clinical outcome of the cohort of patients studied quiescent status 
was achieved in all patients and 12 (32%) patients (from all 38 patients considered in various 
parts of this study) were cured. The CVMs that were cured had mostly moderate expression of 
both HIF-1α and HIF-2α.  
The possible relationship between the inflammation, angiogenesis and hypoxia as 
discussed in this study is shown in the following diagram. 
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Figure 7. 5. Inflammation, angiogenesis and hypoxia signalling pathways in CVMs 
The morphological heterogeneity of the lesions studied suggests that specific molecular 
patterns may exist within vascular malformations, which may result in further clinical sub-
classification. The results point towards possible specific molecular mechanisms and the 
application of these findings in clinical practice would help to validate these results, as well as 
to elucidate the molecular mechanisms in CVMs.  
This study has helped to improve the understanding of the aetio-pathogenesis of CVMs. 
As more mechanisms associated with angiogenesis are clarified a new approach to the 
understanding and subsequent management of vascular malformations will emerge.  
7.1 EMERGING NEW MARKERS FOR VASCULAR MALFORMATIONS 
There is a need for specific molecular markers not only to differentiate haemangiomas 
from vascular malformations but also to differentiate different categories of CVMs in order to 
predict behaviour and outcome. Arguably, this is achievable once the signalling pathways 
responsible for CVM development and perpetuation are established. The immunohistochemical 
marker GLUT-1 has been reported to accurately distinguish haemangiomas from vascular 
malformations. This marker has been used here to confirm the specimens analysed were 
vascular malformations and not haemangiomas, (vascular malformations do not express GLUT-
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1). However, GLUT-1 does not give any other information about the lesion in respect to its 
behaviour or prognosis.   
Consistent positive staining for NEP in the ECs or, in some cases vessel adventitia of 
CVMs, implies a role for NEP/CD10 in CVM pathophysiology and emerges as a potential new 
diagnostic marker for CVMs biopsies. Tissue markers are rarely used for diagnostic purposes, 
they help to determine prognosis, to monitor treatment and detect recurrences. They may be 
used for diagnosis in conjunction with other parameters. Very few tissue markers are used in 
clinical practice because of lack of specificity. Some non-specific markers have found a place in 
monitoring treatment. NEP/CD10 could help monitoring lesional recurrences and assess if a 
CVM was completely removed at surgery. Those cases of CVM in which NEP stained the 
vessel adventitia had an excellent outcome from surgery, in two cases patients had ulcers and 
they healed following surgery and in one case patient had successful serial debulking with no 
further recurrences.  
How CD10 expression can be utilised in clinical practice, still needs to be assessed and 
additional research work should pe carried out.  
7.2 CLINICAL IMPLICATIONS OF RESULTS 
7.2.1 Anti-angiogenic therapy – rationale of current use, clinical studies and challenges 
This study represents a comprehensive molecular and histological study of CVM tissue. 
The results are unique and could provide valuable information for other angiogenesis related 
research projects such as those focusing on cancer angiogenesis, ischemic heart disease or 
inflammatory conditions such as rheumatoid arthritis.  
The molecular alterations that sustain angiogenesis and hypoxia such as VEGF 
A/VEGFR-1, Tie-2, αVβ3 and αVβ5, HIF, may represent novel targets for CVM treatment 
protocols. Some anti-angiogenic substances have been found to have potent anti-cancer 
properties in ‘in vivo’ experimental studies but to date no anti-angiogenic compounds have been 
tested against CVMs. Since the inhibition of angiogenesis can slow or stop tumor growth or 
even shrink cancers, similar results arguably can be expected in CVMs.  
Avastin (bevacizumab) is amongst the first developed anti-angiogenic substances and in 
fact is a monoclonal antibody. Avastin targets VEGF and its use was reported in relation to 
colonic cancer with evidence to support prolonged survival in patients with metastatic disease.   
Other agents that target VEGF A (sunitinib, sorafenib) are approved drugs but they are reported 
to cause only transient clinical responses (Huang, 2010). Targeting specifically VEGFR-1 is 
currently being investigated in clinical trials in relation to metastatic tumours, along with 
VEGFR-2 receptor as the two receptors have different activities in tumour angiogenesis. New 
components have been in use, incorporating both receptors and binding VEGF with higher 
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affinity than previously reported VEGF antagonists. Although VEGF A expression was 
increased in CVMs (35% of lesions were VEGF A positive), this was not as impressive as the 
over-expression of the other molecular markers. VEGFR-1 was over-expressed in CVMs (81%), 
but not in all of them and currently there is no specific target therapy for this receptor only. 
Should this therapy be considered in CVMs, it would seem logical that only that molecular 
pattern of CVMs showing an over-expression of VEGFR-1 would benefit. Therefore, anti-
VEGF therapy in CVMs is not attractive at present, as the application may be limited and this 
drug comes with many side-effects, some of them quite serious. 
Inhibition of αVβ3 may inhibit angiogenesis and invasion in some cancers but studies 
on animals in which αVβ3 was ‘knocked out’ have given conflicting results as in some cases 
angiogenesis was not compromised (Stupack, et al, 2003).  Many vascular disorders are 
accompanied by alterations in integrin expression. Antagonists of αVβ3 and αVβ5 have been 
shown to block angiogenesis in some cases, suggesting that these integrins are required. As a 
result, integrins are therapeutic targets for treating a number of vascular diseases. A few integrin 
antagonists are being used clinically for cardiovascular and inflammatory diseases. Several 
other integrin inhibitors are being developed for clinical use (Tucker, 2003, Jin 2004). Amongst 
those tested or in clinical trials are Tumstatin, S247, m7E3, Vitaxin, Cilengitide. Their use could 
theoretically be developed in CVMs as αVβ3 appears to be up-regulated and possibly a key 
mediator in the pathogenesis of CVM.  
Targeting Tie-2 is possible as Liu et al (2008) reported the finding of a series of small-
molecule Tie-2 inhibitors, which blocked Ang1-induced Tie-2 auto-phosphorylation and 
downstream signalling, with the aim to treat pathological neovascularisation. The angiopoietin-
Tie system is reported to be attractive for therapeutic intervention because it is crucial for 
angiogenesis and vascular homeostasis and also provides an important link between angiogenic 
and inflammatory pathways (Huang et al, 2010). Agents targeting this system are currently 
being developed in clinical trials in cancers and early reports suggest encouraging results. None 
of the agents are Tie-2 selective at present and their use in CVMs remains just a theoretical 
possibility. 
ET inhibitors have been particularly useful in animal models at preventing hypoxia 
induced structural remodelling, but little evidence suggests that they are useful in reversing the 
vascular remodelling process. 
HIF-1α was reported to be an exciting target for therapy, mostly in cancers (Rapisarda, 
2002). The agents that reduce HIF-1α protein levels do so by decreasing the rate of HIF-1α 
synthesis, or increasing the rate of HIF-1α degradation or both.  There is a multitude of HIF-1α 
inhibitors but they are not detailed here. YC-1 is a potent HIF-1α inhibitor and it has been 
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developed for circulatory disorders because it reduces the growth and vascularity of tumor 
xenografts. This could be developed for cancer patients and also for CVM patients if side effects 
such as hypotension could be controlled (Yeo, et al, 2003) and if it should be proven that HIF-
1α plays a key role in CVM pathogenesis. There are inhibitors of both VEGF and HIF-2α such 
as Neovastat (AE-941), which has been shown to reduce airway inflammation (Lee, Chung, 
2007). It is expected that development of more potent and selective HIF inhibitors will help the 
treatment of HIF-related diseases (Ban et al, 2011). 
Bio reductive drugs are currently being developed as a means of selectively targeting 
hypoxic cells. Hypoxia directed drug delivery systems might offer the potential for selective 
treatment in a whole variety of conditions manifesting chronic hypoxia and inflammation. This 
offers the advantage of tissue specificity with reduced toxicity.  
Future anti-angiogenic treatment may become important in the treatment of a variety of 
conditions. There are a number of issues to be resolved before this can happen. Inhibition of a 
single target by a specific anti-angiogenic agent may lead to the up-regulation of other 
angiogenic factors. The approach has to be multi-factorial as there is a need to combine anti-
angiogenic agents with agents against other mechanisms of action, targeting several angiogenic 
molecules and other pro-angiogenic cell types apart from ECs (Carmeliet, 2005). 
7.3 FUTURE STUDIES 
More research is required to explore angiogenesis, hypoxia and related signalling 
pathways in relation to CVMs.  
The expression of the selected pro-angiogenic and hypoxia markers should be further 
analysed at the molecular level by extraction and quantitation of RNA to detect angiogenic 
markers, HIF-1α, HIF-2α and CAIX using PCR and quantitative real-time PCR technology. 
Primers have already been designed for all these molecules and PCR protocols have been 
established. RNA from diseased and control tissue should be compared to examine the 
expression of hypoxia markers and the selected angiogenic markers in the same tissue. This may 
elucidate the leading control mechanisms in the pathogenesis of CVMs. It may help also to 
clarify the confusion concerning classification of these lesions by consolidating patterns at 
molecular level and relating this to specific clinical characteristics, especially to AVMs.  
A molecular classification may be the answer to the existent confusion in nomenclature 
and classification of CVMs. This study provides a hint to a possible classification of CVMs 
based on CD10 staining but the results need to be further assessed and validated.  
A common international terminology would help to precisely predict outcomes. Further 
analysis of CVMs would indicate which novel or target therapies may be the answer to a cure of 
CVMs or at least to prevent their clinical progression and reduce morbidity.  
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The angiogenic or anti-angiogenic mediators studied here represent very few amongst a 
whole array of such substances. It is known that TGF-β can promote angiogenesis via multiple 
mechanisms, including up regulation of VEGF expression and recruitment of pericytes. Should 
TGF-β prove to be an important mediator in CVM angiogenesis, then TGF-β signalling pathway 
antagonists would be expected to inhibit angiogenesis in CVMs.  
Ephrins are molecules with specificity for arteries or vein from embryonic stages, even 
before the morphology of the vessel is not clear. This area would worth exploring and may 
bring additional information about CVM pathogenesis. It is well known that CVMs are 
represented by a network of vessels, often difficult to identify as arteries or veins, especially 
those subjected to high intra-vascular pressures. 
Matrix metalloproteinases (MMPs) are an important group of enzymes associated with 
invasion and angiogenesis and some of them are related to VEGF A activation. Hypoxia can 
also potentiate invasion by up-regulating proteases such as MMP-9, leading to a cascade of 
responses, which can induce angiogenesis. ET-1, which may be expressed in CVMs, may 
enhance the secretion of ECM-degrading proteinases (Salani et al, 2000). ET-1 activates MMP-
2, MMP-9, MMP-3, MMP-7 and MMP-13. In addition ET-1 enhances activation of MT1-MMP 
and the secretion of TIMP 1 and 2, resulting in the rapid degradation of ECM. These actions 
have been detected in tumours and it is not known if similar pathways are applicable to CVMs. 
MMPs inhibitors have been developed but the early findings revealed substances with serious 
side-effects and they were inappropriately evaluated in late stage disease. More recent MMP 
inhibitors target both tumour invasion and angiogenesis and they are still being developed.  
Immunohistochemical analysis of mediators in agiogenesis on foetal tissue of different 
gestational ages may clarify the signalling pathways and mediators critical to angiogenesis and 
implicated in the aetio-pathogenesis of CVMs. This may demonstrate if these mediators are 
aberrantly expressed or up-regulated. This analysis was beyond the scope of this study.  
There is evidence to suggest that angiogenic ECs may be derived from bone marrow 
precursor cells. These cells have characteristic cell surface antigen expression and have been 
found in the peripheral blood (Asahara et al, 1997). They have also been found to be active at 
sites of angiogenesis. It is not known if bone morrow derived ECs play a role in CVMs 
pathogenesis.  
Understanding of the vascular tree development and of disregulated angiogenesis has 
increased significantly over the last few decades, but there are still many unanswered questions 
because of the complexity of the vascular system. This work contributes to the growing bank of 
data about CVMs and sheds light on possible pathways associated with angiogenesis and 
hypoxia involved in the development of these lesions. It may raise awareness of the thousands 
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of patients who suffers from these debilitating and disfiguring vascular malformations and 
impose clinicians and scientists with access to the tissue to expand and continue the research. 
7.4 LIMITATIONS OF THIS STUDY 
Vascular malformations, the subset of CVMs predominantly studied here are rare 
conditions.  
Therefore, the number of samples analysed in each study is small and no firm 
conclusions can be drawn. However, no detailed investigations such as we presented here have 
been previously performed on vascular malformations. 
The archive (retrospective) tissues were processed according to local standards but it is 
unknown whether all the criteria for collection and processing applied to the prospective 
samples were fulfilled in the archive tissue.  
This work involved mainly immunohistochemical techniques and interpretation made 
use of a scoring system. Although these methods are widely used and accepted, and considered 
appropriate for the analysis performed, the observations were in part subjective.  
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APPENDIX 
APPENDIX TO INTRODUCTION        
A) EVOLUTION OF CLASSIFICATION OF CVMs 
Historically, there were debates whether CVMs represent developmental malformations 
or tumours. They have been named ‘erectile tumours’ by Dupuytren (Jaccoud, 1870). Virchow 
believed CVMs were vascular tumors and was the first to classify them as angioma simplex, 
angioma cavernosum and angioma racemosum, based on histological architecture (Virchow, 
1863). He and Wegener divided then vascular lesions into angiomas and lymphangiomas in 
1880. A further histopathological classification was elaborated (Stout and Lattes, 1967) and this 
included both congenital and acquired vascular lesions under the term ‘angiomatoses’. 
According to this classification, the proliferative lesions in childhood were named ‘benign 
haemoangioendotheliomas’ and the malignant lesions were haemoangioendotheliomas‘.  
At a later stage, vascular tumours showing excessive cellularity have been termed both 
‘benign (neonatal) haemangioendotheliomas’ (Gonzales-Crussi and Hull, 1978 and Stout, 1943) 
and ‘infantile haemangiopericytomas’ (Albrecht, 1904 and Stout, 1942). The terms ‘cellular 
angioma of infancy’ (Taxy and Gray, 1979) or ‘cellular haemangioma’ (Pasyk and Grabb, 1982) 
have been proposed as most appropriate for vascular tumours of infancy and childhood. They 
represented the least mature of the haemangiomas and they were not related to what was known 
as ‘haemangioendotheliomas’. Other authors described vascular tumours in infants and children 
as presenting variable histological characteristics in different areas of the same tumour, such as 
haemangioendotheliomas and haemangiopericytomas (Brihaye and Baleriaux, 1975, Eimoto, 
1977, Balasz and Denes, 1978, Gonzales-Crussi and Hull, 1978, Taxy and Gray, 1979, Pasyk 
and Grabb, 1982). Edgerton, in 1976 proposed a clinical classification of ‘angiomas’ based on 
their natural history. He divided ‘angiomas’ into three categories: those that remained 
essentially unchanged, those expected to resolve spontaneously and those that progress 
(Edgerton, 1976, Gampper and Morgan, 2002). This classification however, did not identify the 
underlying causes accounting for the clinical course of the lesions described. Further 
classifications of vascular anomalies had been reported and related to their clinical, 
histopathological features, capacity for dynamic growth and involution, as shown in the table 
appendix. 1. (Mulliken and Glowacki, 1982; Finn and Glowacki, 1983; Pasyk and Argenta, 
1984). 
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Tabel appendix. 1. Classification of vascular anomalies  
Cellularly dynamic Cellularly adynamic 
Haemangiomas 
Cellular haemangioma 
Capillary haemangioma 
Cavernous haemangioma 
Mixed haemangioma 
Verrucous haemangioma 
Pyogenic granuloma 
Senile angioma 
 
Vascular ectasies 
Salmon patches 
Naevus flammeus (Port wine stain) 
Naevus araneus 
Multiple teleangiectasies 
Congenital phlebectasia 
Angioma serpiginosum 
Venous lake 
Angiokeratomas 
Angiokeratoma Mibelli 
Angiokeratoma Fordyce 
Angiokeratoma circumscriptum 
Solitary and multiple angiokeratomas 
(Imperial and Helwig type) 
Angiokertaoma corporis diffusum(Fabry’s 
disease) 
Congenital arteriovenous malformations* 
*Congenital arteriovenous malformations include rheologic dynamic vascular lesions. 
 (Adapted from ‘Vascular Birthmarks’, Pathogenesis and Management, edited by Ryan, JR and Cherry, 
GW, Oxford University Press, 1987, p4) 
A new concept of predominantly arterial, venous and lymphatic lesions or arteriovenous 
and mixed lesions was introduced and first acknowledged by Malan in 1974. CVMs, have been 
most commonly, incorrectly and invariably termed haemangiomas (‘birthmarks’), until 1980 
when Mulliken and Glowacki divided them into haemangiomas and vascular malformations 
(venous, lymphatic and arteriovenous) based on the cellular (endothelial) proliferative 
characteristics of these lesions (Mulliken and Glowacki, 1982) (Table appendix.2) 
Tabel appendix. 2. Classification of vascular anomalies based on EC characteristics  
Haemangioma Vascular malformation 
Superficial 
Subcutaneous 
Mixed 
 
Capillary C 
Venous (V): low flow 
Lymphatic (L) 
Arterial (A):high flow 
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Often absent at birth 
Appearance during first weeks of life 
Proliferation, stabilisation, spontaneous, 
gradual involution 
Arteriovenous (AV) 
Complex combined (CV, CL, CVL, CAV, 
CLAV, etc) 
Present at birth 
 
No spontaneous regression 
Adapted from Plast Reconstr Surg 1982, 69:412-420 
The simple distinction of a vascular anomaly as being either a tumour or a vascular 
malformation was essential from a clinical prospective as the two conditions are different 
anatomo-pathological entities and have a different natural history and specific management 
issues. 
The word haemangioma has been applied to any vascular anomaly, and the terminology 
used in the literature to describe haemangiomas has been even more confusing because there 
was no clinico-histological correlation and several terms have been used for the same lesion. 
‘Strawberry haemangioma’, ‘raspberry haemangioma’, ‘cherry haemangioma’, ‘juvenile 
haemangioma’ are just few terms used in the past and they do not define histological structure. 
These were derived from the blame being placed on the mother for eating too much or too little 
of certain fruits during pregnancy, depending on a local culture. Most physicians identified 
these lesions in Latin as naevus maternus. 
Terms such as ‘capillary’ or ‘cellular’ haemangiomas have been used by physicians for lesions 
predicted to involute. However, there are ‘capillary’ lesions such as port-wine stains that do not 
involute.  
Terms such as ‘capillary or cavernous haemangioma’ were erroneously used to describe 
vascular malformations, especially venous malformations that have been inaccurately named 
‘cavernous haemangiomas’. It is now recommended to avoid these terms to prevent confusion 
between haemangioma and vascular malformations and prevent incorrect diagnosis and 
management (Mulliken, 1993, Hand and Frieden, 2002). 
Rosai and Ackerman, 2004 in their Surgical Pathology included haemangiomas within 
the ‘tumors and tumor-like conditions’ of blood and lymph vessels and stated they occupy an 
undefined zone between hamartomatous malformations and true neoplasms. They have been 
classified based on their clinical appearance and calibre of the vessel involved into: capillary, 
cavernous, venous, racemose, cirsoid, arteriovenous, intramuscular, spindle cell and hobnail 
haemagiomas, along with and other benign or malignant vascular lesions. However, both the 
clinician and the the histopathologist no longer find this classification useful. 
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The Hamburg classification of CVMs, which has become widely accepted emerged as 
an important step towards a better understanding of these lesions and it was adopted at the 7
th
 
International Workshop on Vascular Malformations in Hamburg, Germany in 1988 (Belov, 
1990). This classification takes account of the predominant anatomical (truncular or 
extratruncular) and patho-physiological type (predominantly arterial, venous, lymphatic, 
arteriovenous fistulae or combined) of CVMs (Table appendix.3.). 
Tabel appendix. 3. Hamburg classification (Belov, 1989) 
 
                             Type 
                              Form 
     Truncular    Extratruncular 
Predominantly arterial 
malformations 
 
 
 
Predominatly venous  
malformations 
 
 
Predominantly lymphatic  
malformations 
 
 
Predominantly as a-v fistulae 
characterized malformations 
 
Combined vascular  
malformations 
Aplasia  
Obstruction 
Dilatation 
 
 
Aplasia  
Obstruction 
Dilatation 
 
Aplasia  
Obstruction 
Dilatation 
 
Deep a-v  fistulas 
Superficial a-v fistulas 
 
Arterial and venous 
without shunt 
Haemolymphatic 
with or without shunt 
Infiltrating 
Limited 
 
 
 
Infiltrating 
Limited 
 
 
Infiltrating 
Limited 
 
 
Infiltrating 
Limited 
 
Infiltrating 
haemolymphatic 
Limited 
haemolymphatic 
 
This classification emphasises that the CVM can sometimes involve more than one 
vascular system and can present clinically as different forms of malformation, not only as 
arterial, venous, lymphatic, and capillary malformations but also as combined arteriovenous or 
haemolymphatic malformations (Belov, 1990, Belov, 1993). Each lesion is sub-classified 
according to the embryonal stage at which the developmental arrest occurred. The 
Appendix 
 183 
extratruncular form occurs at an earlier stage of embryonal life than the truncular form (Belov, 
1993, Woolard, 1922, Bastide and Lefebvre, 1989, Lee, 2004). 
The International Society for the Study of Vascular Anomalies (ISSVA) founded in 
1992 aims to advance clinical and scientific knowledge in all aspects of vascular anomalies, 
proposed a classification for these lesions based on cellular features, flow characteristics and 
clinical behaviour in 1992, as shown in Table appendix.4 (Enjolras, 1997).  
Tabel appendix. 4. ISSVA* Classification of Vascular Anomalies 1992 
 Vascular Tumour                                                                                                                  
 
                            Vascular Malformations 
              Simple                      Combined 
Haemangioma              Capillary malformation            Arteriovenous fistula, arteriovenous 
proliferative phase                                                         malformation, capillary-venous 
                                                                                       malformation, capillary-lymphatic- 
                                                                                       venous malformation (Klippel- 
                                                                                       Trenaunay syndrome) 
                                                                              
Involutive phase         Lymphatic malformation        Lymphatic-venous malformation,                                                                                                               
                                   (macrocystic, microcystic,      capillary-arteriovenous 
                                    mixed)                                    malformation (Parkes-Weber 
                                                                                    syndrome), capillary-lymphatic- 
                                                                                    arteriovenous malformation 
Other tumours           Venous malformation 
Adapted from http://radiographics.rsnajnls.org 
*ISSVA = International Society for the Study of Vascular Anomalies 
This classification was further amended and in 1996 and was adopted as official. 
Tabel appendix. 5. Amended classification system for CVMs by the ISSVA, 1996  
Tumours 
Haemangioma of infancy 
Lobular capillary haemangioma (pyogenic granuloma) 
Rapidly involuting congenital haemangioma (RICH) 
Non-involuting congenital haemangioma (NICH) 
Tufted angioma (angioblastomaof Nakagawa) 
Kaposiform haemangioendothelioma 
Congenital eccrine angiomatous hamartoma 
Spindle-cell haemagioendothelioma 
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Malformations 
Capillary malformation (port-wine stain) 
Venous malformation, including blue rubber bleb nevus (Bean) syndrome 
Lymphatic malformation (lymphangioma; cystic hygroma) 
Arteriovenous malformation (including Bonnet-Dechaume-Blanc, Wyburn-Mason, and Cobb 
syndromes) 
Capillary-lymphatic-venous malformation (most common type seen in limbs with Klippel-
Trenaunay syndrome) 
Parkes-Weber syndrome (combined malformation with arteriovenous fistulae) 
Cutis marmorata teleangiectatica congenital 
Glomuvenous malformation (glomangioma-venous malformation, including glomus tumour) 
(Adapted from ISSVA classification) 
It has been stated that using this classification system, at least 90% of vascular 
anomalies seen in infants and children can be categorised without the need of additional 
investigations or histological examination (Hand and Frieden, 2002). 
The consideration of haemodynamic status of the CVM was first introduced by 
Mulliken in 1993 and subsequently another important classification was defined, dividing 
CVMs into high (fast) flow such as arteriovenous malformations, arterial malformations, and 
arteriovenous fistulas and low (slow) flow lesions such as capillary malformations, venous 
malformations, and lymphatic malformations (Jackson, Carreno et al, 1993). This is a 
radiological classification based on the vascular dynamics of the lesion and presence of 
arteriovenous shunting and refers to the speed of flow through the lesion and the rate of 
shunting between the arterial and venous components. This classification is important as a guide 
for clinicians to choose the appropriate form of treatment. It is important to note that various 
eponymous syndromes fall into these categories of vascular anomalies depending on their 
anatomical location. This emphasise the importance of describing a complex-combined vascular 
lesion based on the underlying vascular defect (Enjorlas, Chapot et al, 2004). 
Kawanabe et al proposed another classification system of vascular lesions in 1996, in 
which the treatment was selected based on the flow characteristics of the lesion, which in fact 
represents a fusion of previous classifications (Table appendix.6.). 
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Tabel appendix. 6. Classification of surface vascular lesions  
Traditional classification 
Capillary haemangioma 
Strawberry haemangioma 
Strawberry nevus 
Port wine stain 
Flame nevus 
Cavernous haemangioma 
Venous angioma 
Lymphangioma 
Arteriovenous malformation 
Classification of Jackson et al, 1993 
Haemangioma 
Vascular malformation 
Low-flow lesion 
High-flow lesion 
Lymphatic malformation 
Flow-related classification and recommended treatment 
Slow-flow lesion: sclerotherapy 
Intermediate-flow lesion: sclerotherapy (plus embolisation) 
High-flow lesion: embolisation (plus scelotherapy) 
Adapted from http://radiographics.rsnajnls.org 
Subsequently, it has been reported that the erythrocyte glucose transporter protein-1 
(GLUT-1) is strongly and diffusely expressed by the ECs of haemangiomas during all stages of 
their natural history (Blei, 2005, North and Waner, 2000), but it is not expressed in other CVMs. 
This new finding was included into the ISSVA classification (Table appendix.7). 
Tabel appendix. 7. Current classification of the ISSVA 
Vascular tumors Vascular malformations 
Haemangioma of infancy (GLUT-1 positive) 
   Superficial 
   Deep 
   Mixed 
Congenital haemangioma 
   Rapidly involuting congenital haemangioma 
Simple malformation 
   Capillary (port-wine stain) 
    Venous 
    Lymphatic 
      Microcystic (e.g., lymphangioma) 
      Macrocystic (e.g., cystic hygroma) 
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(RICH) 
   Non-involuting congenital haemangioma 
(NICH) 
Kaposiform haemangioendothelioma 
Tufted angioma 
Pyogenic granuloma (lobular capillary 
haemangioma) 
Haemangiopericytoma 
    
    Arteriovenous malformation (AVM) 
Combined malformation 
   Capillary-lymphatic-venous (includes most 
cases of Klippel-Trenaunay) 
    Capillary-venous (includes mild cases of 
Klippel-Trenaunay) 
    Capillary-venous with arteriovenous 
shunting and/or fistulae (Parkes-Weber 
syndrome) 
    Cutis marmorata telangiectatic congenita 
 (Adapted from Curr Opin Pediatr 17:501-509. 2005 Lippincott Williams & Wilkins) 
Although this classification has been extremely useful for many specialists there are 
rare situations in which clinical and histologic overlap between vascular tumors and 
malformations have been identified (Garzon, 2000, Hand and Frieden, 2002). 
A useful clinical sub-classification was issued for AVMs – the ISSVA-Schobinger 
staging (Kohout, Hansen et al, 1998). According to this, AVMs can be classified into four 
clinical stages: 1. dormancy, 2. expansion, 3. destruction and 4. destruction and congestive 
cardiac failure (Table appendix.8.). 
Tabel appendix. 8. ISSVA-Schobinger staging  
I (quiescence) Pink bluish stain, warmth, and  
Arteriovascular shunting 
II (expansion) Same as stage I, plus enlargement, pulsations, 
thrill, bruit, and tortous/tense veins 
III (destruction) Same as stage II, plus dystrophic skin changes, 
ulceration, bleeding, persistent pain, or tissue 
necrosis 
IV (decompensation) Same as stage III, plus cardiac failure 
  
Houdart et al, 1993, have proposed a classification of intracranial arteriovenous 
malformations based on angiographic appearances of these lesions and this is currently applied 
and used to plan treatment of peripheral AVMs. This classification applies only to HF lesions 
and complements Mulliken’s classification. Based on this classification, there are three types of 
fistulas within AVMs: a. Arteriovenous in which maximum three separate arteries are supplying 
a single venous component; b. Arteriolovenous in which multiple arteries communicate with a 
single central dilated venous component; c. Arteriolovenulous in which there are many 
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communications between arterioles and venules (Figure appendix.1.). This classification helps 
establish the access route in the process of embolisation of the vascular anomaly, as a method of 
treatment of these lesions, which will be dicussed later. 
 
Figure appendix. 1. Angio-architectural classification of AVMs 
Angio-architectural classification of AVMs, adapted from Interventional Neuroradiology (1993) 35: 381-
385 – a proposed angiographic classification of intracranial arteriovenous fistulae and malformations by 
Houdart et al. 
Histology textbooks present additional extensive classifications of CVMs but they have 
little clinical applicability as features described are overlapping or non-specific (Weisse and 
Goldbloom, 2001).  
The term ‘angiodysplasia’ has been used in the past to describe CVMs but is currently 
considered inappropriate as it has the propensity to add to already existent confusion (Lee, 
Laredo et al, 2007).  
In describing various vascular anomalies the terms ‘congenital’ and ‘acquired’ have 
been aknowledged. Experts (Mulliken, Fishman and Burrows, 2000) have recently stated that 
the term ‘congenital’ should probably be restricted to a vascular lesion that is present and fully 
developed at birth and the term ‘acquired’ should be applied to lesions appearing after the first 
year of life, in spite of the fact that this late lesions could still be present at birth, as in vascular 
malformations, although not clinically apparent. 
Haemangiomas as the most common lesions of the CVMs have been debated more. 
However, the majority of haemangiomas are self-limiting and only few of them (10-20%) 
require aggressive treatment (Mueller and Mulliken, 1999). Vascular malformations represent 
the real challenge for any specialist and little research has addressed these lesions, mainly due to 
c 
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lack of tissue as operative treatments were used sparingly due to their high risk of major 
haemorrhage associated with surgery. Reference will be mostly made to AVMs and 
haemangiomas, lesions which can be difficult to distinguish on occasions.  
B) INVESTIGATIONS OF CVMs 
Diagnosis of all vascular anomalies is based on detailed and accurate clinical history 
and thorough physical examination. Several other means to further investigate and assess the 
lesion are available, ranging from non-invasive to less invasive and invasive methods. There is 
no single test that would indicate best management for a particular lesion but choosing the 
appropriate imaging techniques are critical in establishing the diagnosis, assessment, treatment 
and prognostic. Emphasis is placed on non-invasive techniques wherever possible, but 
especially in children. The objective in the diagnosis of vascular anomalies is the precise 
identification of each component of the vascular defects. It is known that several different 
defects can coexist in the same region or affecting different areas and the truncular and 
extratruncular forms developed from different stages of embryogenesis, can also coexist (Lee, 
2004). 
Below is a brief description of the standard radiological investigations used for vascular 
anomalies, but also details of these studies tailored to the main categories of vascular anomalies 
considered here, including when are they employed and how can they differentiate between the 
known sub-categories of vascular anomalies. Selective invasive studies are reserved to plan 
treatment.             
Common radiological investigations 
Plain X-rays, although not routinely performed, may be useful to assess bone and joint 
deformities associated to some categories of vascular anomalies as previously discussed. 
Colour Duplex Doppler ultrasonography is a convenient, rapid and non-invasive 
method of assessing most vascular anomalies. The ultrasound probe emits a continuous beam of 
ultrasound waves that deflects from red cells moving inside the blood vessels comprising the 
anomaly. The frequency of signals reflected shifts in proportion to the velocity of the cells being 
presented as acoustic signals. Duplex scanning combines image with Doppler signals such as 
red colour indicates flow away and blue towards the ultrasound probe. This helps to 
differentiate high-flow from low-flow lesions and to detect size of vessels, and extent of lesion. 
Computer tomography (CT) is still used but has been mostly replaced by magnetic 
resonance imaging (MRI), which is a better method for evaluation of vascular anomalies. Spiral 
CT with three-dimensional reconstructions is used to assess bony abnormalities prior to surgery 
or if MRI is contraindicated. Phleboliths may be demonstrated on CT. 
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MRI offers the best imaging for vascular anomalies is non-invasive and is the most 
useful test for initial assessment, planning management and follow-up. Rak et al (1992) 
described the MR appearance of symptomatic vascular anomalies and indicated that MRI was 
essential in separating vascular lesions into high flow and low flow types. There are specific 
examination protocols for these lesions, using both T1-weighted and T2-weighted imaging. The 
distinction between venous malformations and arteriovenous malformations and fistulae is on 
T2-weighted MR images. These demonstrate venous malformations ‘bright’, of a very high 
signal intensity and arteriovenous malformations and fistulae have little or no signal due to the 
phenomenon known as ‘flow void’. 
Angiography is an invasive study, usually considered for lesions selected for treatment 
if clinical examination and ultrasonography indicated a high-flow lesion. Angiography on low-
flow lesions is inaccurate and not useful. Angiography on high-flow lesions allow identification 
of the arterio-venous communications, which helps planning best approach for treatment that 
may be performed at the same time (embolisation, further discussed in the next sub-chapter). 
Haemangiomas 
In over 93% of cases the diagnosis of haemangioma is based on clinical features 
(Gampper et al, 2002). Deep haemangiomas in particular may be difficult to differentiate from 
other soft tissue tumours. 
Ultrasonography can differentiate a haemangioma in a proliferative phase, which 
exhibit fast-flow. It can also differentiate a deep haemangioma from a venous malformation but 
it may be difficult to differentiate a proliferating haemangioma from an arterio-venous 
malformation as both may have fast-flow. This study is often useful to follow–up response to 
therapy but provides limited information. 
MRI is the gold standard and superseded the other techniques in assessing such 
lesions.This may require sedation or general anaesthesia in children less than 6 years of age 
(Mulliken et al, 2000). Heamangiomas appear on MRI as fast-flow lesions with flow voids and 
tissue predominance and they may be difficult to differentiate from AVMs (Esterly, 1996). They 
are iso-intense or hypo-intense to muscle on T1-weighted imaging and hyper-intense on T2-
weighted imaging. They enhance homogenously with intravenous gadolinium (Gampper et al, 
2002). 
Nuclear scanning with technetium Tc 99m-tagged red blood cells may be used when 
multiple deep haemangiomas or visceral lesions are suspected (Barton et al, 1992). 
Angiography has value when the presentation of the haemangioma is atypical, or if 
embolisation or surgery is considered (Esterly, 1996). 
Appendix 
 190 
Biopsy of haemangiomas is rarely necessary and there is a risk of un-controllable 
bleeding. Biopsy may be useful to differentiate atypical cases from other soft-tissue tumours, 
such as myofibromatosis, kaposiform haemangioendothelioma (a low grade sarcoma), and 
rhabdomyosarcoma (Frieden et al, 1997). 
Venous malformations 
The presence of a venous malformation is confirmed using non-invasive or less invasive 
tests including MRI T2-weighted image, duplex ultrasonography, whole body blood pool 
scintigraphy (WBBPS), transarterial lung perfusion scintigraphy (TLPS), air plethysmography, 
MR venography (MRV) and/or MR arteriography (MRA), CT with contrast and tri-dimensional 
reconstruction, radioisotope (RI) lymphoscintigraphy, ultrasound lymphangiography, MR 
lymphangiography (Lee at al, 2007). These studies help in diagnosing the lesion and assessing 
the extent of the malformation before treatment.  
Ultrasonography should be the initial imaging modality used and it demonstrates 
absence of flow or low-velocity venous flow (Dubois et al, 2001). The absence of flow may 
suggest thrombosis. 
On CT scan, venous malformations appear as hypo-attenuated, heterogenous lesions 
that enhance slowly at the periphery after contrast injection. (Dubois et al, 2001). 
MRI scan provides the most information. Venous malformations are hypo-intense on 
T1-weighted MR images and hyper-intense on T2-weighted images. MRV is useful for 
assessment of extensive lesions affecting extremities. 
Invasive studies including standard or selective angiography, phlebography, ascending, 
descending, and/or segmental venography, or percutaneous lymphangiography are usually 
performed on symptomatic lesions, with the aim of establishing the best therapeutic strategy 
(Lee et al, 2007).These techniques also help identify mixed lesions such as a venous 
malformation with arteriovenous components. Direct phlebography may be performed to obtain 
a more detailed analysis of the lesion or as part of sclerotherapy treatment. It involves the 
injection of contrast into the venous system, which may be a foot vein, (ascending venography), 
on the femoral vein (descending venography) or into a specific venous segment (segmental 
venography). Venography may or may not demonstrate communications between deep veins 
and a venous malformation. Hypoplasia or aplasia of the deep venous system may be found in 
almost 50% of venous malformations (Eifert et al, 2000) and this may represent a 
contraindication to removing large superficial veins (Rosen et al, 2000). 
Transarterial lung perfusion scintigraphy (TLPS) was developed as a test less invasive 
than angiography, for the physiological assessment of the arteriovenous shunting status of the 
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vascular lesions located in the lower extremities. This can provide accurate information on the 
reduction of the shunting volume post-treatment (Lee et al, 2005). 
Arteriovenous malformations (AVMs) 
If treatment and especially surgical treatment is contemplated, these selected lesions 
would have been assessed by ultrasonography, MRI and/or magnetic resonance angiography 
(MRA). The superselective angiography is performed close to the planned intervention. Direct 
opacification of the nidus (the confluence of abnormal vessels, where arteriovenous shunting 
occurs without a capillary bed), helps diagnosis and treatment (Hyodoh et al, 2005). 
Foetal diagnosis of vascular anomalies 
Diagnosis based on ultrasound evaluation of the developing foetus is increasingly 
possible. Marler et al, 2005 published a review with their experience with 29 patients having 
pre-natally diagnosed vascular anomalies. They concluded that vascular anomalies can be 
diagnosed in the second and third trimesters of prenatal development but the technique is 
unreliable. This has psychosocial and ethical implications and currently postnatal evaluation and 
diagnosis remains the accepted standard (Arneja et al, 2008). 
C) TREATMENT OF CVMs 
The appropriate management of vascular anomalies is dependent on an accurate 
diagnosis. The decision to treat a vascular anomaly is still are one of the most difficult clinical 
decisions due to their extremely variable clinical presentation ranging from asymptomatic 
lesions to life threatening conditions.  
The concepts of management of vascular anomalies have changed over the last few 
years and a slightly more robust and logical approach has been introduced based on the general 
acceptance of the Hamburg classification and, on the introduction of a multidisciplinary team 
approach to their management (Lee, 2002).The multidisciplinary team approach involves the 
participation and coordination of many specialists. This provides full integration of all therapies 
available, adapted to each individual case. (Lee et al, 2007). This approach is not evidenced 
based and published outcomes of various surgical or interventional techniques recommended by 
the multidisciplinary teams are rather obscure.  
The treatment strategy is usually focused on the ‘primary’ lesion, followed by treatment 
of ‘secondary’ disorders associated with the vascular lesion. Treatment methods are based on 
the exact characterisation of the haemodynamic nature of the lesion. Treatment is usually 
reserved for symptomatic lesions but large, cosmetically un-acceptable lesions, or those in 
critical locations may also be considered for treatment even though the lesion is asymptomatic. 
Guidelines for treatment indication for CVMs have been published by Lee in 2004 and 
they are given in the table below. 
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Tabel appendix. 9. Treatment indications for congenital vascular malformations 
Treatment indications for congenital vascular malformations 
1. Absolute indication 
Haemorrhage: caused mostly by VM or AVM 
Increasing or progressing risk of high-output heart failure: AVM 
Secondary complication of chronic venous hypertension: AVM or VM 
Lesions located at a life- and/or limb-threatening region (e.g. airway): VM or AVM 
Lesions threatening vital functions: various CVMs 
2. Relative indications 
Disabling pain and/or discomfort of progressive nature 
Functional disability or impairment affecting daily activity and quality of life 
Cosmetically severe deformity accompanied by physical and/or psychological disability with 
severe negative impact on quality of life 
Vascular-bone syndrome with rapid progress and long-bone growth discrepancy accompanied 
by significant pelvic tilt and/or compensatory scoliosis 
Lesions located in a region associated with a potentially high risk of complication (e.g., 
haemarthrosis and/or trauma-prone condition; deep vein thrombosis) 
Lesions with recurrent infection (local and/or systemic sepsis) 
Lesions with persistent lymph leakage 
Adapted from Ann Vasc Surg 2004; 18:380-392, Critical Issues in Management of Congenital Vascular 
Malformation, By Lee BB 
Similar treatment indications were published for AVMs by Zhou et al in 2005. Appropriate time 
of treatment depends on the type of vascular anomaly (Lee et al, 2002). Life or leg-threatening 
malformations require urgent treatment. 
General concepts of treatment of vascular anomalies 
C.1 Conservative 
Conservative methods in the management of vascular anomalies range from simply 
observing the lesions at regular intervals, educating the patients or parents, application of 
elasticated compression garments, to local, intra-lesional or systemic pharmacotherapy. 
C.2 Endovascular techniques 
Intentional occlusion of the blood flow within the vascular lesion is used by 
interventional radiologists who employ image guided procedures known as endovascular 
techniques, mainly embolisation and sclerotherapy. The vascular lesions can be closed by 
advancing a small plastic tube into the feeding artery of the lesion. This is used to inject small 
particles of foreign materials such as medical glue, alcohol, small beads or coils, which are 
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floated into the vascular lesion until this is full and the flow has ceased. Sclerotherapy means 
delivery of an ablative or irritant liquid directly into the abnormal blood vessels, usually via a 
percutaneously placed cannula. Embolisation is reserved for high-flow vascular anomalies and 
sclerotherapy may be effective in high or low flow lesions. These therapies aim to cause a 
combination of vascular thrombosis and endothelial ablation resulting in fibrosis. 
Endovascular techniques were introduced in the early 1970s and have been increasingly 
employed as they developed during the last decade. Recent advances in endovascular equipment 
and imaging allow safe supra-selective catheterization and embolisation of feeding vessels of 
high flow lesions, aiming to induce localised vascular thrombosis (Svendsen, 1994). Embolising 
or sclerosing agents such as absolute ethanol, polidocanol (Aethoxysklerol; Kaigen, Osaka, 
Japan), ethanolamine oleate (Oldamin for injection; Grelan Pharmaceutical, Tokyo, Japan), n-
butyl cyanoacrylate (Histoacryl; B. Braun, Melsungen, Germany), various types of coils, 
polyvinyl alcohol foam powder (Ivalon; Cook, Bloomington, Ind), superabsorbent polymer 
microspheres, detachable balloons, foam pledgets have been used in various combinations, with 
different protocols, depending on the location, severity and extent of the lesion (Hyodoh et al, 
2005). 
The flow of AVMs can be reduced by embolic therapy but such treatment may be short-
lived or palliative in long term (Hyodoh et al, 2005, Enjolras, 1997, Marchiano, 1996, White, 
2000).These techniques are often used in the treatment of CVMs, when feasible. They are 
especially important when the risk of bleeding associated with surgery is too high, the location 
of the lesion or the infiltration of important or vital structures prevents a surgical excision or 
debulking. Percutaneous sclerotherapy is accepted as independent therapy for vascular 
malformations
 
(Hyodoh et al, 2005). Embolisation of venous malformations is known to have 
disappointing results but percutaneous sclerotherapy may be effective in these lesions (Lee, 
2001). Repeated courses of sclerotherapy can lead to clinical improvement of venous 
malformations (Suh, 1997). This technique can also be used as an adjuvant therapy to surgery. 
Pre-operative embolisation is known to facilitate surgery and decrease operative blood loss 
(Zhou et al, 2005, Lee, 2007, Rosen et al, 2000). Post-operative supplemental endovascular 
therapy has also been reported to improve outcome of surgical therapy such as surgical excess is 
avoided. (Lee et al, 2007). 
New strategies of combining embolisation materials such as coils, particles or N-buthyl 
cyano-acrylate with absolute alcohol have been introduced, aiming to gain synergistic effects 
and to reduce complications reported with absolute alcohol (Lee, 2004). Re-canalisation and 
recurrence of the lesion are the main limitations of these therapies as well as: skin necrosis, 
nerve damage, inadvertent embolisation of normal tissues, thrombo-embolism.  
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The last decade has seen a major change to the strategy for CVM management resulting 
from the realisation of the harm caused by the embolisation of feeding vessels. This is now 
condemned since all the extratruncular CVM lesions may be stimulated by the embolisation of 
the feeding arteries. Endovascular therapies requires specialist skills as they are potentially 
dangerous and can lead to complications such as full-thickness skin necrosis, nerve injury, 
bleeding, muscle atrophy and contracture, deep vein thrombosis, pulmonary embolus, 
haemolysis, renal toxicity and even cardiac arrest. This is why these techniques are usually 
employed on symptomatic lesions only, used alone or in association with surgery.  
C.3 Surgery  
Surgical therapy for various vascular anomalies is initially aimed at the primary lesion 
and has the aim to decrease haemodynamic activity and the resulting impact on the body. This 
consists of non-radical operations, usually debulking performed in stages. Subsequently, surgery 
aims at improving function, quality of life and cosmetics (Lee, 2004). 
Surgical excision remains the only solution for ‘cure’ of any vascular lesion but usually 
requires radical resection, which has high associated morbidity, mainly major haemorrhage (Lee 
et al, 2007).  
The predominantly conservative treatment approach should be considered a thing of the 
past (Loose, 2007). In order to undertake this complex surgery, special skills and experience are 
required.  
Ligation of the feeding vessels was performed in the past on AVMs but this technique 
led to a rapid development of collateral vessels which made future treatments rather difficult 
(Coleman, 1973, Coursley, 1956, Reid, 1925, Svendsen, 1994, Zhou, 2005).  
Previous studies on AVMs have suggested that a cure can only be expected when the 
whole lesion is removed (Zhou, 2005, Hyodoh, 2005) or the confluence point of the abnormal 
vessels in AVMs, which is called a ‘nidus’ is destroyed (Hyodoh, 2005, Lee, 2007). Surgery 
should involve the ligation of all feeding vessels and the entire malformation. Well-demarcated 
lesions, which are confined to limited anatomical regions, may be removed by performing a 
surgical excision. For patients with life/limb threatening complications of AVMs or with severe 
symptomatology where surgical excision is not technically feasible, debulking surgery (serial 
partial removal) may have significant benefits and does not necessarily lead to recurrences 
(Phillips et al, 2005). Debulking surgery is a controversial procedure but has potential to correct 
severe symptoms (Belov et al, 1990, Loose, 1990, Loose, 2001, Loose, 2007). However, 
debulking is major surgery with significant risks of bleeding and associated complications. 
Published data (Belov, 1990, Belov, 1993, Bastide, 1990, Lee, 2007) have suggested that 
debulking is not conceptually good unless it is warranted to control serious complications. Some 
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authors believe that simple debulking will only stimulate the diffuse infiltrating lesion to grow 
back, as ‘extratruncular’ lesion in Hamburg classification (Belov, 1990). The explanation 
behind this rationale is that these lesions may have characteristics of or represent remnant 
embryonic tissue originating from an early stage of embryogenesis, so that it possesses 
mesenchymal cell characteristics and grow back when stimulated by debulking. To date there is 
no scientific data to support these claims and there is no evidence demonstrating the embryonic 
origin of CVM tissue. Partial excisions do not imply worsening symptoms or recurrences 
(Phillips et al, 2005). Excision may be performed at an early stage for well-localised stage 1 
AVMs (see Schobinger stages). 
Compartmentalization using non-absorbable sutures is another surgical option in 
selected cases (Jackson, 2005). This involves ‘over sewing’ the AVM vasculature and inducing 
thrombosis. In theory, this is a mechanism of feeding artery ligation and may indicate its 
liability to recurrence.  
Specific treatment methods 
Haemangiomas 
It is estimated that 10-20% of haemangiomas require intervention (Mueller et al, 1999) 
and it is universally accepted that the majority of haemangiomas do not need treatment as they 
undergo spontaneous involution (Fishman et al, 1993). Rudimentary knowledge of the 
pathogenesis of haemangioma led to empirical and unsatisfactory therapies (Tan et al, 2000, 
Mulliken et al, 1995, Hasan et al, 2000). 
Treatment decisions in respect to infantile haemangioma take into account the size and 
location of the lesion, the age of the patient, the growth phase of the haemangioma, associated 
features and the potential for psychosocial distress for parents and patient. 
Observation is all that is required for small, harmless lesions but parents of an affected 
child need detailed explanation of the condition and reassurance. Edgerton (1976) named this 
approach ‘masterful neglect’ and Mulliken et al (1988) emphasised the principle primum non 
nocere. A useful principle in the treatment of these lesions is that of ‘active non-intervention’ 
(Garzon et al, 2000). 
Large lesions, especially those affecting the face can cause serious distress to the 
parents and sometimes to the child. Haemangiomas leading to complications require treatment. 
There is a sub-category of haemangiomas between the harmless and the complicated lesions 
treatment of which is still debated by specialists. Although usually harmless, some specialists 
would intervene in such cases, to prevent psychological problems developing in early childhood 
in an affected child. 
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Local therapies are available for ulcerated or bleeding lesions.These include: daily 
application of a topical antibiotic, non-stick wound dressings, hydrocolloid dressings, hydrated 
petrolatum, viscous lignocaine, corticosteroids.  
Pain management may be indicated. Pulsed-dye laser has been reported to help healing and pain 
(Achauer et al, 1991, Morelli et al, 1994). Excision can be performed on an ulcerated lesion of 
the scalp, torso or extremity but rarely is performed for a facial lesion. Haemangiomas of the 
eyelid may be troublesome and those not responding to medical therapy require excision or 
debulking. Prominent haemangiomas in involuting phase may be considered for excision in the 
pre-school period. Skin changes resulting in the involuted phase can be dealt with by excision 
and only rarely are reconstructive techniques required. Bleeding is dealt with by compression 
and only occasionally requires suturing of the bleeding points or excision. Diffuse, large 
infiltrative haemangiomas can lead to life-threatening haemorrhage. These lesions are usually 
in-operable and they are treated with blood transfusions, parenteral nutrition and anti-angiogenic 
drug therapy to stimulate their involution (Mulliken et al, 2000). 
Topical corticosteroids have been reported to be effective in small, superficial 
haemangiomas. Injection of corticosteroids may be considered in small, localised cutaneous 
haemangiomas. Since the 1960s systemic corticosteroids have represented the first-line 
treatment in complicated, life-threatening haemangiomas. Recombinant Interferon alpha is 
considered a second-line drug for complicated or life-threatening haemangiomas but some 
clinicians recommend its use as a first line drug (Mulliket et al, 2000). There is no evidence of 
any benefit by administering corticosteroids and Interferon alpha together. OK-432 is a 
denaturated streptococcal protein which is reported to stimulate the immune response and 
accelerate the resolution of a haemangioma (Kim et al, 2004). Bleomycin injected directly into a 
lesion has been reported to be effective, but its mode of action in haemangiomas is still to be 
established (Sarihan et al, 1997). Chemotherapeutic agents such as vincristine and 
cyclophosphamide have been used in exceptional cases (Frieden et al, 1997). Vincristine is 
effective in the setting of vascular lesions associated with Kasabach-Merrit phenomenon but is 
gaining increased recognition as a potential agent for infants with steroid-resistant 
haemangiomas or those who cannot tolerate steroids. 
Embolisation is indicated in fast-flow haemangiomas causing congestive heart failure, 
airway or ocular obstruction, life-threatening coagulopathy, and not-responding to other 
therapies. Endovascular therapies are not used for routine management of haemangiomas. 
Photocoagulation using laser therapy is debated. Several types of lasers have been used 
in the treatment of haemangiomas including flash lamp-pumped pulsed-dye, carbon dioxide, 
neodymium: yttrium-aluminum-garnet, potassium-titanyl-phosphate or argon lasers (Gampper 
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et al, 2001). The pulsed-dye laser penetrates up to the dermis and only the superficial surface of 
the haemangioma is affected. The lesions this treated are usually amongst those that are 
clinically insignificant. Continuous-wave carbon dioxide laser (Sie et al, 1994) is an accepted 
laser therapy applied in the proliferative phase of subglottic haemangioma but tracheostomy is 
often required to maintain the airway. Another current laser therapy is the use of a bare fiber 
(Nd: YAG) inserted through multiple needle passages into the haemangioma (Berlien et al, 
1990). 
Radiation therapy use has been reported in severe, life-threatening haemangiomas, not 
responding to other treatments (Caldwell et al, 1995). This method was popular in the 1940s and 
1950s but subsequently abandoned as outcomes were worse than leaving the lesion un-treated. 
Dondon et al, 2004, presented data documenting the increase in cancer mortality in adults after 
radiotherapy for cutaneous haemangiomas during childhood. 
Cryotherapy, in the form of topical liquid nitrogen and carbon dioxide have been used 
in the treatment of superficial haemangiomas but has limited acceptance due to subsequent 
scarring and hypopigmentation (Cremer, 1998, Edgerton, 1976). 
Supportive measures are implemented, such as diuretics and digoxin in cases of high-
output cardiac failure, oral antibiotics for infected lesions, depending on the specific 
complication. 
Compression therapy has been tried for haemangiomas but with no evidence that this 
would accelerate the involution of the lesion. 
The prospect of new inhibitors of angiogenesis and their use in this field is a current 
matter of debate. 
Venous malformations 
Loose published in 2007 the principles of therapeutic strategy for these lesions: 1. active 
causal treatment, abolishing the haemodynamic dysfunction, 2. harmonised individual 
treatment, 3. early operation in childhood, 4. radical operation without loss of function, 5. 
operative treatment by stages, 6. combined treatment. 
Most venous malformations are treated conservatively as many authors suggested that 
asymptomatic lesions can be safely observed.  
Elastic compression garments may help by reducing the swelling, pain and risk of 
coagulopathy in an affected limb. Prophylactic aspirine (80mg daily) has been recommended to 
prevent painful thrombotic episodes and phlebolith formation (Marler et al, 2005). Intravascular 
coagulopathy may need control with heparin. Infected ulcerated lesions are treated with 
antibiotics with guidance from the wound swabs taken prior to commencement of the antibiotic 
treatment. 
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Aggressive intervention in young patients is usually pursued in lesions causing 
impairment of vital functions or those causing the vascular bone syndrome resulting in leg 
length discrepancy (Lee et al, 2005). An affected lower extremity can be complicated by pelvic 
tilting and scoliosis. To avoid such complications, stapling epiphysiodesis of the knee cartilages 
is often performed but this intervention may exacerbate the lesion (Enjolras et al, 2004). 
Surgical treatment alone or in combination with pre-operative endovascular techniques 
is considered optimal management for the truncular form of these lesions with no risk of 
recurrence (Loose, 1989, Mattasi, 1989). These treatment methods are also used for 
extratruncular lesions with an accepted risk of recurrence. The removal of extratruncular lesions 
together with muscles or bone segments may be inevitable. This approach supports Malan’s 
opinion that the criteria applied to surgical treatment in vascular malformations are not different 
from those applied in ‘cancer surgery’, meaning extreme and radical resections may be required, 
even when this leads to considerable disfigurement (Malan, 1974). The surgical tactics are 
adjusted to the pathological form of malformation (Loose, 2007) and may represent: 1. an 
operation to reduce the haemodynamic activity of the malformation (venous hypertension); 2. 
an operation to eliminate the malformation; 3. reconstructive surgery. 
Severe venous malformations resulting in a non-functional limb require early 
amputation followed by early rehabilitation with the use of prosthesis. (Lee et al, 2007).  
Supra-selective catheterisation of feeding vessels and the trans-catheter administration 
of embolic agents have revolutionised the treatment of venous malformations.  
Vein stripping for superficial veins causing discomfort may be performed once the deep 
veins have been assessed and proven adequate. 
Some venous malformations such as those containing a localised slow-flow nidus can 
be successfully treated with sclerotherapy (Hyodoh et al, 2005). Multiple sessions of 
sclerotherapy are usually necessary and they have a palliative effect as venous malformations 
have the potential to re-canalise and recur (Mulliken et al, 2000). Lee et al (2001) reported that 
absolute ethanol sclerotherapy can lead to excellent results in complex forms of venous 
malformations with considerable but acceptable morbidity and with no recurrence or 
deterioration of symptoms at 10 months. 
Foam sclerotherapy has been reported to have excellent outcomes and is favoured over 
liquid therapy (Pascarella et al, 2005). 
Endovenous thermal ablation such as laser or radiofrequency ablation, have been used 
to treat venous malformations with acceptable results (Sidhu et al, 2005). 
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Arteriovenous malformations 
These are high-flow (HF) lesions and they are the most difficult vascular lesions to 
treat. Complete destruction of the nidus of an AVM is the only way to cure these lesions but this 
is often difficult to achieve.  Small, superficial AVMs can be excised but most AVMs are large, 
diffuse and infiltrating important adjacent structures, therefore very difficult or impossible to 
excise (Jackson et al, 1996). Early stage (I and II) lesions can be resected and reconstructed 
easily.  
Embolisation and surgery are the main therapeutic options for these lesions. It is 
advised that the intervention should be delayed until serious complications occur. Emergency 
embolisation may be necessary in cases of congestive heart failure. In some cases, embolisation 
worsens the patients’ symptoms, due to aggravation of adjacent tissue ischaemia (Burrows, 
2006). The usual strategy in AVMs is arterial embolisation of the nidus, 24-72 hours in advance 
of surgical intervention, in attempt to decrease intra-operative haemorrhage. This can be 
performed by an arterial or venous approach, depending on the angiographic classification of 
the AVM, as described by Houdart et al. in 1993. Pre-operative embolisation does not minimise 
the extent of the resection. The surgeon must decide on the extent of the section. Inappropriate 
surgical intervention may stimulate ‘dormant’ vascular malformations to become active and 
symptomatic (Hyodoh et al, 2005).  Extensive AVMs infiltrating vital anatomical structures 
may be amenable to palliative embolisation only and debulking may have a limited role. When 
wide excisions are performed and primary closure is not possible, the resulting defect may 
require reconstruction with skin grafts, local flaps or free tissue transfer. Surgery on very large 
AVMs may require the use of cardiopulmonary bypass and hypothermic cardiac arrest in order 
to limit blood loss (Mulliken et al, 1978). Surgery on extensive AVMs is controversial because 
is difficult to predict the outcome. Further research into these lesions in an attempt to design 
new ablative therapies may benefit patients with inoperable disease. 
Treatment of AVMs with laser, steroids, or irradiation has not been effective. 
D) THEORIES AROUND AETIO-PATHOGENESIS OF CVMs 
D.1 Angiosomes theory 
  The arteries supplying CVM tissue with blood are responsible for the supply of the 
skin and the underlying structures. The anatomical territory of a source artery in the skin and 
deep tissues was found to correspond in most cases and this gave rise to the angiosome concept. 
It was found that arteries follow closely the connective tissue framework of the body. The 
primary supply to the skin is by direct cutaneous arteries which vary in calibre, length and 
density in different areas. This primary supply is reinforced by numerous small indirect vessels, 
which are terminal branches of arteries supplying the deep tissues. The angiosome territories 
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have been established for most anatomical regions and this information provides data for the 
surgeon to help plan safer incisions and better reconstructive flap procedures. It also provides 
information that may help explain the development of some vascular anomalies and help in 
planning their management (Houseman et al, 2000). Vascular studies with in vivo angiogram 
studies of vascular malformations in the head and neck showed that the site of these 
malformations coincides with the so called ‘choke anastomotic zones’ that linked adjacent 
angiosomes. Houseman found that in the head and neck areas, the angiosomes anastomose with 
one another either by large ‘true anastomoses’ without change in calibre or in some areas by 
reduced calibre ‘choke’ anastomoses. The anastomoses between angiosomes usually occur 
within tissues- skin, muscle, fat, gland or bone- not between them. In some sites the connection 
is almost non-existent and is formed by minute vessels. The choke anastomoses link adjacent 
vascular territories and the malformations are always fed by two or more arteries. Authors 
emphasised that it is likely that choke vessels regulate flow between angiosomes under normal 
circumstances. They also indicated that it seems possible that the factors that regulate the 
development and function of these choke vessels are either deficient or abnormal and that this 
has led to the development of vascular anomalies. In 1794 John Hunter stipulated that a foetus 
had a fixed number and pattern of blood vessels at some stage of embryonic development and 
that subsequent change in their anatomy was a response to pre-natal and post-natal growth and 
development. 
D.2 Genetic theories 
It is recognised that haemangiomas occur sporadically but more recently data 
accumulating suggests that is likely that haemangiogenesis involves a genetic alteration. Blei et 
al, 1998, reported six families in whom haemangiomas or vascular malformations were present 
in multiple generations, suggestive of an autosomal dominant inheritance. Also, several of the 
patients with haemangiomas had relatives with vascular malformations, suggesting a possible 
common underlying genetic linkage. In three of these families genetic mutations were linked to 
the long arm of chromosome 5 (5q) (Walter et al, 1998). Ritter et al, 2002, published for the 
first time data demonstrating dynamic expression of a variety of genes functioning as growth 
factors, signal transduction and immune response in haemangiomas. They identified T cells in 
haemangiomas and indicated that the high expression of 2, 3 dioxygenase, a T cell-related 
enzyme, may modulate the haemagioma life-cycle (Ritter et al, 2003). 
Another theory is that vascular malformations follow the somatic mosaic hypothesis of 
Happle, who stipulates that the presence of the mutation in the zygote is embryonic lethal, but 
there may be a mosaic distribution with cells bearing the mutation surviving in proximity to 
normal cells.  
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Genetic studies are beginning to identify changes in the cascade of development and 
processes that caused vascular malformations (Vikkula et al, 1998). A mutation in the gene 
encoding for receptor kinase Tie-2 causes familial cutaneous-mucosal venous malformations 
(Vikkula et al, 1996, Boon et al, 1994). This receptor is expressed specifically by ECs. Another 
venous malformation subtype called glomuvenous malformation is often familial and caused by 
the gene glomulin found on the short arm of chromosome 1(1p) (Brouillard et al, 2002). Over-
expression of VEGF-C leads to lymphatic EC proliferation and vessel enlargement (Dumont et 
al, 1998, Jeltsch et al, 1997). Angiopoietin-1 deficiency causes defects in the vascular wall and 
over-expression leads to increased vascularisation (Suri et al, 1996, Suri et al, 1998). Multiple 
cerebral ‘cavernous’ venous malformations are inheritable and are caused by mutations in 
KRIT-1 (Laberge-le Couteulx et al, 1999). 
Some mutations associated with vascular anomalies have been localised to known genes 
or mapped to specific chromosomal regions but others remain obscure. Known genes include 
AGGF1 for Klippel-Trenaunay syndrome, RASA1 for capillary malformations, KRIT-1, 
MGC4607, PDCD10 for cerebral cavernous malformations, VEGFR-3, FOXC2, NEMO, 
SOX18 for lymphoedema, ENG, ACVRLK1, MADH4 for HHT, NDP for Coats’disease, 
Notch3 for CDASIL, PTEN for Proteus syndrome. 
Sato et al (1995) speculated that arteriovenous malformations also result from a somatic 
mutation in endothelial or perivascular cells.  
One hypothesis invokes a somatic mutation, the local loss or gain of genetic material 
during foetal development that produces an altered cell line that is stimulated by autocrine or 
paracrine signalling. Therefore, one of the most accepted theories explaining the development of 
haemangiomas concerns the primary defect intrinsic to ECs (Tille et al, 2004, Boye et al, 2001). 
Boye et al, 2001, observed that ECs isolated from haemangiomas in nine infants exhibit 
enhanced proliferation and migration but this cell migration in the presence of the angiogenic 
inhibitor endostatin, was not inhibited but rather stimulated, suggesting a an altered cellular 
phenotype. These results indicate that haemangiomas represent clonal expansions of abnormal 
ECs and that they may be caused by a somatic mutation in a gene that regulates ECs 
proliferation (Walter et al, 2002 and Boye et al, 2001). This would mean that all ECs composing 
a haemangioma originate from the same progenitor cell that carries the somatic mutation and 
causes the abnormal proliferation.  
 The peripheral, sporadic, vascular malformations with no proven genetic mutations to 
date represent the focus of this study. 
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D.3 Miscellaneous theories 
There is some speculation that haemangiomas may arise from ectopic placenta or a shift 
of the endothelium to the placental phenotype, due to the increased risk of haemangiomas in 
children of mothers who had chorionic villus sampling and due to shared immunoexpression 
between placental tissue and haemangiomas (GLUT-1, FCβRII, merosin, etc) (Burton et al, 
1995, Bree et al, 2001, North et al, 2000). Embolic placental ECs could reach foetal tissue from 
chorionic villi through right-to-left shunts characteristic of the normal foetal circulation. The 
placental origin theory is attractive because it would explain the exclusively perinatal or 
congenital presentation of the haemangiomas. The increased incidence of haemangiomas 
associated with chorionic villus sampling, which on occasions disrupt vascular structures, 
suggests that errors in vasculogenesis may provide a fertile field in which haemangiomas later 
proliferate (Drolet et al, 1999).  
A viral cause has been suspected but the angiogenic human herpes virus 8, the common 
agent in Kaposi sarcoma, has not been found in human haemangioma (Dupin et al, 1998). 
Parapox virus infection causes proliferation of ECs and dilatation of cutaneous blood vessels in 
humans (Lyttle et al, 1994). The avian haeamangioma virus has been identified in spontaneous 
‘haemangioma-like’ lesions in hens (Soffer et al, 1990). 
D.4 Endothelial cells in CVMs 
In an adult the average EC divides only twice in a lifetime. However, EC proliferation 
can be very rapid when needed, such as in a wound healing process. Therefore, the EC 
proliferation must be kept under tight control. EC activation status is determined by a balance 
between positive and negative regulators of EC proliferation, migration and proteinase 
production (Pepper et al, 1996). 
Dosanjh et al, 2000 described that the ECs in haemangiomas converted to a spindle-
shaped morphology similar to that of foetal ECs and concluded that both cell morphology and 
protein expression of neonatal haemangioma ECs were more characteristic of embryonic 
microvascular ECs, suggestive of a dysfunction in the normal growth and maturation of ECs in 
haemangioma.  
Pasyk et al, 1982 conducted an ultrastructural study on haemangiomas and confirmed 
the existence of two types of immature cells, ECs and pericytes in the same lesion. The presence 
of the crystalloid inclusions in the ECs and absence of the Weibel-Palade bodies, deficiency of 
factor VIII and absence of tissue fibrinolytic activity, all suggested that ECs in these lesions are 
immature. 
Kleinman et al, 2003, demonstrated increased levels of circulating EC precursors in 
children with haemangiomas. Yu et al, 2004, showed the presence of EC precursor cells in 
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proliferating haemangioma and speculated that they may contribute to the growth of 
haemangioma. 
There may be aberrant pericyte-endothelial interactions and signalling in the growth of 
the thin walled and ectatic vessels of the vascular malformations. Stabilisation of the ECs and 
their signalling pathways has been identified as important in controlling these malformations. 
Therefore, the receptors involved in the cellular interactions between endothelium, pericytes, 
smooth muscles, may become targets of future therapies. 
The cells cultured from AVMs in skin are different from normal ECs in culture. They 
have a higher rate of proliferation and a lack of inhibition by known angiogenic inhibitors, such 
as interleukin 1β, tumor necrosis factor α, interferon-γ, TGFβ, and a lack of expression of 
leucocyte adhesion molecules (Wautier et al, 1999). 
Recent studies imply EC are directly involved in the pathology of haemangiomas and vascular 
malformations through different mechanisms. This is why further characterisation of the ECs in 
vascular malformations is essential in understanding the key role and mechanism by which 
these cells trigger the pathways leading to the progression and involution of these lesions. 
E) OTHER MOLECULES ASSOCIATED WITH CVM RELATED ANGIOGENESIS 
Basic fibroblast growth factor (bFGF) induces cell proliferation in a variety of cell types 
of mesodermal and neuro-ectodermal origin. In vivo, bFGF may play a role in embryonic 
development (Kimelman et al, 1987) and induces neovascularisation in different angiogenesis 
assays (Folkman et al, 1987). Purified bFGF induces migration and proliferation of ECs in 
tissue culture (Shing et al, 1984). Also, anti-bFGF has been shown to inhibit angiogenesis in 
normal wound repair, indicating that bFGF is intrinsically involved in normal neo-
vascularisation (Broadley et al, 1989). 
Basic FGF is up-regulated during proliferation in haemangiomas. Urinary bFGF levels 
are usually high in infants with proliferating haemangiomas and diminish to normal levels 
during regression (Mulliken et al, 2000).  
TGF-β and its receptors TGF-βR1 and TGF-βR2 may regulate some very early events 
in EC differentiation and may contribute to endothelial maturation (Risau et al, 2000). Humans 
with mutations in TGF-β signalling pathway genes show a range of vascular defects including 
dilated, fragile and haemorrhagic vessels, defective re-modelling, severe vascular malformations 
including AVMs, disrupted vascular smooth muscle cell recruitment and maintenance 
(Vargesson et al, 2003). 
TGF-β is a multifunctional polypeptide that regulates the proliferation and 
differentiation of various cells with an angiogenic effect in vivo but inhibits the growth of ECs 
in vitro. It may induce differentiation of mesenchymal cells into pericytes and smooth muscle 
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cells (Rohovsky et al, 1996) inhibit ECs proliferation and stimulate matrix deposition (Hirschi 
et al, 1996). Decreased TGF-β may lead to increased proliferation of ECs.  
Pepper et al (1993) demonstrated that TGF-βR1 at relatively high concentrations (5-
10ng/l) inhibited EC invasion and capillary lumen formation, while lower concentrations 
(100pg/ml-1ng/ml) of TGF-βR1 potentiated the effect of bFGF- and VEGF-induced 
angiogenesis in vitro. These results support the belief that the nature of the angiogenic response 
elicited by a specific cytokine is contextual, depending on the presence and concentration of 
other cytokines in the pericellular environment of the responding EC.  
Eph receptor tyrosine kinases and their ligands (ephrins) play a key role during the 
development of the embryonic vasculature but their role and regulation in adult angiogenesis is 
still to be defined. Ephrins help establish clear molecular differences in arterial and venulous 
ECs at very early stages of development, when there is no clear morphological distinction 
between presumptive arterial and venous domain. 
The differences between arteries and veins are imprinted early in embryogenesis such that 
arterial ECs express the transmembrane ligand ephrin-B2 and veins express the receptor Eph-B4 
(Wang et al, 1998). However, it remains unclear as to where and how the critical interactions 
occur between cells expressing these markers (Wang et al, 1998). The widespread expression of 
other B-class family members indicates these molecules play a critical role in vascular 
development (Adams et al, 1999). 
Vihanto et al, 2005 implied that hypoxia up-regulated Ephs and ephrins in the skin. 
Ephrins cannot induce potent mitogenic responses from target cells and have been mostly 
implicated in the process of neural cell guidance. B-ephrins can promote attachement of ECs to 
extracellular matrix components by activating integrin function (Huynh-Do et al, 1999) and it 
has been speculated that integrin regulation may be important for Eph function. Like the 
Angiopoietins, the ephrins seem to act primarily in later stages of vascular development, 
although they may contribute to the initial formation of vessels.  
F) PHYSIOLOGY RELATED TO STUDY OF HYPOXIA 
F.1 Measurement of blood gases 
This measurement evaluates how effectively the lungs are delivering oxygen to the 
blood and how efficiently they are eliminating carbon dioxide from it. This test also indicates 
how well the lungs and kidneys are interacting to maintain normal blood acidity.  The 
measurement of blood gases is usually done to assess respiratory disease and other conditions 
that may affect lungs, to manage patients receiving oxygen. At the same time the test gives 
information about the kidney function. This analysis is often performed during general 
anaesthesia, especially for complex, lengthy cases. Measurement of blood gases is traditionally 
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performed on blood from an artery but venous blood could also be used. The test measures the 
partial pressure of oxygen and carbon dioxide in the blood, the oxygen content, oxygen 
saturation, bicarbonate content and blood pH. Oxygen in the lungs is carried to the tissues 
through the bloodstream, but only a small amout of this oxygen can dissolve in arterial blood 
depending on pO2, which is the pressure that the gas exerts on the walls of the arteries. 
Measuring the partial pressure of oxygen is in fact measuring how much oxygen the lungs are 
delivering to the blood. The oxygen that is not dissolved in the blood combines with 
haemoglobin. The oxygen measurement in blood gases analysis indicates how much oxygen is 
combined with the haemoglobin. For this measurement a heparinised, freshly withdrawn, 
bubble-free arterial or venous blood sample is necessary. Prompt analysis of the sample is 
required as any delay reduces the pH and pO2 and increases pCO2. Air bubbles lead to a false 
increase in pO2. This measurement was used on a group of CVM patients in this study and 
details of the methods and bood gas analyser used are given later. 
F.2 Blood-tissue gas exchange  
This term represents the movement of oxygen from the blood stream into the tissues. 
Oxygen moves between the systemic capillary blood and the tissues by simple diffusion. It is 
known that a gas diffuses from an area of higher partial pressure to an area of lower partial 
pressure. There are two sites of exchange of oxygen and carbon dioxide: the lungs and the 
tissues. The exchange of gases between the air in the pulmonary alveoli and the blood in the 
pulmonary capillaries is called external respiration. Internal respiration is the exchange of gases 
between the blood in the systemic capillaries and the tissues. The rate of transfer of O2 through 
tissue is proportional to the tissue area, with the difference in oxygen partial pressure between 
the two sides inversely proportional to the thickness (West, 2004).  
Oxygen diffused in blood at the lung level is bound to haemoglobin to form the 
oxyhaemoglobin complex. 98.5% of all oxygen in blood is carried bound to haemoglobin. 
Because of this, the % of haemoglobin molecules carrying oxygen is important.  
Oxyhaemoglobin can be caused to release oxygen by the addition of H
+
 ions. The difference in 
pH of arterial (7.44) and venous blood (7.35) is sufficient to cause the release of O2 to the 
tissues, where the partial pressure of oxygen at rest is about 40mmHg.  Therefore, a lower pH in 
tissue can determin the oxygen to be delivered by haemoglobin as well as increased 
temperature, increased levels of 2,3-diphosphoglycerate and CO2. The quantitative analysis of 
oxygen/carbon dioxide exchange in tissues is rather difficult due to experimental challenges in 
accurately determining pO2 and pCO2 in tissues. The increase in tissue blood flow (given in 
CVMs by an increase of vessel number or blood vessel diameter) is an effective way of 
increasing tissue O2 supply. High blood flow means further increase in blood flow becomes 
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ineffective because the O2 supply by diffusion is limited. There are two physiological ways of 
improving diffusion conditions of O2 in tissues. One is an increase in the capillary diameter thus 
increasing the surface available for diffusion. The other is the opening of closed, unperfused 
capillaries increasing the capillary density and reducing the diffusion distance (Piper, 1982). 
These are theoretical models and in real tissues oxygen diffusion mechanisms are more 
complicated. In CVM, and especially in AVMs capillary shunting has been described, therefore 
there is a high chance that the corresponding tissue will be hypoxic even in spite of a high pO2 
within the CVM vessels.  
F.3 Account of ventilation-perfusion inequality 
In an ideal lung the ventilation/perfusion (V/Q) ratio is 1. A real lung is not ideal and 
there are always differences in V/Q ratio in different parts of the lung. One factor influencing 
the V/Q ratio is gravity. When an area of lung receiving blood is not ventilated (for example due 
to a blockage in the airways), then, that blood passes through the lung without receiving any 
oxygen. This blood flow represents a pulmonary shunt. Shunted blood with its very low oxygen 
content mixes with the rest of the pulmonary blood and lowers the overall oxygen content of the 
mixture. The pulmonary shunt represents a form of V/Q inequality. An area with no perfusion is 
termed dead space. To interpret a blood gas analysis of the blood within the CVM vessels, 
arteries and veins, it is important to understand V/Q inequality and underlying clinical 
pathology that can lead to V/Q inequality, and exclude patients with conditions that may alter 
the results. Therefore, all participants with respiratory disorders, musculo-skeletal diseases and 
depression of the brain’s respiratory center should be excluded.  
F.4 Oxygen delivery to tissues and oxygen consumption 
An abnormally low pO2 in tissues is called tissue hypoxia. This is frequently caused by 
low oxygen delivery. An adult at rest uses about 250 ml of oxygen every minute and this means 
that about 25% of the arterial oxygen is used every minute. Generally, there is more oxygen 
delivered to the tissues than the amount used by tissues. When oxygen consumption is high, the 
increased oxygen requirement is provided by an increase in cardiac output. Low cardiac output, 
low haemoglobin, will lead to an inadequate oxygen delivery to tissues. If the oxygen delivery 
to tissues falls in respect to oxygen consumption, tissues will extract more oxygen from the 
haemoglobin. This can happen up to a threshold and what follows is anaerobic metabolism and 
lactic acidosis (Law, Bukwirwa et al, 1999). Tissue hypoxia can be due to a low pO2 in arterial 
blood caused for example by pulmonary disease (‘hypoxic hypoxia’), or a reduced ability of 
blood to carry O2 as in anemia or carbon monoxide poisoning (‘anaemic hypoxia’), or due to a 
reduction in blood flow, either generalised, as in shock, or localised because an obstruction 
(‘circulatory hypoxia’).  
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To accurately assess oxygenation in CVMs patient studied ideally should have 
haemoglobin within normal range and patients with cardiac diseases known to affect the cardiac 
output should be excluded.  
APPENDIX TO MATERIAL AND METHODS 
A) HISTOCHEMICAL STAINS PROTOCOLS 
A.1 Deparaffinising the slides 
To melt the wax away from the fixed tissue, before staining slides were heated on a hot 
plate to 60°. Slides were then immersed twice into separate jars of xylene (Genta Environmental 
Limited, York, UK), which is a wax solvent, each time for 20 minutes. Slides were then drained 
of xylene and dipped into 100% alcohol to remove the wax solvent. This procedure was 
repeated three times to allow alcohol to rinse the slides thoroughly. The slides were then dipped 
in 100% alcohol (IMS 99%) (Genta Environmental Limited, York, UK) for two minutes. At the 
end the slides were rinsed in tap water and then in distilled water.  
A.2 Haematoxylin and eosin staining (H&E) 
H&E is a basic histo-chemical stain and helps to differentiate nuclei from other tissue 
components. Haematoxylin is not a dye, and develops colouring properties on oxidation to 
haematin. Haematoxylin has very little tissue affinity and requires the help of an inorganic 
molecule to attach to tissue. Eosin is an acid dye, which is negatively charged and attaches to 
the tissue of opposite charge. 
De-waxed paraffin sections are immersed in Harris’ haematoxylin (Surgipath Europe 
Limited) between 30 seconds to a few minutes, rinsed in running tap water and then 
differentiated by immersing into 70% acid alcohol (70% alcohol with 100% HCl to make a 
0.5% solution) for 30 seconds. They are rinsed again in running water, blued in ammoniated 
water (approximately 30 seconds), washed in tap water again and immersed in 1% aqueous 
eosin (Surgipath Europe Limited) (time of staining varies), which stains cytoplasm. They are 
then rinsed in running tap water, dehydrated through 3 changes of ascending alcohols (starting 
with 70% and finishing with 99%) for about 4 minutes, followed by 3 changes of xylene (2 
minutes). Once slides are cleared, they are mounted using automatic slide mountant (Leica 
CV5000). Some of the slides analysed were stained on an automatic H&E stainer, which used 
the protocol described above (Autostainer, Vision Biosystem, UK). Nuclei stained blue and 
other tissue components appeared in shades of red and pink. 
A.3 Masson’s Trichrome  
This histochemical technique aims to differentially stain connective tissue. Trichrome is 
so named because it selectively colours the tissue in three colours and helps the differentiation 
between muscle and collagen. Connective tissue and smooth muscle cells stain differently 
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because the staining affinity of the tissue is affected by molecular size, density of tissue, pH and 
use of colourless dyes such as phosphomolybdic and phosphotungstic acid, which help stainig 
the connective tissue. This stain will demarcate muscle and red blood cells (red), collagen 
(green) and nuclei (blue/black). Apart from showing a clear definition between the collagen and 
smooth muscle, Masson’s Trichrome helps define the different layers of smooth muscles such 
as circular and longitudinal.  
The reagents used in the Charing Crosss Hospital protocol used here were 5% chromic 
acid, 1% chromazone red in 1% acetic acid, 1% phosphomolybdic acid and 1% light green in 
1% acetic acid. By sequentially applying acid dyes in ascending order of size, differential 
staining is achieved due to varying pore sizes in connective tissue components. Wide spread 
connective tissue in a section usually provides an internal control but a freshly fixed piece of 
heart or intestine can be used as control for this stain.  
One % Chromazone red (Surgipath Europe Limited) in 1% acetic acid is applied to de-
waxed tissue sections for 5 minutes. Sections are rinsed again in distilled water and 
differentiation is achieved with phosphomolybdic acid (Surgipath Europe Limited) applied for 
5-10 minutes. Sections are rinsed with distilled water and the trichrome mixture (2 parts 1% 
chromazone red in 1% acid acetic, 4 parts 1% phosphomolybdic acid, and 6 parts 1% light green 
in 1% acetic acid) is applied for 10 minutes. They were then rinsed in phosphomolybdic acid, 
treated with acetic acid for 2 minutes, dehydrated, cleared and mounted.  
A.4 Elastic Van Gieson 
This technique is used to demonstrate elastic fibres. Elastic stains have an affinity for 
sulphur compounds which may be found in elastic fibres. Control sections may not always be 
required but lung, skin and artery may be used. There are two components to this staining: Van 
Gieson stain differentiates between muscles and connective tissue and Verhoeff’s elastic stain is 
a haematoxylin stain containing ferric chloride and Wright’s iodine solution.  
Tissue sections to be analysed were treated with 70% alcohol and Millers stain was 
applied for 2 hours followed by differentiation in 70% alcohol. Millers stain is harmful and 
flammable. Concentrated acid was prepared in fume cupboard and always handled with rubber 
gloves.Van Gieson stain (5-10 ml 1% acid fuchsine in distilled water, in 100 ml saturated picric 
acid) was applied for 5 minutes. Picric acid has a molecular weight of 229, penetrates into tissue 
and is held by hydrogen bonds. Acid fuchsin has a molecular weight of 585, has difficulty 
penetrating some structures and stays mostly on the surface, and it is therefore easily washed 
off. These solutions give the differential staining between connective tissue and muscles. 
Sections were then rinsed in distilled water, blotted, dehydrated in absolute alcohol, cleared and 
mounted. Elastic fibres show in black, collagen in red and muscle in yellow. 
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A.5 Toluidine blue  
This stain is performed to demonstrate meta-chromatic substances. Mast cells are 
widely distributed in the connective tissue. Their cytoplasm contains granules composed of 
heparin and histamine, which are meta-chromatic. Acid mucins react with certain cationic dyes 
and ‘polymerise’ them to a form which has a different absorbtion characteristic to the normal 
dye. Tissue appropriate to the meta-chromatic substance to be demonstrated such as cartilage for 
chondroitin sulphate, intestine containing mast cells for heparine sulphate may be used as 
control material.  
 Reagents used were 0.3% potassium permanganate, 0.2% Toluidine Blue and 0.2% 
uranyl nitrate. Uranyl nitrate is radioactive but of low radiotoxicity; dry powder is therefore kept 
in a metal container. De-waxed slides were then treated with permanganate for 5 minutes, rinsed 
in water, bleached with oxalic acid and Toluidine Blue was applied for 2 minutes. After rinsing 
in distilled water, uranyl nitrate was applied for 10 seconds or until the differentiation is 
complete as visualised microscopically. Sections were rinsed once more in distilled water, 
blotted, dehydrated, cleared and mounted. Mast cell granules and acid mucins show in 
red/violet. Metachromasia, tissue elements staining a different colour from the dye solution, is 
due to the pH, dye concentration and temperature of the basic dye.   
B) COMPUTERISED IMAGE ANALYSIS-ASSESSMENT OF COLLAGEN PROCENTAGE 
Defining the region of interest (ROI) 
This defines the area of interest on any given slide for particle detection. This was 
important if there were areas on slides which were not uniformly stained or should not be 
included. By choosing the option of drawing the area of interest on the projected field, it was 
possible to exclude such areas. For this, image was selected, ‘Analysis’ option was chosen and 
‘Define ROI’ used. Using ‘Draw ROI’ option the area of interest was defined.  
Setting colour threshold 
This command was used to set the logical thresholds for binarisation of true colour 
images in stained slides used in this study. From each of the projected field at 40 x 
magnification, several pixels were sampled. RGB colour model was used. Using this lower and 
higher limit of red, green and blue parts of the hue, saturation and intensity (HSI) was defined. 
All values were between 0 and 255, except hue. As the exact thresholds for the stained areas 
were not known, they were defined by selecting a set of points in the image, whose pixel values 
then defined the limits. From the ‘Image’ menu ‘Set colour threshold’ was chosen. The option 
‘New’ enabled the cursor to be moved to the area of interest and hotspots defined. By clicking 
on more than one hotspot after pressing ‘Add’, the threshold can be widened to include both 
image limits and image thresholds. To check the accuracy of defined threshold, image was 
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opened again, and ‘Set colour threshold’ option was chosen, and ‘Preview’ gave the defined 
threshold. Using the preview function, this range of threshold can be projected on the field 
repeatedly for comparison with another field. This was repeated until the chosen set of threshold 
values agreed with most of stained areas of interest. To reduce the chance of excluding 
potentially low uptake areas, at least 5-10 different slides were studied in this way before 
selecting a particular threshold for detection of stained areas. This threshold was saved for that 
particular stain.  
Binarising of the image 
Once the colour threshold for the field of interest was chosen, the image was converted 
to a binary format. This defined the thresholds on the image, resulting in a black and white 
picture as every pixel within the defined colour range turns white while the rest turn black. 
Thus, the stained areas of interest will be white.  
Morphological filter 
The main task in IA is the detection of objects in binary images. Sometimes objects, 
which were close together, but not touching, have to be treated as one single object and other 
times as separate. This problem was solved based on mathematical morphological theories. The 
central techniques were erosion (shrinking of an object), dilation (expansion of object), or 
combination. To execute this, ‘Morphological filter’ option was chosen on ‘Operate’ menu. This 
compares the value of central pixel with the values of all pixel set. This was followed by 
application of filter ‘Erosion’, which separated the single objects that touch each other, by 
decreasing the size of individual objects which do not touch each other and increase the size of 
objects. Small holes in the objects were closed and small irregularities at the periphery of 
objects were equalised.  
Define detection 
This was used to parameterise the detection. As the region of interest in individual 
fields was chosen, ‘ROI’ option was used and for border particle definition, ‘Truncate’ was used 
to cut off the particles outside the ROI.  
Detection of particles 
The command ‘Detect’ in the ‘Analysis’ menu was used to analyse the chosen image in 
the display buffer for particles, based on the settings of the threshold values. If the particle falls 
outside the set threshold, it was neglected.  
ROI results 
This gave the results of measurements. The average percentage expression of positive 
stain on the different fields was analysed for each slide and represented the collagen percentage. 
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IA resulted in a set of values that indicated the stain percentage in the area of interest (ROI). 
These values were averaged to give a mean percentage stain for one CVM or control specimen.  
C) IMMUNOHISTOCHEMICAL STAINING PROTOCOL 
The following steps were taken in the process of immunohistochemical staining: 1) tissue 
processing, 2) antigen retrieval, 3) background blocking, 4) primary antibody application, 5) 
secondary antibody application, 6) substrate preparation, 7) development, 8) counter-staining 
and 9) image analysis 
C.1 Tissue processing for IHC 
Immunohistochemical stains were performed on tissue sections cut at 3μm from 
paraffin-embedded blocks on a microtome. The sections were floated in water and picked up on 
APES-coated (3-amino-propyl-triethoxysilane), formalin dipped slides. Tissues have negative 
charge and by treating the slides with an agent with positive charge such as APES, the tissue 
sections adhered better.  Sections were allowed to dry overnight at room temperature and heated 
to 40-60°C at least an hour prior to staining. The tissues on the slides were treated with 2% 
solution of 30% H2O2 in Methanol for 3 minutes, which blocked the endogenous peroxidases 
present in erythrocytes, leucocytes and other cells, which otherwise may lead to high non-
specific background staining. Aqueous H2O2 is diluted with Methanol to prevent damage to 
peroxidase rich tissue. The slides were rehydrated by washing them in running water before 
proceeding to antigen retrieval. 
C.2 Antigen retrieval 
Formalin, like other Aldehyde-based fixatives can mask certain tissue antigens. This 
effect is thought to be the result of formation of methylene bridges, which occur between 
reactive sites like amines, thiols, aromatic rings, on different portions of the same molecule or 
of adjacent proteins. Time, temperature and fixative concentration are all variables related to the 
extent of masking. This antigenic masking can be reversed, and the visualisation of antigens can 
be significantly improved by using antigen retrieval techniques. These techniques represent the 
application of heat for varying lengths of time to formalin-fixed paraffin embedded tissue 
sections in aqueous solution, a procedure named heat induced epitope retrieval (HIER) or using 
proteolytic enzymes, a procedure named proteolytic enzyme induced epitope retrieval (PIER). 
Microwave oven, pressure cookers and steamers are commonly used as heating methods for 
HIER.  
The following methods were used in our research work: heating by pressure cooking, 
microwaving and enzymatic digestion as shown in the following table. 
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Tabel appendix. 10. Antibodies and antigen retrieval methods used 
Antigen  Retrieval method 
CD3 Pressure cooking 
CD20 Pressure cooking 
Factor VIII Protease enzyme digestion for 10min at 37°C 
CD68 Protease enzyme digestion for 5min at 37°C 
Ki67 Pressure cooked for 90 seconds 
Alpha SMA-1 None 
S100 None 
VEGF A None 
VEGFR-1 None 
Tie-2 Pressure cooked for 90 seconds 
αVβ3 Protease enzyme digestion for 15min 
αVβ5 Protease enzyme digestion for 15min 
TGFβ Pressure cooked for 90 seconds 
HIF-1α Pressure cooked for 90 seconds 
HIF-2α Pressure cooked for 90 seconds 
ET-1 Pressure cooked for 90 seconds 
ETA Pressure cooked for 90 seconds 
ETB Pressure cooked for 90 seconds 
CD10 Pressure cooking 
GLUT-1 Pressure cooked for 90 seconds 
CAIX Protease enzyme digestion for 15min at 95°C 
ERβ None 
Progesteron receptor (PR) Pressure cooked for 90 seconds 
 
The methods were optimised following a preliminary study in which tissue slides were 
subjected to different methods of antigen retrieval, then immunostained and assessed for the 
quality of tissue preservation and consistency of staining. Section of CVMs and control tissue 
were processed through microwave heating, pressure cooking and enzymatic digestion and then 
immunostained with selected antibodies at different dilutions. The immunostained slides were 
analysed together with a consultant pathologist and the best antigen retrieval method and 
antibody dilution was chosen for each antigen. 
Citrate buffer was used in this study for HIER. This was obtained from 21g citric acid and 10 
litres distilled water. The pH was adjusted to 6.0 using 265ml of 1M sodium hydroxide (NaOH).  
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Pressure cooking was applied to tissue sections on APES coated slides, which were placed in 
a metal rack with at least one space between each slide. This allowed bubbles to flow freely 
between the slides without disrupting the tissue sections. The citrate buffer (1400ml) was 
brought to boil in the pressure cooker on the hotplate with the lid open. The slides were lowered 
into the boiling buffer and lid locked. The pressure cooker took about 5 minutes to reach 
pressure with all the weights on. The cooker was allowed to continue for 90 seconds from the 
point when steam was escaping from under the weights at a steady rate. It was then removed 
from hot plate and kept under cold running water until valves released. The lid was opened and 
the slides were placed in a tap water bath. This antigen retrieval technique was used for CD3, 
CD20, CD10, Ki67, HIF-1α and HIF-2α antibodies.  
The enzymatic technique was used for antigen retrieval for Factor VIII and CD68 
immunostaining, using protease XXIV. 0.01% Protease XXIV was mixed with TBS (pH 7.6) at 
37°C. Sections of tissue on APES slides were placed in distilled water at 37°C. A bath of 100ml 
of TBS was pre-warmed to 37°C and 0.01g of protease was added just before introducing the 
slides. The protease dissolved immediately. The slides were left in the bath for 5 minutes and 
then removed and washed in tap water.  
C.3 Blocking of non-specific binding 
This was carried out using normal serum from the host species in which the secondary 
antibody to be used was raised. This binds to protein-binding sites by either non-specific 
absorption or by binding to specific but un-wanted antigens in tissue. The secondary antibodies 
used were human anti-mouse and anti-rabbit antibodies, at 1:10 concentration in TBS (6.4g 
Tris, 44ml in HCl, 80g Sodium Chloride, and 10ml distilled water). The tissue sections were 
ringed with PAP pen and blocked with chosen serum. This was left to react for 10 minutes to 
achieve antigen blocking. The blocking buffer was then drained off the tissue which was not 
washed.  
C.4 Primary antibodies used for IHC 
The primary antibodies and dilutions used in this research are listed below (Table 
appendix. 11.).They were separetly applied to tissue sections and incubated at room temperature 
for an hour. The slides were then washed twice with TBS. Primary antibodies were omitted for 
negative control sections. 
Tabel appendix. 11. Primary antibodies for immunohistochemistry and dilutions used 
Antigen Antibody Antibody dilution 
CD3 Monoclonal anti-human, Vector 
Laboratories, VP-C316 
1:100 
CD20 Monoclonal anti-human, Dako, M0755 1:600 
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Factor VIII Polyclonal anti-human, Dako, A0082 1:800 
CD68 Mouse monoclonal antihuman, DAKO, 
Clone 2B11+PD7/26 
1:200 
Ki67 Monoclonal anti-human, Vector 
Laboratories, VP-K542 
1:200 
SMA 1-α Monoclonal anti-human, Sigma, A2547 1:6000 
S100 Polyclonal, anti-human, Dako, Z0311 1:1000 
VEGF A Monoclonal antihuman, Labvision 1:2000 
VEGFR-1 Mouse monoclonal anti-human, R&D 
Systems, Clone 49560 
1:100 
Tie-2 Mouse monoclonal anti-human, R&D 
Systems, Clone 83715 
1:100 
αVβ3 Mouse monoclonal anti-human, Chemicon, 
Clone LM609 
1:200 
αVβ5 Mouse monoclonal anti-human, Chemicon, 
Clone P1F6 
1:200 
TGFβ Mouse monoclonal anti-human TGF Beta, 
Serotec, Clone TB21 
1:50 
HIF-1α Mouse monoclonal anti-human, Labvision 1:100 
HIF-2α Mouse monoclonal anti-human, Novus 
Biologicals 
1:150 
ET-1 Mouse monoclonal anti-human, Abcam, 
Clone TR.ET.48.5 
1:20 
ETA Rabbit polyclonal anti-human, Abcam  1:50 
ETB Rabbit polyclonal anti-human, Abcam 1:50 
CD10 Novocastra 1:30 
GLUT-1 Mouse monoclonal anti-human, Abcam, 
Clone SPM498 
1:100 
CA IX R&D Systems  
ERβ Rabbit monoclonal anti-human 1:200 
Progesteron Monoclonal anti-human 1:150 
 
A section from all CVM cases studied was immunostained for GLUT-1, since vascular 
malformations do not express this marker but haemangiomas are positive. 
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C.5 Application of secondary antibodies 
The primary antibodies used in this study were raised in mouse or rabbit, therefore anti-
mouse and anti-rabbit antibodies were used as secondary antibodies. A biotin label was used in 
order to generate amplification, as is required in the ABC technique for IHC. Biotin has a high 
affinity for avidin, which in turn conjugate to an enzyme to amplify the signal. This is why 
biotinylated human anti-mouse and anti-rabbit antibodies were used as secondary antibodies for 
this study. The antibody was applied at dilution 1:400 in TBS and sections were incubated at 
room temperature for 35 minutes. 
C.6 ABC peroxidase technique 
The ABC (Avidin-Biotin complex) Peroxidase technique was used for IHC staining and 
is the standard technique in surgical pathology at Charing Cross Pathology Department, where 
this work was performed. This represented a variation of the indirect technique of IHC staining, 
where an unlabelled primary antibody (first layer) reacts with tissue antigen and a labelled 
secondary antibody (second layer) reacts with the primary antibody. This method is different 
from what is called the direct method, where a labelled antibody reacts directly with an antigen 
in the tissue.  
The ABC technique involves three layers. The first layer is the un-labbeled primary antibody; 
the second layer is the biotinylated secondary antibody and the third layer, the complex of 
avidin-biotin peroxidase. The peroxidase is then developed by the DAB to exhibit a colorimetric 
effect.  
 
Figure appendix. 2. The ABC peroxidase technique for immunohistochemistry 
(The principle of ABC peroxidase 3 layer technique, adapted from www.aasp.org/shap/issues) 
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Avidin is a large glycoprotein with a molecular weight of 68 Kilodaltons, found in egg white 
and has a very high affinity for the small molecule vitamin, biotin with a molecular weight of 24 
Kilodaltons. The affinity of avidin to biotin is over one million times higher than antibodies 
have for most antigens and this binding is irreversible. Avidin has 4 binding sites for biotin and 
most proteins including enzymes like peroxidases can be conjugated with several molecules of 
biotin. These properties allow macromolecular complexes to be formed between avidin and 
biotinylated enzyme. Biotin can be conjugated to a variety of biological molecules such as 
antibodies. Avidin has the disadvantage that it has a high isoelectric point of about 10 and 
therefore they are positively charged at neutral pH. This is why it may bind to negatively 
charged structures such as a cell nucleus. Another disadvantage is that avidin reacts with 
molecules like lectins via the carbohydrate moiety. To avoid these problems, avidin can be 
replaced with streptavidin. Streptavidin is a protein with a molecular weight of 60 Kilodaltons 
isolated from bacterium Streptomyces avidinii, and similar to avidin, has four high affinity 
binding sites for biotin. The physical properties of streptavidin make it more suitable for IHC 
because it has an isoelectric point close to neutral pH and has fewer strongly charged groups at 
pH used for IHC. It also does not bind to lectins.  
The ABC technique used in this study utilised streptavidin biotin complex in pre-formed 
complexes. Streptavidin and horse radish peroxidase (HRP) were mixed for at least 30 minutes 
at room temperature to prepare the complexes, which were then attached to the biotinylated 
antibody. These complexes were diluted 1:100 using TBS and were left for 35 minutes on the 
slides after which they were reduced with TBS.  
C.7 DAB visualisation 
DAB (3, 3 – di aminobenzidine) produces a brown precipitate which is insoluble in alcohol. 
In the presence of H2O2, DAB was converted to this coloured product and water by peroxidase. 
As the HRP is attached to the antigen via the avidin-biotin complex, adding DAB will produce 
an enzymatic reaction which will lead to an insoluble visible DAB precipitate. A combination of 
10ml of distilled water, 4 drops of buffer stock, 8 drops of DAB stock and 4 drops of hydrogen 
peroxidase were added to the antibody treated slides for 3-5 minutes. They were then washed 
with running tap water and counter stained with Haematoxylin. The antigenic sites were stained 
dark brown from DAB precipitate and the nuclei blue from Haematoxylin. The slides were then 
mounted with aqueous mounting medium, sealed with wax and marked. 
D) HISTOLOGICAL MORPHOLOGY ASSESSMENTS 
D.1 Assessment of blood vessel number 
The number of vessel present per microscopic field was considered an index for 
comparison of morphological and angiogenic change in this study and it was assessed using 
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AnalySIS software. Factor VIII (known as the von Willebrand factor) was used to delineate 
blood vessels in CVM and control tissue as this marker was considered to best visualise ECs 
lining the blood vessels. Factor VIII is a glycoprotein present in EC and shows a granular 
pattern of reactivity. Factor VIII stain was positive in ECs which delineated the blood vessels 
and it was used to count vessel numbers. 
                                           
             Figure appendix. 3. Positive expression of Factor VIII immune-staining CVM tissue 
The number of vessels was quantified by counting the number present in one field at 
x40 magnification. All vessels with a visible lumen present per field were counted, including 
those showing as incomplete vessels in the studied section. AnalySIS software allowed to point 
count the cells. The slide above shows a typical field with blood vessels delineated by the 
brown-stained ECs. Immunostaining for Factor VIII followed the protocol described earlier. On 
the projected image on the AnalySIS software, the touch count option allowed interactive 
counting of number of objects of interest. To ensure that each object was counted only once, it 
was marked with an overlaying dot. The number of dots was recorded on an Excel spreadsheet. 
The CVM or control tissue was scanned along the areas of interest for 5 different fields. Each of 
the fields at x 40 magnification was found to cover 40,000μm2 of the slide. The average of the 
blood vessel counts was calculated and considered as the vessel count per microscopic field.  
D.2 Assessment of blood vessel diameter 
Blood vessel diameter was measured to assess morphological changes and angiogenesis in 
CVMs. It has been suggested that abnormal local concentrations of angiogenesis mediators such 
as VEGF, regulates vessel diameter and  are responsible for increased blood vessel diameter, but 
this has not been proven for CVMs. 
Appendix 
 218 
                                       
       Figure appendix. 4. Line representing measurement vessel diameter using Factor VIII stain 
The blood vessel diameter was measured at x40 magnification using the images 
captured from the Factor VIII stained slides as these showed the blood vessel contour clearly. 
The largest apparent length of the blood vessel was chosen as the maximum blood vessel 
diameter and this was measured for each vessel seen on a given field provided the vessel had a 
lumen. The diameter included the outer border of the dark brown stain of the ECs. Incomplete 
vessels seen on each field were also included and the measurement was carried out in the same 
manner. The software AnalySIS allowed the measurement of the distance between two points 
on a straight line. The command ‘arbitrary distance’ on the AnalySIS software aided the 
measurement of the distance between two points at any position or direction on the projected 
image. The measurement was marked with a line as an overlay. The software allowed multiple 
measurements. Five different fields of interest for each analysed slide were considered and for 
each field an average diameter was obtained as a result of measuring all vessel diameters 
present per field. The average diameter for the five fields analysed, was the specimen average 
blood vessel diameter. 
                                   
                     Figure appendix. 5. Use if  IA to calculate average blood vessels diameter 
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The average diameter for the above field was obtained by adding measured diameters of all 
blood vessels seen on the field and dividing the sum by the number of vessel seen. 
D.3 Assessment of cell count 
The inflammatory cell infiltrate of the CVM or control tissues was analysed using the 
immunohistochemical techniques described earlier with CD68 for macrophages, CD3 for 
lymphocytes T cells, CD20 for lymphocytes B cells and ki67 for proliferative cells. All these 
cells were quantified by counting the number of cells per field with x40 magnification, which 
represented 1mm
2
. Toluidine blue histochemical stain was also used to identify mast cells. 
The CVMs as well as the control tissue were initially screened using the H&E stained 
slides to identify any technical faults, tissue abnormalities, granulomas and to select the fields of 
interest represented by the abnormal blood vessels seen in CVMs and their vicinity, as well as 
the vascular parts of the control tissue, rather than the surrounding fat or stromal tissue. The 
H&E screening also helped to confirm the distribution of the positive reaction when this was 
analysed on immunostained slides.   
                                  x10 
            Figure appendix. 6. H&E stain of a CVM, showing a representative field for analysis 
               The brown-stained inflammatory cells (as seen in figures 4.5 and 4.6) were counted 
using AnalySIS software, which was used to point count the cells. The touch count option of the 
AnalySIS software allowed interactive counting of cells of interest and each cell was marked 
with an overlying dot so that it was counted once only. Cells with clear demarcation of 
cytoplasm and nucleus were selected to avoid including stain artefacts. The number of cells was 
counted on 5 different relevant fields for each section and the result recorded on an Excel 
spreadsheet. The average of the 5 fields was calculated and taken as the cell count per field. 
Similar techniques were used for counting mast cells on Toluidine stain and cells positive for 
CD3, CD20 and ki67 immunostains.  
 Light microscopy was also used to count macrophages and mast cells in the 
preliminary study (17 CVM specimens and 10 control specimens). A 1 mm
2 
microscopic grid 
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under light microscopy was used by two independent observers to count the cells observed, over 
5 different fields. The quality of data collected was assessed by analysing the inter-observer 
agreement.  
D.4 Assessment of nerve fibres number 
Nerve fibres have been seen in close association with abnormal vascular channels seen 
in CVMs. Nerve fibre count was performed as part of the morphological analysis of CVM since 
vessel and nerve development share some common biochemical mediators such as ephrins. 
Nerve fibres count was analysed using S100 immunostained CVM or control tissue. The slides 
stained with S100 showed typical brown staining of the nerve fibre (as shown in the figure 3.5), 
which were counted using x40 objective, on five different fields, as previously described. The 
average number of nerve fibres considered the nerve fibres number per field.  
D.5 Assessment of % area of collagen 
Masson’s Trichrome stain was used to analyse the area of collagen present in CVMs 
and control tissue as this stain differentially stains the connective tissue. Collagen stained green 
and the muscle and red blood cells stain red. Nuclei stain blue/black as showed in figures 3.6, 
3.9, 3.10 and 3.11. 
The measurement of collagen area in one field was performed using IA, which 
calculated the average procentage area that stained green and corresponded to the collagen 
distribution. The quality of the Masson’s Trichrome staining was assessed using positive 
controls to ensure uniformity of analysis. IA of 5 different fields was performed for each of the 
tissue sections at 40 x magnification. From each field of interest, the collagen areas were 
sampled. Their red, green, blue and hue, saturation and intensity values were stored. Once the 
field was chosen and projected on the computer screen, IA involved a number of stages, which 
are detailed elsewhere. 
D.6 Qantitative analysis of immunostains 
Quantitative assessment of immunostaining was not performed using IA since there was 
more variation between batches of staining which made interpretation very difficult. Instead, a 
conventional three-tier grading system was used.  
The staining localisation and intensity for each of the markers were independently 
assessed by two observers (NM and AF). These two independent observers examined all 
sections randomly and the inter-observer agreement was analysed at the end using kappa 
coefficient analysis. The two observers met to agree the number of CVMs and control 
specimens to be analysed, to clarify for each marker the criteria for assessment with respect to 
localisation of the stain, to differentiate between diffuse and focal staining, and technical 
artefact. It was agreed that negative staining would score 0, focal areas with sparse staining or 
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occasional isolated positive staining would score 1, weakly positive staining or,at least one 
focus with intense positive staining or diffuse weak to moderate staining would score 2 and 
strongly positive, intense staining would score 3. Diffuse,
 
sparse immunoreactivity observed 
throughout tissue sections
 
was considered to represent background or non-specific staining
 
and 
thus was graded negative. For each specimen the immunostaining was assessed in five different 
microscopic fields by each observer, one using light microscope and the other using IA.  
D.7 General description of CVM morphology 
Image analysis was used to scan all sections from 17 specimens included within the 
pilot study. These included: H&E, Elastic Van Gieson, Masson’s Trichrome, SMA 1-α, ki-67, 
CD68, Factor VIII, S100 and Toluidine Blue. A comprehensive description of the presence of 
small, medium or large vessels, thick o thin vessels, precence of stromal cellular infiltrate, type 
and location of the infiltrate in relation to the blood vessels, presence of proliferative cells, 
disruption of internal or external elastic lamina, presence of collagen or fat infiltrate, location of 
the nerve fibres in relation to the abnormal channels comprising the CVM, presence of 
macrophage or any other features were recorded. This descriptive analysis was used to establish 
if these were morphological features that correlated with clinical behaviour of the CVM and 
outcome.  
D.8 IHC controls 
Positive controls tissues were collected in accordance with recommandations on the datasheet 
for each primary antibody and under the guidance of an experienced pathologist. 
 
Tabel appendix. 12. Positive control tissue for immunohistochemical studies 
Antigen Control tissue 
CD3 Tonsil 
CD20 Tonsil 
Factor VIII Vessels 
CD68 Tonsil 
Ki67 Tonsil 
SMA1- α Muscle 
S100 Melanoma 
VEGF A Vessels 
VEGFR-1 Skin 
Tie-2 HUVEC 
αVβ3 Skin  
αVβ5 Skin 
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TGFβ Prostate 
HIF-1α Synovium 
HIF-2α Synovium 
ET-1 Human bowel 
ETA Placenta, Liver 
ETB Liver 
CD10 Tonsil 
GLUT-1 Oesophagus 
CAIX RCC, gastric mucosa 
ERβ Breast 
Progesteron Breast 
 
Negative controls were used to test the specificity of the antibody used. This was done by 
omitting the primary antibody in the process of tissue staining. CVM and control vessel tissue 
were used for this purpose.  
E) WESTERN BLOT PROTOCOL FOR HIFs PROTEIN ANALYSIS 
Western blot analysis is an immunoblotting technique which provides information about 
presence, molecular weight, and/or quantity of an antigen by combining protein separation via 
gel electrophoresis with specific recognition of antigens by antibodies. This method is designed 
for separating a complex mix of protein on a gel, and then for transferring the proteins to a 
nitrocellulose membrane. Membrane bound proteins can then be probed with various antibodies 
to determine expression of proteins of interest. Immunoblotting is useful when the antigen of 
interest is insoluble or readily degraded and cannot be easily immunoprecipitated. Since most 
gel electrophoresis procedures result in denaturation of the antigen, only polyclonal and 
monoclonal antibodies that recognise the denaturated form of the antigen can be utilized in 
immunoblotting.  
The Western blot technique is described in detail below. 
Buffers are solutions which reduce the change of pH on addition of small amounts of 
acid or base, or on dilution. A number of different buffers are usually necessary for Western blot 
analysis.  
To prepare samples for running on a gel, tissues need to be lysed to release the HIF 
proteins. This solubilises the proteins and they can migrate individually through a separating 
gel. The lysis buffer used was an 8M urea in Milipore H20 (1/10 vol Glycerol, 1/20 vol 
20%SDS, 1/1000 vol 1M DTT, 1/100 vol 1M Tris pH 6.8). Phenylmethylsulphonyl fluoride 
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(PMSF) was added just before use (1/100 vol from a 50mM stock). A protease inhibitor tablet 
(Roche) was added to tissue immediately before use (one tablet for every 10mls of buffer).  
 The frozen tissue sample to be analysed is cut on dry ice to prevent thawing and tissue 
degradation. The cut section is further divided into very small pieces so that it can be 
homogenised properly. Tissue is placed into a tube, urea buffer (as detailed above) is added and 
both are homogenised immediately. The tube is kept on ice at all times. Between samples the 
homogeniser is wiped with paper towel and then briefly run into water. The tissue samples are 
left on ice for ten minutes and then the tubes are centrifuge at 1000 rpm, 4°C for 5 min. Protein 
extract is then removed to an Eppendorf tube. Samples are stored at -20°C or -80°C (the later 
being preferable). The protein extract is quantified using the Pierce BCA protein assay.                
 Antibodies usually recognise a small portion of the protein of interest and to enable 
access of the antibody to this portion is necessary to unfold the protein by denaturing the 
protein. A loading buffer with an anionic denaturing detergent is used for this purpose (25ml 4x 
TrisHCL/SDS, pH 6.8, 20 ml glycerol (Merck AnalaR, Germany), 4g SDS, 3.1g DTT (Sigma 
Aldrich, UK), 10 mg bromophenol blue, add H2O to 100ml). This is usually kept frozen and 
defrosted just before use. The protein extract is mixed with the loading buffer up to 100µl final 
volume. The gel required a load of at least 30µg of protein per lane. Samples are then heated for 
5 min at 95°C, spin down and left at room temperature but kept on ice, for loading. The next 
stage is the gel electrophoresis, meaning separating the proteins according to their molecular 
weight. The protein extract is run on standard 6% SDS gel, with stacking gel. Gels are placed in 
the electrophoresis tank as instructed by the manufacturer and bathed in the running buffer (2L 
of running buffer - 1g/L SDS (Merck AnalaR, Germany, no 444464T), 3g/L Tris base (Merck 
AnalaR, Germany, no 103156X), 14.4g/L Glycine (Merck AnalaR, Germany, no 101196X) or, 
if using new gels (Tris- acetate), 0.5 liter of 20X running buffer is made: 50mM TRIS base 
(60.6g), 50 mM Tricine (89.5g), SDS 0.1% (10g), which again is kept frozen at 20°C and 
defrosted just before use. A positive control lysate is used to demonstrate that the protocol is 
efficient and correct and that the antibody recognises the target protein, which may not be 
present in tissue samples. The Rainbow molecular weight marker is used to determine the 
protein size and to monitor the progress of the electrophoretic run. Approximate 10µl is loaded 
on the electrophoresis gel. The samples are then loaded and run at 80V until proteins have run 
into gel, then the gel is turned up to 150V. When the dye molecule (the ‘migration front’) 
reaches the bottom of the gel, the power is turned off. The gel is not stored and the transfer stage 
is commenced immediately. A wet transfer was carried out and 3L of transfer buffer was made 
up (3g/L of Tris base, 14.4 g/L Glycine, 200mls of Methanol/L). The transfer membrane, a 
Nitrocellulose membrane, (Immobilon-P, Millipore) is placed next to the gel and the gel and 
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membrane are sandwiched between sponge and paper as follows. The gel is transferred into 
transfer buffer in a small container and place on filter paper. The transfer membrane is cut to the 
exact size of the gel. Six pieces of paper are cut to exact size of gel. The transfer membrane is 
activated by placing it in methanol for 20 seconds then in water for 2 minutes. Transfer 
membrane is then put into transfer buffer for 10 minutes.  
Two sponge layers are put into the transfer buffer - 3L solution. The transfer perforated cassette 
is placed flat on the bench – black side to the back. The 1st layer of sponge is placed on the 
bottom. Three sheets of filter paper soaked in transfer buffer are then layered over this – 
ensuring there are no air bubbles between the layers. The gel is layered on, again ensuring there 
are no air bubbles. The activated membrane is layered onto the gel. Three more pieces of filter 
paper soaked in transfer buffer are placed on the top and then the 2
nd
 sponge over all. The 
cassette is closed, sealed and placed into the transfer tank. The cooler element is placed inside 
tank or the tank is transfered to cold room. The 3L of transfer buffer is poured in – the tank is 
placed on the stirrer and the flea is added to stir gently. The lid is put on connect to potentiostat 
and run for one and a half hours at 100V, or overnight at 20V and then in the morning 30 
minutes at 60V. The membrane is then blocked to prevent non-specific background binding of 
the primary or secondary antibodies to the membrane. For this purpose, the membrane is placed 
in blocking buffer (minigel to make up 200mls - PBS (Merck AnalaR, Germany), 10g 5% fat-
free milk powder (Premier Bands UK LTD), 2g 1% BSA (Sigma Aldrich, UK), 0.2mls 0.1% 
Tween (Sigma Aldrich, UK)) for 1 hour gently tipping on platform at room temperature. The 
membrane is incubated first with the primary antibody and then with the secondary antibody. 
The primary antibody is added to the blocking buffer at a concentration of: 1:250 for HIF-1α – 
transduction labs monoclonal clone 54, 1:1000 for HIF-2α (Novus Biologicals catalogue 
number NB-100-132) and then incubated with the membrane for 1 hour. One ml per blot was 
used at room temperature, in small closed boxes, to prevent drying. The membrane was then 
washed 4 times for 5 minutes in PBS/0.01%Tween, shaking vigurously. The secondary goat 
anti-mouse antibody was added at a concentration of 1:5000 (Dako Cytomation P0447) in 
blocking solution and left for 1 hour. The membrane was washed again 4 times for 5 minutes in 
PBS/0.01%Tween. For visualisation of the protein bands the developing stage is performed. The 
ECL kit (Amersham Biosciences RPN2106), ‘Protex’ metal box in which to expose film, 
transparency (to place between film and membrane), film (Kodak MXB Film 100 NIF, 
18x24cm, autoradiography film blue sensitive), pippetor with tips, scissors, Falcon tube, are 
brought to dark room. The chemiluminescent reagent is prepared: 1 ml of ECL solution 1 and 1 
ml of solution 2 are mixed after removing them from 4°C and allowing them to warm at room 
temperature. ECL solution is pipetted over membrane and is allowed to spread by capillary 
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action over the membrane. The solution is left for 1 minute on a flat surface without moving it. 
Excess ECL is dabbed off using blue towel or the membrane was picked up with forceps and the 
excess of chemiluminescent reagent was allowed to run off. The membrane was placed protein 
side down onto cling film (to ensure a flat air bubble free contact) and wrapped up. Then this is 
exposed to X-Rays in a ‘Protex’ box for several different exposure times, 5 minutes, 10 
minutes, or 30 minutes depending on speed of development and the films are then developed.  
F) PROTOCOL FOR BLOOD GASES ANALYSIS STUDY 
Prospectively, blood samples were obtained from research participants with CVMs 
from within the vascular malformation and from systemic venous and arterial blood during 
planned surgery for their vascular lesion.  
Four blood samples were obtained from each participant, from arterial and venous 
vessels distal to the malformation; venous vessels from the contralateral limb to the 
malformation and the malformation itself, each sample consisting of approximately 2 mls blood. 
All patients had their samples taken during the induction of anaesthesia for the operative 
management of their CVM or during the procedure itself. This way patient discomfort was 
reduced to minimum. The patient laid semi recumbent on a bed with the chosen, non-dominant 
arm supported on a pillow. The required equipment was assembled in a clean tray. Under 
aseptic conditions the artery required was identified in the desired area which is cleaned 
appropriately. To withdraw blood from the malformation, artery or venous vessels a needle was 
inserted, bevel facing upwards, towards the vessel at an angle of 20-30˚ to the horizontal of the 
blood vessel. A syringe was used and gentle aspiration applied. Once the required amount of 
blood is obtained (1-2 mls) the needle was withdrawn from the patient and safely disposed of in 
a sharps’ bin. Cotton wool balls or gauze squares were applied to the puncture site for a 
minimum of 5 minutes before inspecting the area for swelling or bleeding. If they occured, 
pressure was re-applied for a further 5 minutes. Similar procedures were used to obtain an 
equivalent blood sample from the abnormal blood vessels comprising the vascular malformation 
affecting the same participant. The CVM samples in this study were obtained by the consultant 
surgeon doing the operation. Venous samples were obtained in a similar manner, mostly from 
patient’s arms, unless the CVM lesion prevented the sampling. In this case the venous sample 
was taken from lower limbs. Venous samples had to be taken away from the CVM lesion.  
All samples were taken at the same time. For analysis blood samples obtained as 
described were transferred into an arterial blood gas syringe, clearly labelled and coded and 
immediately analysed on a blood gas machine for the partial pO2 and pH using standard 
methods with the Rapid point 405 analyser system available on site. This is operated using a 
touch sensitive visual display unit.  
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Principle of analysis 
The pO2 sensor is a complete electrochemical cell that incorporates amperometric 
technology. The sensor consists of a platinum cathode and a silver anode, an electrolyte solution 
and a gas permeable membrane. A constant (polarizing) voltage is maintained between the 
anode and the cathode. As dissolved oxygen passes through the membrane into the electrolyte 
solution it is reduced at the cathode. The circuit is completed at the anode when the silver is 
oxidized. The amount of reduced oxygen is directly proportional to the number of electrons 
gained at the cathode. Reference range for pO2: 10.7-14.0 kPa (arterial blood), 5.3-6.7 kPa 
(venous blood). 
This study involved blood sampling from subjects affected by CVMs and undergoing 
surgery for excision or debulking of vascular malformations. The subjects were identified in 
vascular clinic at Hammersmith Hospital or as inpatients at Charing Cross Hospital or 
Hammersmith Hospital, prior to their operation. All patients with respiratory diseases, acute or 
chronic, patients with musculoskeletal diseases, malignancy, inflammatory diseases, conditions 
causing depression of brain’s respiratory center or other conditions where angiogenesis or 
hypoxia may be altered, were excluded (see 2.1), so that the results of this study are not skewed. 
All patients received in advance an invitation letter to participate in this study and an 
information sheet about the study. Written informed consent was obtained from each participant 
after explanation of the procedure is given and verbal consent obtained before the patient is put 
to sleep for his/her planned operation. 
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APPENDIX – CLINICAL PICTURES 
This addition shows pictures of patients with CVM, from whom tissue was prelevated for this 
study under the conditions described in Chapter 2.  
                                                                   
a)  b) 
    
c)                                                                   d) 
              e)  f)  
                                                    Figure appendix. 7. CVM image 1  
1a)-d) 64-year-old male with a large borderline HF AVM involving the left upper arm, at different 
stages post-surgery; e) Selective angiography from left profunda brachii showing marked vascular 
staining within the mass and some early venous return. The performing radiologist comment was 
that the rate of the a-v shunting was not especially rapid; c) Un-enhanced coronal STIR (Phillips 
1.5T)  images demonstrates the extent of the lesion, which involves all the muscles of the upper arm, 
with some sparing of the most medial aspect of these muscles (arrows). 
nidus 
28cm 
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                                   a) 
 
                                          b) 
                                                        Figure appendix. 8. CVM image 2 
MRI chest (Philips 1.5T) of a 22-year-old male showing the extent of a complex AVM, which 
involves the right thoracic wall and right loin, causing compressive effect. The fat suppressed 
coronal breath-hold (FFE/M2D) images (a) and (b) demonstrate multiple tortuous vessels (see flow 
voids-arrows) within in chest wall, extending sub-diaphragmatically and their association with 
kypho-scoliosis.  
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                                     a) 
                                    b) 
                                   c) 
                                                        Figure appendix. 9. CVM image 3  
a) 58-year-old female with a thoraco-abdominal LF vascular malformation of the left 
chest/abdominal wall with evidence of previous surgery and remnant vascular lesion with changes 
within the skin and subcutaneous fat (arrows); b) Axial STIR through the abdomen (Philips 1.5T) 
demonstrating the extension of the vascular malformation to the abdominal wall with nodular 
protrusions into the abdominal cavity (arrow); c) Clinical picture of the same patient 
demonstrating the final operative result after multiple debulking interventions.                                                      
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       a)      b) 
 
                                              c) 
                                                       Figure appendix. 10. CVM image 4 
a), b) - 35 year old male suffering end-stage complications of a LF VM, with airway and upper 
gastro-intestinal obstruction symptoms. Tracheostomy was inserted. Salvage procedure was 
performed to relieve compression; c) the right cranio-facial LF VM is extending behind the 
nasopharynx and is causing marked deviation of the oropharynx and larynx. Enhanced axial CT 
image at the level of C2, shows the VM crossing the midline and deviating the oropharynx to the 
left, with multiple dilated small vessels extending throughout the whole of the pharynx. 
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a)   b) 
c)   d)    
e)    f) 
                                                           Figure appendix. 11. CVM image 5 
a)-f) - 29 year old female with a HF AVM over left forearm. She developed a bleeding ulcer 
following a session of embolization and required serial debulking and ultimately an amputation of 
her forearm due to bleeding complications, infection and severe pain. 
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a) 
                                 
    b)                                                   
                                                           Figure appendix. 12. CVM image 6 
a) Macroscopic image of a resection specimen of a LF VM infiltrating gastrognemius muscle; b) LF 
VM specimen removed from forearm                                              
Gastrognemius muscle 
Venous malformation 
Appendix 
 
 233 
APPENDIX-FINAL COMMENTS 
COMMENTS ON STATISTICS USED IN THIS RESEARCH WORK AND DIFFICULTIES 
WITH STUDY DESIGN 
When this study was commenced, it was well known that we are many years away from 
a cure for CVMs as there was very little information in the literature about pathogenesis of 
CVMs. The current treatment of CVMs is not satisfactory as very few lesions achieve a cure, 
usually by surgical means. Therefore, we had and still have to invest time and work to 
understand these difficult and complex vascular malformations and to identify medical means 
such as drugs or a combination of drugs and surgery in order to induce regression of these 
lesions.  
Although it is well known that there is no ideal study, the author of this study would 
like emphasize few issues and flaws in relation to the statistics used in this research work, as 
well as some of the difficulties encountered when this study was designed and performed. 
In order to assess sample size required for this study it was found that there were no 
data available for estimation of power calculations in assessing the expression of angiogenesis 
and hypoxia markers in CVMs or control tissue in humans using immunohistochemistry. The 
calculation of the sample size was based solely on values found in literature in healthy controls 
for serum VEGF. It was hypothesized that serum levels of VEGF are directly proportional to 
their tissue expression and it was found that to achieve 90% power at 1% significance level, 
considering multiple testing, the study would require 60 subjects, 30 in CVM group and 30 in 
the control group. More than 30 subjects were considered for most variables tested in this study 
but in some instances the author was limited by the fact that some tests could only be performed 
on frozen tissue; therefore a smaller number of subjects were tested for those variables. The 
reason for this is that frozen tissue was only available prospectively and when sufficient tissue 
was redundant from surgery. In these cases, archived tissue which was formalin fixed and used 
to tests other variables could not be used. 
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All analyses in this study were performed on 10 control subjects instead of 30 as was 
initially planned. Given the uniformity of results on the 10 samples tested the author concluded 
it was unnecessary to extrapolate a significant amount of work to another 20 extra subjects.    
One of the most important flaws in this study is the use of multiple analyses on the 
same small dataset, which could potentially lead to the increase in type I error. A Bonferroni 
correction was applied to the histological morphology and immunohistochemical dataset 
analyses, such that p<0.005 indicates significance. Although this method is acceptable for a 
small number of simultaneous tests, it may be over-conservative, and perhaps other tests such as 
the least significant difference test, Scheffe’s test or Newman-Keuls tests should have been 
considered to enable the reader to better understand significant findings in this study. 
Following the results obtained, especially in the morphological part of the study, the 
author should have considered analysing whether data obtained was parametric or not, such as 
parametric tests should have been used in any appropriate circumstances as they are more 
powerful, rather than just simply assuming data were non-parametric.  
In the attempt to establish links and pathways between the stromal infiltrate in CVMs, 
angiogenesis and hypoxia markers, multiple correlations were performed in this study using 
Spearman rho correlation coefficient. One could also argue why this method was used to 
establish correlations between variables since other methods are also available. Various 
approaches are possible for each type of data and here data could have been summarised by 
means of a regression line. The choice is partly a matter of personal preference, hoping to 
present data in the simplest and clearest way possible.  
Although multiple correlations were performed on a small dataset, and a correlation 
coefficient was calculated, this was the way the author decided to emphasize results, being 
aware of the multiple testing and possibility that the resulted statistically significant results may 
not be as significant as quoted in figures. On the other hand, the validity of the results can be 
observed in the histological and immunohistochemical images presented in this study and 
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perhaps one would say that so extensive statistical analyses were not necessary for the type of 
study proposed. 
The results of these statistical calculations do not determine on their own further actions 
but they are interpreted in a clinical context. The author has not drawn any firm conclusions on 
the basis of the statistically significant results presented in this study but they only limited to 
their sensible interpretation. 
In the immunohistochemical part of this study results were read by two independent 
observers and were compared for their agreement using kappa coefficient test. The Bland-
Altman plot is another method used to compare two measurement techniques and quantify inter-
observer agreement. This is a simple approach because it focuses exclusively on the differences. 
In this study a statistician was consulted for this purpose, who suggested that kappa coefficient 
method was more appropriate for dataset obtained. Even so, the kappa coefficient obtained 
(0.32), although satisfactory, this is not great and perhaps the author should have considered re-
analysing data again at a later stage, given the subjectivism and human error factor involved in 
the scoring method used for interpreting immunohistochemical results. Image analysis could 
have decreased the human error in this study. This was not used due to difficulties resulted from 
staining tissues in different batches. The immunohistochemical stains for a given variable had 
different background of staining and made impossible a uniform reading of staining results. . In 
retrospect, the author would have waited to obtain all specimens required for study before 
performing any staining such as all staining are performed at once. 
In the chapters 2 and 3, the majority of results are presented in tables. However, graphs 
are often better than tables when there is a need to provide a summary message, although tables 
usually give more precise information. Some of graphs and tables in this work should have been 
better labelled, additional legends would have been useful in some cases and error bars should 
have been depicted in graphs.  
Another significant flow in this study is concerning the tissue used for analyses in this 
study. This is a mix-up of archived and prospectively collected tissue. Although the archived 
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tissue was collected and preserved using the Departmental standard techniques, this was 
carefully checked against the histopathological reports to ensure vascular malformations were 
considered and also checked with patient’s medical records, still the author had no control on 
this part of study. In addition, CVM analysed were not classified by any of the currently used 
classifications. The author ensured these lesions were not haemangiomas, therefore all were 
GLUT-1 negative and the fact that they were unclassified vascular malformations was part of 
the study design, given the persistent confusion in the literature in respect to CVM 
classification. All CVMs could retrospectively be matched according to the current accepted 
classifications.  
Controls were carefully chosen in this study such as they represent a close match to the 
tissue analysed. Skin vessels were deemed best controls as they were represented by blood 
vessels embedded in stromal tissue and located peripheral, similar to CVMs. In the pilot part of 
this study, individual veins, redundant following varicose veins surgery or remnant arteries and 
veins following plastic surgery interventions were considered but they lacked the surrounding 
stromal tissue and were abandoned. Skin controls used in this study originated all in female 
patients and for a better comparison male subjects should have been considered. Also, the skin 
used had different origin (abdomen, chest, limbs) and this in itself could represent a source of 
variability, although this was not observed in the samples analysed.  
CVMs are present at birth and therefore it would have been interesting to analyse foetal 
tissue for the histochemical and immunohistochemical expression of analysed markers. 
Although ethical approval was obtained for analysis of foetal tissue in this respect, this would 
have been in itself a whole study and beyond the initial proposal for this study. 
The method used to measure blood vessel diameter in this study is not a standardised 
method but the author preference as described in the Methods chapter. There are other 
alternatives to measure blood vessel diameters and author accepts that as well as the fact that 
measuring diameters bi-dimensionally on stained slides, this is somehow ‘artefact’ as it 
represents a snap shot of a section through the CVM tissue and not true diameters in totality.  
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Specific chemical mediators were chosen to be analysed using immunohistochemical 
methods in this study and the decision in this respect lies with the author. Although it was 
desirable to know the expression of even more markers of angiogenesis and hypoxia in CVM, 
one has to confine his work as it is impossible to analyse everything. With the increased 
understanding of angiogenesis pathways, the markers were chosen from those involved in the 
few likely pathways possible to be dis-regulated in CVMs, knowing that CVMs result from 
faulty angiogenesis.  
The results from the investigation of hypoxia in CVMs in this study would have been 
more relevant should the author have found means of measuring tissue hypoxia in CVMs. This 
route was explored and discussion with scientists with experience in investigating tissue 
hypoxia took place. The outcome was that even trying to measure tissue hypoxia using 
microelectrodes placed in CVM tissue, this will add a factor of error caused by the tissue 
necrosis induced by the placement of microelectrodes into tissue and therefore leading to mis-
reading of tissue hypoxia.  
Although this study has limited clinical application at present, the results obtained add 
to the literature and scientific knowledge and represent a thorough basic analysis and an 
excellent background for pursuing this research work further, especially in the current context 
when technology moves at high speed. With the advances in gene analysis technology, gene 
arrays availability, rapid expansion of genomics and proteomics technologies, significant 
amount of information can be obtained from a very limited amount of tissue, which may be 
obtained from biopsies or, great advantage may be taken from the CVM tissue bank available in 
Histopathology Department at Charing Cross Hospital. Worldwide there is a lack of CVM 
tissue and this is the reason that data described here is missing in the literature and practically 
there is very little scientific data on vascular malformations. 
The author takes responsibility for the fact that this study is far from perfect but this 
basic study is a novelty and should be pursued, especially HIF work which appears promising in 
relation to its clinical applications.  
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